Dapagliflozin and Cardiovascular Outcomes in Type 2 D

New England Journal of Medicine
380, 347-357
DOI: 10.1056/nejmoa1812389

Citation Report

#	Article	IF	Citations
4	American Heart Association Scientific Sessions 2018. Journal of Diabetes, 2019, 11, 261-264.	0.8	1
5	Empagliflozin as an adjunctive therapy for type 1 diabetes. Annals of Translational Medicine, 2018, 6, S134-S134.	0.7	0
8	The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1287-1302.	1.5	78
9	Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?. Cell Metabolism, 2018, 28, 813-815.	7.2	23
10	The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes. Progress in Cardiovascular Diseases, 2019, 62, 364-369.	1.6	19
11	An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials. Expert Opinion on Investigational Drugs, 2019, 28, 811-820.	1.9	16
12	Dapagliflozin vs nonâ€SGLTâ€2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLAREâ€TIMI 58 trial: A nationwide observational study. Diabetes, Obesity and Metabolism, 2019, 21, 2651-2659.	2.2	10
13	Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovascular Diabetology, 2019, 18, 99.	2.7	111
14	The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. Diabetes Care, 2019, 42, 1921-1929.	4.3	47
15	Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. Trends in Endocrinology and Metabolism, 2019, 30, 578-589.	3.1	43
16	Sodiumâ€“glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments. European Cardiology Review, 2019, 14, 23-32.	0.7	44
17	Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial. Diabetology and Metabolic Syndrome, 2019, 11, 62.	1.2	9
18	The effects of sodiumâ€glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Failure, 2019, 6, 927-935.	1.4	64
19	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia, 2019, 62, 1854-1867.	2.9	58
21	Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy â€“ A Retrospective Observational Study. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 663-671.	0.6	6
22	Effects of the sodiumâ€glucose coâ€transporterâ€2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2667-2673.	2.2	73
23	What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?. Diabetes Therapy, 2019, 10, 1719-1731.	1.2	5
24	Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice. Advances in Therapy, 2019, 36, 2895-2909.	1.3	11

#	Article	IF	Citations
25	Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. Cardiovascular Diabetology, 2019, 18, 106.	2.7	21
26	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs. Cardiac Failure Review, 2019, 5, 27-30.	1.2	7
27	The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4253-4263.	1.8	57
28	Adoption of New Glucose-Lowering Medications in the U.S.â€"The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technology and Therapeutics, 2019, 21, 702-712.	2.4	82
29	Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care, 2019, 42, 1912-1920.	4.3	35
30	Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus. Kidney and Blood Pressure Research, 2019, 44, 984-992.	0.9	53
32	Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program. Diabetes Therapy, 2019, 10, 1893-1907.	1.2	2
33	Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome. Diabetic Medicine, 2019, 36, 1643-1651.	1.2	16
34	Sodium-glucose cotransporter 2 inhibitors for type 2 diabetesâ€"cardiovascular and renal benefits in patients with chronic kidney disease. European Journal of Clinical Pharmacology, 2019, 75, 1481-1490.	0.8	7
36	Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. Journal of Diabetes and Its Complications, 2019, 33, 107402.	1.2	25
37	SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. International Journal of Environmental Research and Public Health, 2019, 16, 2965.	1.2	153
38	The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes. Endocrinology and Metabolism, 2019, 34, 106.	1.3	14
39	Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovascular Diabetology, 2019, 18, 107.	2.7	111
40	Diabetes and stroke. Practical Diabetes, 2019, 36, 126-131.	0.1	1
41	Evaluation of the effect of sodiumâ€"glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPERORâ€Reduced trial. European Journal of Heart Failure, 2019, 21, 1270-1278.	2.9	155
42	New Insights Into Mechanisms of Acute Kidney Injury in Heart Disease. Canadian Journal of Cardiology, 2019, 35, 1158-1169.	0.8	12
43	Looking for safety but overlooking efficacy: Non-inferiority trials of anti-diabetics. European Journal of Internal Medicine, 2019, 67, e9-e10.	1.0	0
45	HipertensiÃ³n arterial en la enfermedad renal crÃ³nica. Medicine, 2019, 12, 4772-4778.	0.0	1

#	Article	IF	Citations
46	The future of new drugs for diabetes management. Diabetes Research and Clinical Practice, 2019, 155, 107785.	1.1	28
47	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 2019, 140, 739-750.	1.6	211
48	Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?. Metabolism: Clinical and Experimental, 2019, 98, iii-ix.	1.5	24
49	A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion. Kidney and Blood Pressure Research, 2019, 44, 449-456.	0.9	21
50	Heart Failure: Complications of Type 2 Diabetes. Journal of Korean Diabetes, 2019, 20, 1.	0.1	0
51	The Dapagliflozin And Prevention of Adverseâ€outcomes in Heart Failure (DAPAâ€HF) trial: baseline characteristics. European Journal of Heart Failure, 2019, 21, 1402-1411.	2.9	159
52	Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2019, 155, 107791.	1.1	6
53	Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance. International Journal of Molecular Sciences, 2019, 20, 3289.	1.8	37
54	Do GLPâ€1RAs and SGLTâ€2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 2274-2283.	2.2	26
55	Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?. Archives of Medical Sciences Atherosclerotic Diseases, 2019, 4, 13-15.	0.5	1
56	Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus. Current Diabetes Reports, 2019, 19, 54.	1.7	18
57	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1câ€"Translating Evidence into Practice. Diabetes Therapy, 2019, 10, 1595-1622.	1.2	36
58	Sodium Glucose Cotransporter 2 Inhibition and the Visualization of Kidney Hemodynamics. Circulation, 2019, 140, 316-318.	1.6	7
59	Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis â€the STOP DKA protocol. Diabetes, Obesity and Metabolism, 2019, 21, 2189-2191.	2.2	1
60	Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3647-3660.	1.8	18
61	Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors. Journal of Korean Diabetes, 2019, 20, 87.	0.1	0
62	Clinical aspects of heart failure in individuals with diabetes. Diabetologia, 2019, 62, 1529-1538.	2.9	14
63	Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovascular Diabetology, 2019, 18, 94.	2.7	30

#	Article	IF	Citations
64	Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics. International Journal of Molecular Sciences, 2019, 20, 3552.	1.8	33
65	Use of Insulin in the Inpatient Setting: Need for Continued Use. Current Diabetes Reports, 2019, 19, 64.	1.7	3
67	Trends of mortality in diabetic patients in Taiwan: A nationwide survey in 2005â€“2014. Journal of the Formosan Medical Association, 2019, 118, S83-S89.	0.8	29
68	Cardiologist as a cardiometabolic specialist. Journal of Clinical Hypertension, 2019, 21, 1432-1435.	1.0	3
69	The efficacy of Nigella Sativa L extracts to reduce cardiovascular disease risk in diabetic dyslipidemia. AIP Conference Proceedings, 2019, , .	0.3	3
70	SGLT2 inhibitors and the changing landscape for treatment of diabetes . Therapeutics and Clinical Risk Management, 2019, Volume 15, 861-867.	0.9	6
71	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 38.	0.4	1
72	Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. Diabetic Medicine, 2019, 36, 1063-1071.	1.2	8
73	Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan. Journal of the Formosan Medical Association, 2019, 118, S74-S82.	0.8	11
74	SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1001-1012.	1.1	23
75	Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications. World Journal of Diabetes, 2019, 10, 324-332.	1.3	13
76	Use of sodiumâ€glucose coâ€transporterâ€2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. Diabetes, Obesity and Metabolism, 2019, 21, 2354-2367.	2.2	22
77	Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2422-2428.	2.2	40
78	Cardiac ischemiaâ€“reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity. Cardiovascular Diabetology, 2019, 18, 85.	2.7	29
79	Changes in the Prescription of Glucoseâ€Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. Journal of the American Heart Association, 2019, 8, e012244.	1.6	8
80	Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence. International Journal of Molecular Sciences, 2019, 20, 3152.	1.8	7
81	A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes. Case Reports in Endocrinology, 2019, 2019, 1-4.	0.2	4
82	A year in type 2 diabetes mellitus: 2018 review based on the Endorama lecture. Hormones, 2019, 18, 401-408.	0.9	2

#	Article	IF	Citations
83	Evaluation of the effects of sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPERORâ€Preserved Trial. European Journal of Heart Failure, 2019, 21, 1279-1287.	2.9	205
84	Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 155, 107808.	1.1	11
85	Studies With Molecules Within the Same Class, but With Different Designs Yield Different Results. EMPA-REG, CANVAS and DECLARE. Revista Espanola De Cardiologia (English Ed), 2019, 72, 1095-1096.	0.4	0
86	Hypoxia-inducible factor-1Î± is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Scientific Reports, 2019, 9, 14754.	1.6	106
87	Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments. Journal of Echocardiography, 2019, 17, 177-186.	0.4	15
88	Empagliflozin in type 1 diabetes . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1555-1561.	1.1	8
89	Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis. PLoS Medicine, 2019, 16, e1002942.	3.9	65
90	Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1783-1794.	1.1	9
91	Hypertension Treatment in Diabetes. Heart Failure Clinics, 2019, 15, 551-563.	1.0	4
92	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. Journal of the American College of Cardiology, 2019, 74, 1926-1942.	1.2	39
93	SGLTâ€2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. Journal of the American Heart Association, 2019, 8, e013389.	1.6	119
94	Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose coâ€transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Pharmacoepidemiology and Drug Safety, 2019, 28, 1620-1628.	0.9	36
95	Unraveling the Molecular Mechanism of Action of Empagliflozin in HeartÂFailure With Reduced Ejection Fraction WithÂorÂWithout Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840.	1.9	65
96	Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. Metabolism: Clinical and Experimental, 2019, 101, 154001.	1.5	67
97	Personalized Management of Type 2 Diabetes. Current Diabetes Reports, 2019, 19, 115.	1.7	10
98	The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update. Biomedicine and Pharmacotherapy, 2019, 120, 109526.	2.5	15
101	The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metabolism, 2019, 30, 847-849.	7.2	39
103	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 2019, 10, 1347.	1.3	81

#	Article	IF	Citations
105	Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus. Circulation Reports, 2019, 1, 405-413.	0.4	19
106	Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. American Journal of Medicine, 2019, 132, S3-S12.	0.6	0
107	Renal Effects of Sodium-Glucose Co-Transporter Inhibitors. American Journal of Medicine, 2019, 132, S30-S38.e4.	0.6	6
108	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Medicine, 2019, 132, S49-S57.e5.	0.6	11
109	Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits. American Journal of Medicine, 2019, 132, S39-S48.	0.6	11
110	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Medicine, 2019, 132, S21-S29.	0.6	2
111	Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection. Journal of the American College of Cardiology, 2019, 74, 2511-2524.	1.2	54
112	Rationale and Design of the CANONICAL Studyâ€€â€• Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus â€•. Circulation Reports, 2019, 1, 347-351.	0.4	5
114	Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. Stroke, 2019, 50, 3347-3354.	1.0	32
115	Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinicianâ€™s Guide . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2125-2136.	1.1	54
117	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Cardiology, 2019, 124, S20-S27.	0.7	26
118	Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits. American Journal of Cardiology, 2019, 124, S36-S44.	0.7	63
119	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. Heart Failure Clinics, 2019, 15, 519-530.	1.0	2
120	Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. Cmaj, 2019, 191, E1128-E1135.	0.9	17
121	Mineral and Electrolyte Disorders With SGLT2i Therapy. JBMR Plus, 2019, 3, e10242.	1.3	28
122	Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis. Journal of the American Heart Association, 2019, 8, e011640.	1.6	35
123	Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Therapy, 2019, 10, 2201-2217.	1.2	11
124	Les inhibiteurs de SGLT2 : simple innovation, ou rÃ©el progrÃ¨s ?. Medecine Des Maladies Metaboliques, 2019, 13, S1-S2.	0.1	0

#	Article	IF	Citations
125	Ã‰tudes cardiovasculaires chez le patient diabÃ©tique de type 2 Ã risque : conclusions et impact des essais publiÃ©s en 2017-2018. Medecine Des Maladies Metaboliques, 2019, 13, S10-S24.	0.1	6
128	Treatment of heart failure with sodium glucose coâ€transporterâ€2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions. Diabetic Medicine, 2019, 36, 1550-1561.	1.2	4
129	Individually Silicaâ€Embedded Gold Nanorod Superlattice for High Thermal and Solvent Stability and Recyclable SERS Application. Advanced Materials Interfaces, 2019, 6, 1900986.	1.9	8
130	SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes and Endocrinology,the, 2019, 7, 949-958.	5.5	69
131	How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1667-1669.	2.2	8
132	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovascular Diabetology, 2019, 18, 138.	2.7	48
133	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetes Therapy, 2019, 10, 1733-1752.	1.2	47
134	Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Progress in Cardiovascular Diseases, 2019, 62, 349-357.	1.6	56
135	The Pleiotropic Effects of Sodiumâ€“Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. Diabetes Therapy, 2019, 10, 1771-1792.	1.2	44
136	The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study. Expert Opinion on Pharmacotherapy, 2019, 20, 2185-2194.	0.9	2
137	Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Cardiovascular Diabetology, 2019, 18, 110.	2.7	27
138	Cardiovascular outcome trials of the newer anti-diabetic medications. Progress in Cardiovascular Diseases, 2019, 62, 342-348.	1.6	22
140	Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus . Vascular Health and Risk Management, 2019, Volume 15, 365-373.	1.0	10
141	Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Advances in Therapy, 2019, 36, 2567-2586.	1.3	12
143	Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review. Diabetes Therapy, 2019, 10, 1753-1769.	1.2	11
144	Atrial Fibrillation and Diabetes Mellitus. Journal of the American College of Cardiology, 2019, 74, 1107-1115.	1.2	205
146	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2019, 140, 1693-1702.	1.6	371
147	Early Rapid Decline in Kidney Function as a Beneficial Sign After Starting Antihypertensive Medication. Journal of the American Heart Association, 2019, 8, e013145.	1.6	2

#	Article	IF	Citations
149	Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus. Current Opinion in Nephrology and Hypertension, 2019, 28, 321-327.	1.0	19
150	The right place for Sulphonylureas today: Part of â€˜Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitusâ€™. Diabetes Research and Clinical Practice, 2019, 157, 107836.	1.1	23
151	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology,the, 2019, 7, 845-854.	5.5	595
152	Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. Diabetes Research and Clinical Practice, 2019, 157, 107835.	1.1	8
153	Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ: British Medical Journal, 2019, 366, l4772.	2.4	69
154	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 1569-1577.	1.6	94
156	Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovascular Diabetology, 2019, 18, 112.	2.7	109
157	Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs. Cardiovascular Diabetology, 2019, 18, 115.	2.7	9
158	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes: A Network Meta-analysis. SSRN Electronic Journal, 2019, , .	0.4	0
159	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Scientific Reports, 2019, 9, 13009.	1.6	60
160	Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients. Medicina (Lithuania), 2019, 55, 592.	0.8	14
161	SGLT-2 inhibitors for people with type 2 diabetes â€“ Authors' reply. Lancet, The, 2019, 394, 560-561.	6.3	6
162	Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure. American Journal of Cardiology, 2019, 124, 1790-1796.	0.7	28
163	New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 1113-1117.	0.4	2
164	ADA, Endocrine Society issue key updates to diabetes guidelines. Pharmacy Today, 2019, 25, 22-23.	0.0	0
165	Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension. American Journal of Hypertension, 2020, 33, 207-213.	1.0	18
166	Heart-Failure Therapy â€” New Drugs but Old Habits?. New England Journal of Medicine, 2019, 381, 2063-2064.	13.9	9
167	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	13.9	4,108

#	Article	IF	Citations
168	Management of type 2 diabetes: now and the future. Clinical Medicine, 2019, 19, 403-405.	0.8	3
169	Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors. Current Cardiology Reports, 2019, 21, 130.	1.3	38
170	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2019, 140, 1463-1476.	1.6	279
171	A Call for More Complete Reporting of Cardiovascular Death. Circulation, 2019, 140, 887-888.	1.6	4
172	Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet, The, 2019, 394, 1519-1529.	6.3	210
173	Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. Diabetology and Metabolic Syndrome, 2019, 11, 80.	1.2	38
174	Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgraduate Medicine, 2019, 131, 555-565.	0.9	10
175	Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study. Cardiovascular Diabetology, 2019, 18, 120.	2.7	47
176	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocrine Reviews, 2019, 40, 1447-1467.	8.9	210
177	Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents. Cardiovascular Diabetology, 2019, 18, 124.	2.7	17
179	Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing. CKJ: Clinical Kidney Journal, 2019, 12, 620-628.	1.4	13
180	Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881987540.	1.4	23
181	Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK. Diabetes Therapy, 2019, 10, 2131-2137.	1.2	20
182	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. American Heart Journal, 2019, 218, 57-65.	1.2	4
183	Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation, 2019, 140, 1115-1124.	1.6	33
184	Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes . Clinical Pharmacology: Advances and Applications, 2019, Volume 11, 133-143.	0.8	9
185	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failureâ€"Related Outcomes. Circulation, 2019, 140, 1613-1622.	1.6	58
186	Understanding and preventing atherosclerosis: from bench to bedside. European Heart Journal, 2019, 40, 323-327.	1.0	4

#	Article	IF	Citations
187	Mineralocorticoid Antagonism and Diabetic Kidney Disease. Current Diabetes Reports, 2019, 19, 4.	1.7	30
188	FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later. Diabetes, Obesity and Metabolism, 2019, 21, 1073-1078.	2.2	33
189	Management of diabetes mellitus in patients undergoing liver transplantation. Pharmacological Research, 2019, 141, 556-573.	3.1	23
190	Sodiumâ€glucose coâ€transporterâ€2 inhibitor use and risk of lowerâ€extremity amputation: Evolving questions, evolving answers. Diabetes, Obesity and Metabolism, 2019, 21, 1223-1236.	2.2	29
191	Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 1237-1250.	2.2	190
192	Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the â€œCardiac Benefitsâ€•of Empagliflozin Independent of its Hypoglycemic Activity?. Cardiovascular Drugs and Therapy, 2019, 33, 87-95.	1.3	51
193	Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs, 2019, 79, 219-230.	4.9	170
194	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2. American Journal of Medicine, 2019, 132, e599-e609.	0.6	10
195	CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. Diabetes Research and Clinical Practice, 2019, 153, 30-40.	1.1	5
196	Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction. Circulation Research, 2019, 124, 1618-1632.	2.0	39
197	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	2.9	490
198	Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. Current Atherosclerosis Reports, 2019, 21, 31.	2.0	8
199	Incorporating individualised care into UK diabetes guidelines. Practice Nursing, 2019, 2019, 130-133.	0.1	0
200	Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000â€“2018. Primary Care Diabetes, 2019, 13, 409-421.	0.9	13
201	Sodiumâ€glucose coâ€transporter inhibitors: Medications that mimic fasting for cardiovascular prevention. Diabetes, Obesity and Metabolism, 2019, 21, 2211-2218.	2.2	14
202	Response to letter from Dr Oliviera in relation to our publication: A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin. Regulatory Toxicology and Pharmacology, 2019, 106, 347-348.	1.3	0
203	SGLT2 inhibitors in T2D and associated comorbidities â€” differentiating within the class. BMC Endocrine Disorders, 2019, 19, 64.	0.9	10
204	Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3296-3302.	1.8	11

#	Article	IF	Citations
205	The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes. Journal of Clinical Medicine, 2019, 8, 864.	1.0	17
206	SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Medicina (Lithuania), 2019, 55, 268.	0.8	47
207	Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. Current Cardiology Reports, 2019, 21, 70.	1.3	88
208	Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. Case Reports in Endocrinology, 2019, 2019, 1-4.	0.2	9
209	Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials, 2019, 20, 374.	0.7	35
210	Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?. Expert Review of Clinical Pharmacology, 2019, 12, 693-695.	1.3	2
211	CREDENCE and DELIGHT deliver on renal benefits. Nature Reviews Nephrology, 2019, 15, 459-460.	4.1	3
212	GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis. PLoS ONE, 2019, 14, e0217701.	1.1	14
213	Dapagliflozin: A Review in Type 2 Diabetes. Drugs, 2019, 79, 1135-1146.	4.9	109
214	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. Diabetes Care, 2019, 42, 1716-1723.	4.3	10
215	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLAREâ€“TIMI 58 randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 606-617.	5.5	482
216	The expanding rÃ©sumÃ© of SGLT2 inhibitors. Lancet Diabetes and Endocrinology,the, 2019, 7, 585-587.	5.5	3
217	Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease. Journal of the American College of Cardiology, 2019, 73, 2971-2975.	1.2	5
218	An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opinion on Drug Safety, 2019, 18, 691-701.	1.0	17
219	Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?. Current Diabetes Reports, 2019, 19, 39.	1.7	3
220	Renal effects of sodiumâ€“glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. Postgraduate Medicine, 2019, 131, 367-375.	0.9	3
221	The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2019, 18, 64.	2.7	32
222	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. CKJ: Clinical Kidney Journal, 2019, 12, 313-321.	1.4	35

#	Article	IF	Citations
223	Triple therapy with lowâ€dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2152-2162.	2.2	15
224	Lifetime benefits of early detection and treatment of diabetic kidney disease. PLoS ONE, 2019, 14, e0217487.	1.1	20
225	A 24â€week, randomized, doubleâ€blind, activeâ€controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, Obesity and Metabolism, 2019, 21, 2248-2256.	2.2	16
226	Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Metaâ€Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. Journal of the American Heart Association, 2019, 8, e012356.	1.6	73
227	Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes Care, 2019, 42, 1464-1472.	4.3	5
228	Effects of Dapagliflozin on Volume Status When Added to Reninâ€“Angiotensin System Inhibitors. Journal of Clinical Medicine, 2019, 8, 779.	1.0	61
229	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 841-851.	13.9	1,002
230	Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovascular Diabetology, 2019, 18, 76.	2.7	50
231	SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3077-3087.	1.8	74
232	Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. Life Sciences, 2019, 230, 19-27.	2.0	22
234	Sodiumâ€“Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research. Diabetes, 2019, 68, 1109-1120.	0.3	38
235	Transcultural Diabetes Care in The United States â€“ A Position Statement by the American Association of Clinical Endocrinologists. Endocrine Practice, 2019, 25, 729-765.	1.1	19
236	Heart Failure With Preserved Ejection Fraction In Perspective. Circulation Research, 2019, 124, 1598-1617.	2.0	500
237	Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials. Advances in Therapy, 2019, 36, 1549-1573.	1.3	3
238	A Big Win for Diabetic Kidney Disease: CREDENCE. Cell Metabolism, 2019, 29, 1024-1027.	7.2	23
239	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 1880-1882.	13.9	65
240	Quantitative Systems Pharmacology: An Exemplar Modelâ€Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 380-395.	1.3	33
241	Diving into the unknown: sodiumâ€“glucose cotransporterâ€2 inhibitors in heart failure without diabetes. European Journal of Heart Failure, 2019, 21, 874-876.	2.9	4

#	Article	IF	Citations
242	Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors. Journal of Diabetes and Its Complications, 2019, 33, 567-571.	1.2	9
243	A safety update on sodium glucose coâ€transporter 2 inhibitors. Diabetes, Obesity and Metabolism, 2019, 21, 34-42.	2.2	61
244	What does sodiumâ€glucose coâ€transporter 1 inhibition add: Prospects for dual inhibition. Diabetes, Obesity and Metabolism, 2019, 21, 43-52.	2.2	69
245	Effects of sodiumâ€glucose cotransporter inhibitors on cardiorenal and metabolic systems: Latest perspectives from the outcome trials. Diabetes, Obesity and Metabolism, 2019, 21, 5-8.	2.2	5
246	Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies. Diabetes and Vascular Disease Research, 2019, 16, 415-423.	0.9	21
247	Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes, Obesity and Metabolism, 2019, 21, 19-23.	2.2	22
248	Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey. Diabetes Therapy, 2019, 10, 1523-1530.	1.2	8
249	Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLAREâ€“TIMI 58 for the basic science community. Cardiovascular Research, 2019, 115, e54-e57.	1.8	8
250	A review of the mechanism of action, metabolic profile and haemodynamic effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors. Diabetes, Obesity and Metabolism, 2019, 21, 9-18.	2.2	69
251	Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovascular Diabetology, 2019, 18, 59.	2.7	14
252	Assessment of the benefitâ€“risk balance of SGLT2 inhibitors: Commentary on a new â€˜French paradoxâ€™. Diabetes and Metabolism, 2019, 45, 319-321.	1.4	8
253	Seventh World congress on controversies to consensus in diabetes, obesity, and hypertension. Journal of Diabetes, 2019, 11, 628-631.	0.8	1
254	Key Updates in Cardio-Nephrology from 2018: Springboard to a Bright Future. CardioRenal Medicine, 2019, 9, 222-228.	0.7	2
255	SGLT2 inhibition to address the unmet needs in diabetic nephropathy. Diabetes/Metabolism Research and Reviews, 2019, 35, e3171.	1.7	23
256	Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 429-441.	5.5	137
257	SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease. Lancet Diabetes and Endocrinology,the, 2019, 7, 414-415.	5.5	0
258	SGLT2 Inhibition. Journal of the American College of Cardiology, 2019, 73, 1945-1947.	1.2	14
259	Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 447-455.	1.1	13

#	Article	IF	Citations
260	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. Diabetes and Vascular Disease Research, 2019, 16, 399-414.	0.9	26
261	Acute kidney injury with sodiumâ€glucose coâ€transporterâ€2 inhibitors: A metaâ€analysis of cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2019, 21, 1996-2000.	2.2	55
262	Statistical Appraisal of 6ÂRecentÂClinicalÂTrials in Cardiology. Journal of the American College of Cardiology, 2019, 73, 2740-2755.	1.2	24
263	Will the new hypoglycaemic agents be effective on renal and cardiovascular protection in diabetes and renal diabetic disease?. Nefrologia, 2019, 39, 3-10.	0.2	3
264	Cardiologists' approach to managing cardiovascular risk in patients with type 2 diabetes. Journal of Diabetes, 2019, 11, 605-609.	0.8	1
265	Sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin improves cardiac function in nonâ€diabetic rats with left ventricular dysfunction after myocardial infarction. European Journal of Heart Failure, 2019, 21, 862-873.	2.9	236
266	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	2.6	232
267	How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol. Diabetes Therapy, 2019, 10, 1163-1170.	1.2	3
268	Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. Trends in Molecular Medicine, 2019, 25, 640-655.	3.5	19
269	Similar effectiveness of dapagliflozin and GLPâ€1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. Diabetes, Obesity and Metabolism, 2019, 21, 1886-1894.	2.2	17
270	Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!. Journal of Diabetes and Its Complications, 2019, 33, 465-467.	1.2	6
271	SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018). Expert Opinion on Therapeutic Patents, 2019, 29, 369-384.	2.4	19
272	Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?. Diabetes and Vascular Disease Research, 2019, 16, 303-309.	0.9	25
273	Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1935-1942.	1.8	7
274	Protective effect of sodiumâ€“glucose cotransporterÂ2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and typeÂ2 diabetes. Journal of Diabetes Investigation, 2019, 10, 1510-1517.	1.1	16
275	Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials. Endocrine, 2019, 65, 15-24.	1.1	25
277	A trial to evaluate the effect of the sodiumâ€“glucose coâ€transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPAâ€HF). European Journal of Heart Failure, 2019, 21, 665-675.	2.9	264
278	Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial. BMC Cardiovascular Disorders, 2019, 19, 60.	0.7	16

#	Article	IF	Citations
279	Analysis from the EMPA-REG OUTCOMEÂ® trialÂindicates empagliflozin may assist in preventingÂtheÂprogression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney International, 2019, 96, 489-504.	2.6	77
280	Realâ€world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. Diabetes, Obesity and Metabolism, 2019, 21, 1661-1667.	2.2	18
281	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 140, e596-e646.	1.6	1,789
282	The Serendipitous Story of SGLT2 Inhibitors in Heart Failure. Circulation, 2019, 139, 2537-2541.	1.6	51
283	The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. Diabetes Care, 2019, 42, 931-937.	4.3	147
284	Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2019, 39, 469-476.	1.1	2
285	Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on <scp>SGLT</scp>â€2 inhibitors and <scp>GLP</scp>â€1 receptor agonists. Journal of Internal Medicine, 2019, 286, 16-31.	2.7	24
286	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 2019, 139, 2516-2527.	1.6	224
287	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	1.6	415
288	News from the American Heart Association: more on sodiumâ€“glucose coâ€transporter 2 inhibitors, diabetes and heart failure. European Journal of Heart Failure, 2019, 21, 261-263.	2.9	2
289	An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. Expert Opinion on Pharmacotherapy, 2019, 20, 781-790.	0.9	4
291	Sodium glucose cotransporter (SGLT)â€2 inhibitors: Do we need them for glucoseâ€lowering, for cardiorenal protection or both?. Diabetes, Obesity and Metabolism, 2019, 21, 24-33.	2.2	17
292	Heart failure and diabetes: management and open issues. Herz, 2019, 44, 203-209.	0.4	2
293	Highlights from the 2018 American Heart Association Scientific Sessions in Chicago, Illinois. Journal of Thrombosis and Thrombolysis, 2019, 47, 596-599.	1.0	0
294	Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. Current Medical Research and Opinion, 2019, 35, 1305-1306.	0.9	1
295	Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Scientific Reports, 2019, 9, 3256.	1.6	14
296	Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 275-285.	1.5	53
298	What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes. American Journal of Medicine, 2019, 132, 1027-1031.	0.6	0

#	Article	IF	Citations
299	Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus. Chronic Diseases and Translational Medicine, 2019, 5, 25-36.	0.9	4
300	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1520-1574.	1.8	305
301	Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea. Endocrinology and Metabolism, 2019, 34, 70.	1.3	1
302	Nine contemporary therapeutic directions in heart failure. Heart Asia, 2019, 11, e011150.	1.1	2
303	The Growing Case for Use of SGLT2i in Heart Failure. JACC Basic To Translational Science, 2019, 4, 38-40.	1.9	4
304	Sodium-glucose cotransporter inhibitors: beyond glycaemic control. CKJ: Clinical Kidney Journal, 2019, 12, 322-325.	1.4	23
306	Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. Diabetes Care, 2019, 42, 1067-1074.	4.3	121
307	Improving Outcomes in Patients With Diabetes Mellitus. Journal of the American Heart Association, 2019, 8, e011971.	1.6	4
308	Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis. Diabetes Therapy, 2019, 10, 891-899.	1.2	13
309	Update on heart failure management and future directions. Korean Journal of Internal Medicine, 2019, 34, 11-43.	0.7	84
310	Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Expert Review of Clinical Pharmacology, 2019, 12, 299-308.	1.3	23
311	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. Journal of the American College of Cardiology, 2019, 74, 1376-1414.	1.2	820
312	2019 ACC/AHA Guideline on the Primary Prevention of CardiovascularÂDisease. Journal of the American College of Cardiology, 2019, 74, e177-e232.	1.2	1,038
313	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 140, e563-e595.	1.6	1,676
314	Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 356-367.	5.5	210
315	Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis. Journal of Endocrinological Investigation, 2019, 42, 1165-1169.	1.8	28
316	Navigating the â€œMACEâ€•in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits. Diabetes, Obesity and Metabolism, 2019, 21, 1780-1789.	2.2	31
317	Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation, 2019, 139, 2822-2830.	1.6	167

#	Article	IF	Citations
318	Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes. Journal of Diabetes Science and Technology, 2019, 13, 995-1000.	1.3	28
319	Sodiumâ€glucose coâ€transporterâ€2 (SGLTâ€2) inhibitors and cancer: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2019, 21, 1871-1877.	2.2	46
321	Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. Metabolism: Clinical and Experimental, 2019, 96, 92-100.	1.5	40
322	SGLT receptors and myocardial ischaemia-reperfusion injury: inhibition of SGLT-1, SGLT-2, or both?. Cardiovascular Research, 2019, 115, 1572-1573.	1.8	7
323	Eligibility of patients with type 2 diabetes for sodiumâ€glucose coâ€transporterâ€2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry. Diabetes, Obesity and Metabolism, 2019, 21, 1985-1989.	2.2	15
324	Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2019, 21, 1790-1800.	2.2	28
326	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	13.9	3,760
328	Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials. Cardiovascular Diabetology, 2019, 18, 47.	2.7	15
329	Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?. Expert Opinion on Pharmacotherapy, 2019, 20, 1087-1090.	0.9	4
330	Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. Metabolism: Clinical and Experimental, 2019, 96, vi-xi.	1.5	6
331	Prise de position de la SociÃ©tÃ© Francophone du DiabÃ¨te (SFD) : Ã©valuation du rapport bÃ©nÃ©fices-risques des inhibiteurs de SGLT2. Medecine Des Maladies Metaboliques, 2019, 13, 195-209.	0.1	7
332	SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgraduate Medicine, 2019, 131, 251-260.	0.9	55
333	An update on the safety of SGLT2 inhibitors. Expert Opinion on Drug Safety, 2019, 18, 295-311.	1.0	122
334	The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury. Kidney and Blood Pressure Research, 2019, 44, 149-157.	0.9	37
335	Diabetic cardiomyopathy: prevalence, determinants and potential treatments. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881983486.	1.4	76
336	Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus. Journal of General and Family Medicine, 2019, 20, 129-138.	0.3	13
337	Are gliflozins the new statins for diabetes?. Diabetes Research and Clinical Practice, 2019, 153, 191-193.	1.1	5
338	Renal effects of a sodiumâ€glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status. Diabetes, Obesity and Metabolism, 2019, 21, 1715-1724.	2.2	6

#	Article	IF	Citations
339	Effect of SGLT2 inhibitors on body composition, fluid status and reninâ€“angiotensinâ€“aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovascular Diabetology, 2019, 18, 46.	2.7	146
340	Beyond glycemic control: New guidance on cardio-renal protection. Metabolism: Clinical and Experimental, 2019, 99, 113-115.	1.5	5
341	Evidence-Based Cardiovascular Risk Management in Diabetes. American Journal of Cardiovascular Drugs, 2019, 19, 439-448.	1.0	10
342	Primary Prevention of Heart Failure inÂWomen. JACC: Heart Failure, 2019, 7, 181-191.	1.9	33
343	Clinical implications of cardiovascular outcome trials in typeÂ2Âdiabetes. Herz, 2019, 44, 192-202.	0.4	4
344	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucoseâ€lowering medications. Diabetes, Obesity and Metabolism, 2019, 21, 1277-1290.	2.2	64
345	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodiumâ€“Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42, 1147-1154.	4.3	249
346	Management of hypoglycemia in older adults with type 2 diabetes. Postgraduate Medicine, 2019, 131, 241-250.	0.9	63
347	PDM-ProValue meets cardiovascular outcome trials in diabetes. Cardiovascular Diabetology, 2019, 18, 10.	2.7	2
348	SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/obâ^'/â^' mice. Cardiovascular Diabetology, 2019, 18, 16.	2.7	122
349	Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. Frontiers in Endocrinology, 2019, 10, 45.	1.5	94
350	Recent advances in the pathogenesis of microvascular complications in diabetes. Archives of Pharmacal Research, 2019, 42, 252-262.	2.7	43
351	Cardiovascular Protection with Anti-hyperglycemic Agents. American Journal of Cardiovascular Drugs, 2019, 19, 249-257.	1.0	24
352	The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes. Current Medical Research and Opinion, 2019, 35, 1283-1295.	0.9	10
353	Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. British Journal of Clinical Pharmacology, 2019, 85, 1337-1347.	1.1	23
354	Advances in the clinical management of type 2 diabetes: a brief history of the past 15 years and challenges for the future. BMC Medicine, 2019, 17, 46.	2.3	18
355	Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney. Nephrology Dialysis Transplantation, 2019, 34, 2015-2017.	0.4	9
356	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2022-2031.	1.6	523

#	Article	IF	Citations
357	Diabetes Mellitus and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 558-568.	1.1	98
358	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 2019, 21, 386-388.	2.9	24
359	Highlights of AHA Scientific Sessions 2018: a report from the Scientists of Tomorrow. Cardiovascular Research, 2019, , .	1.8	1
360	Uric acid and the cardioâ€renal effects of SGLT2 inhibitors. Diabetes, Obesity and Metabolism, 2019, 21, 1291-1298.	2.2	121
361	Type 2 Diabetes. Annals of Internal Medicine, 2019, 171, ITC65-ITC80.	2.0	46
362	In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function. Annals of Internal Medicine, 2019, 170, JC15.	2.0	0
364	The role of the heart failure nurse and use of sodium glucose cotransporter-2 inhibitors. Journal of Prescribing Practice, 2019, 1, 602-609.	0.1	0
365	Novel research into glucose-lowering drugs for heart failure shows promise. Journal of Prescribing Practice, 2019, 1, 530-531.	0.1	0
366	Newer Oral Antihyperglycemics: From Seinfeld to Breaking Bad. Canadian Journal of Hospital Pharmacy, 2019, 72, .	0.1	0
367	Highlights in heart failure. ESC Heart Failure, 2019, 6, 1105-1127.	1.4	109
368	Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature. Italian Journal of Medicine, 2019, 13, 205-224.	0.2	0
369	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. Journal of the American Society of Nephrology: JASN, 2019, 30, 2229-2242.	3.0	93
370	Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?. BMJ Open Diabetes Research and Care, 2019, 7, e000742.	1.2	25
371	SGLT2 Inhibitors Therapy in Type 2 Diabetes Mellitus. , 2019, , .		1
372	Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ: British Medical Journal, 2019, 367, l5887.	2.4	84
373	Pharmacovigilance assessment of the association between Fournierâ€™s gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Research and Care, 2019, 7, e000725.	1.2	26
374	Simple Glucose Measurement System Based on Uncladded Fiber Bragg Grating Etched with Nitric Acid. Journal of Physics: Conference Series, 2019, 1417, 012004.	0.3	3
375	Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus. Drug Discoveries and Therapeutics, 2019, 13, 322-327.	0.6	1

#	Article	IF	Citations
376	The role of the heart failure nurse and use of sodium glucose cotransporter-2 inhibitors. British Journal of Cardiac Nursing, 2019, 14, 1-12.	0.0	0
377	The Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors. Journal of Korean Diabetes, 2019, 20, 81.	0.1	0
378	Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases. Transplantation Proceedings, 2019, 51, 3275-3280.	0.3	37
379	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Cardiology, 2019, 124, S45-S52.	0.7	62
380	Response by Kato et al to Letter Regarding Article, â€œEffect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitusâ€• Circulation, 2019, 140, e740-e741.	1.6	6
381	Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction. International Journal of Molecular Sciences, 2019, 20, 5668.	1.8	13
382	Renal Effects of Sodium-Glucose Co-Transporter Inhibitors. American Journal of Cardiology, 2019, 124, S28-S35.	0.7	40
383	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care, 2019, 42, 2298-2306.	4.3	157
384	Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review. Cardiovascular Ultrasound, 2019, 17, 26.	0.5	18
385	Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. American Journal of Cardiology, 2019, 124, S3-S11.	0.7	26
386	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 158, 107927.	1.1	16
387	Bringing the novel to the everyday. British Journal of Cardiac Nursing, 2019, 14, 1-2.	0.0	0
388	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S73-S92.	0.6	38
389	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S105-S113.	0.6	9
390	Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. Scientific Reports, 2019, 9, 19351.	1.6	43
391	Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. Clinical Diabetes, 2019, 37, 316-337.	1.2	11
392	Risk factor reduction in type 2 diabetes demands a multifactorial approach. European Journal of Preventive Cardiology, 2019, 26, 81-91.	0.8	13
393	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. European Journal of Preventive Cardiology, 2019, 26, 73-80.	0.8	56

#	Article	IF	Citations
394	Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease. Journal of Diabetes Research, 2019, 2019, 1-7.	1.0	6
395	Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages. Frontiers in Endocrinology, 2019, 10, 820.	1.5	15
396	Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Cardiovascular Diabetology, 2019, 18, 165.	2.7	170
397	Trends in Cause-Specific Outcomes Among Individuals With Type 2 Diabetes and Heart Failure in the United Kingdom, 1998-2017. JAMA Network Open, 2019, 2, e1916447.	2.8	4
398	Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes. Current Diabetes Reports, 2019, 19, 132.	1.7	15
399	Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!. Archives of Medical Science, 2019, 15, 1357-1364.	0.4	31
400	Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2515-2529.	1.1	20
401	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. Current Diabetes Reports, 2019, 19, 157.	1.7	7
402	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008018.	1.4	25
403	Subtypeâ€Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study. Journal of Clinical Pharmacology, 2020, 60, 629-635.	1.0	15
404	Review of cardiovascular outcomes trials of sodiumâ€“glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Current Opinion in Cardiology, 2019, 34, 687-692.	0.8	24
405	Research into glucose-lowering drugs for heart failure treatment. British Journal of Community Nursing, 2019, 24, 560-561.	0.2	0
407	Efficacy of sodium-glucose co-transporter 2 inhibitors in patients with type II diabetes. Medicine (United States), 2019, 98, e18198.	0.4	0
411	Cardioprotective diabetes drugs: what cardiologists need to know. Cardiovascular Endocrinology and Metabolism, 2019, 8, 96-105.	0.5	11
412	How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area. Journal of Diabetes Research, 2019, 2019, 1-9.	1.0	12
413	Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes. Journal of Pharmaceutical Policy and Practice, 2019, 12, 30.	1.1	5
414	Updated management for patients with cardiovascular disease and diabetes. JAAPA: Official Journal of the American Academy of Physician Assistants, 2019, 32, 51-53.	0.1	2
415	Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables. Journal of Hypertension, 2019, 37, 1939-1949.	0.3	7

#	Article	IF	Citations
416	Diabetes and Cardiovascular Disease: an Update. Current Diabetes Reports, 2019, 19, 161.	1.7	53
417	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118.	1.6	22
418	Dapagliflozin and DAPAâ€HF: from glycaemic control to heart failure therapy. Practical Diabetes, 2019, 36, 192-193.	0.1	2
419	SGLT2 inhibitors and urinary tract infections. Nature Reviews Endocrinology, 2019, 15, 687-688.	4.3	21
420	Update in recent clinical trials in heart failure. Current Opinion in Cardiology, 2019, 34, 307-314.	0.8	2
421	Recent advances in diabetes treatments and their perioperative implications. Current Opinion in Anaesthesiology, 2019, 32, 398-404.	0.9	26
422	Predictors of heart failure development in type 2 diabetes. Current Opinion in Cardiology, 2019, 34, 578-583.	0.8	15
423	New drugs for the treatment of chronic heart failure with a reduced ejection fraction. Journal of Cardiovascular Medicine, 2019, 20, 650-659.	0.6	9
424	Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes. Medicine (United States), 2019, 98, e18245.	0.4	54
425	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2549-2557.	1.1	6
426	MÃ©canismes possibles des effets bÃ©nÃ©fiques cardiovasculaires des inhibiteurs SGLT2. Archives of Cardiovascular Diseases Supplements, 2019, 11, S18-S22.	0.0	0
427	Anemia in patients of diabetic kidney disease. Journal of the Chinese Medical Association, 2019, 82, 752-755.	0.6	18
428	Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. Current Diabetes Reports, 2019, 19, 154.	1.7	6
430	Diabetes Mellitus and the Heart. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S102-S104.	0.6	4
431	Reducing Cardiovascular Risk in Diabetes: Insights from Diabetes Trials. Frontiers in Diabetes, 2019, , 119-130.	0.4	0
432	Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia, 2019, 62, 357-369.	2.9	67
433	Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLAREâ€TIMI 58 trial: A nationwide observational study. Diabetes, Obesity and Metabolism, 2019, 21, 1136-1145.	2.2	61
434	Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2019, 8, 45.	1.0	37

#	Article	IF	Citations
435	Cardiovascular effects of SGLTâ€2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand. Diabetes/Metabolism Research and Reviews, 2019, 35, e3124.	1.7	11
436	The renoprotective effects of sodiumâ€glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 1018-1026.	2.2	25
437	Dapagliflozin DECLAREd safe. Nature Reviews Cardiology, 2019, 16, 4-4.	6.1	1
438	Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2019, 20, 277-294.	0.9	31
439	Fournier's gangrene and sodiumâ€“glucose cotransporter 2 inhibitors: Is there a causal association?. Journal of Diabetes, 2019, 11, 340-341.	0.8	8
440	Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. Diabetes, Obesity and Metabolism, 2019, 21, 1081-1087.	2.2	39
441	Post-transplant diabetes mellitus in patients with solid organ transplants. Nature Reviews Endocrinology, 2019, 15, 172-188.	4.3	154
442	Cardiovascular efficacy and safety of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€1 receptor agonists: a systematic review and network metaâ€analysis. Diabetic Medicine, 2019, 36, 444-452.	1.2	30
443	The effect of sodiumâ€glucose cotransporter 2 inhibitors and glucagonâ€like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes. Clinical Cardiology, 2019, 42, 406-412.	0.7	6
444	Reduction in the incidence of myocardial infarction with sodiumâ€“glucose linked cotransporter-2 inhibitors: evident and plausible. Cardiovascular Diabetology, 2019, 18, 6.	2.7	9
445	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation, 2019, 139, 1384-1395.	1.6	205
446	How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes, Obesity and Metabolism, 2019, 21, 968-974.	2.2	66
447	GLP-1 receptor agonists and cardiovascular risk in routine clinical practice. Lancet Diabetes and Endocrinology,the, 2019, 7, 78-80.	5.5	1
448	Nephrotic range proteinuria and acute heart failure. Internal and Emergency Medicine, 2020, 15, 105-108.	1.0	0
449	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Acta Cardiologica, 2020, 75, 211-217.	0.3	3
450	Series: Implications of the recent CVOTs in type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 159, 107726.	1.1	15
451	Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. European Heart Journal, 2020, 41, 1764-1774.	1.0	11
452	Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?. Internal Medicine, 2020, 59, 1-5.	0.3	9

#	Article	IF	Citations
453	Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in type 2 diabetes: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2020, 27, 667-670.	0.8	6
454	Heart failure and diabetes: The confrontation of two major epidemics of the 21st century. Revista Clínica Espanõla, 2020, 220, 135-138.	0.3	6
455	Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers. Nephrology Dialysis Transplantation, 2020, 35, 1570-1576.	0.4	11
456	Effects of sodiumâ€glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and metaâ€analysis. Diabetes/Metabolism Research and Reviews, 2020, 36, e3174.	1.7	8
457	Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With HeartÂFailure. Canadian Journal of Diabetes, 2020, 44, 103-110.	0.4	2
458	The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors. American Journal of Medicine, 2020, 133, 182-185.	0.6	14
459	A LEADER in the management of type 2 diabetes and cardiorenal disease. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 978-984.	0.4	2
460	Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce CardiovascularÂRisk in Adults With Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 2020, 44, 93-102.	0.4	35
461	Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes. Canadian Journal of Diabetes, 2020, 44, 61-67.	0.4	13
462	Emerging glucose-lowering therapies: a guide for cardiologists. Heart, 2020, 106, 18-23.	1.2	6
463	Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 71-76.	1.1	5
464	Weighing Coronary Revascularization Options in Patients With Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 2020, 44, 78-85.	0.4	5
465	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocrine Reviews, 2020, 41, 66-117.	8.9	134
466	An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250Âmg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions. Clinical Pharmacokinetics, 2020, 59, 349-357.	1.6	2
467	Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes. Current Medical Research and Opinion, 2020, 36, 209-211.	0.9	3
468	The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney International, 2020, 97, 202-212.	2.6	225
469	Coâ€morbidities and coâ€medications as confounders of cardioprotectionâ€”Does it matter in the clinical setting?. British Journal of Pharmacology, 2020, 177, 5252-5269.	2.7	90
470	Diabetes drugs and stroke risk: Intensive versus conventional glucoseâ€lowering strategies, and implications of recent cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2020, 22, 6-15.	2.2	36

#	Article	IF	Citations
471	Effects of sodiumâ€glucose cotransporterâ€2 inhibitors on the cardiovascular and renal complications of type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 16-29.	2.2	32
472	Minireview: are SGLT2 inhibitors heart savers in diabetes?. Heart Failure Reviews, 2020, 25, 899-905.	1.7	14
473	Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans. Xenobiotica, 2020, 50, 559-569.	0.5	10
474	Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. Clinical Journal of Gastroenterology, 2020, 13, 83-89.	0.4	7
475	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 97-103.	1.4	14
476	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
477	Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. Journal of Endocrinological Investigation, 2020, 43, 289-304.	1.8	25
478	Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials. Journal of Diabetes, 2020, 12, 279-293.	0.8	7
479	Pathophysiology of Proteinuria: Albuminuria as a Target for Treatment. , 2020, , 211-224.		0
480	Pathophysiology of Diabetic Nephropathy. , 2020, , 279-296.		7
481	Canagliflozin and Amputation Risk: Evidence So Far. International Journal of Lower Extremity Wounds, 2020, 19, 21-26.	0.6	14
482	Challenging 2019 ESC guidelines for the management of type 2 diabetes. Diabetes and Metabolism, 2020, 46, 181-185.	1.4	16
483	Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial. Diabetes Therapy, 2020, 11, 347-358.	1.2	2
484	Class effect: dapagliflozin reduces cardiovascular and kidney events. Kidney International, 2020, 97, 246-248.	2.6	1
485	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). Diabetes Therapy, 2020, 11, 53-70.	1.2	18
486	CREDENCE: A silver lining in the dark cloud of diabetic nephropathy. Journal of Diabetes Investigation, 2020, 11, 527-529.	1.1	2
487	Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12â€week randomized controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 501-511.	2.2	8
488	Fournier's gangrene in patients with type 2 diabetes using secondâ€line antidiabetic medications. Diabetes, Obesity and Metabolism, 2020, 22, 267-271.	2.2	5

#	Article	IF	Citations
489	Effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors in type 2 diabetes in women versus men. Diabetes, Obesity and Metabolism, 2020, 22, 263-266.	2.2	51
490	Basal insulin secretion capacity predicts the initial response and maximum levels of betaâ€hydroxybutyrate during therapy with the sodiumâ€glucose coâ€transporterâ€2 inhibitor tofogliflozin, in relation to weight loss. Diabetes, Obesity and Metabolism, 2020, 22, 222-230.	2.2	3
491	Fournier's gangrene and sodiumâ€glucose coâ€transporterâ€2 inhibitors: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 272-275.	2.2	26
492	Type 2 diabetes mellitus and cardiovascular risk; what the pharmacotherapy can change through the epigenetics. Postgraduate Medicine, 2020, 132, 109-125.	0.9	9
493	The New Biology of Diabetic Kidney Diseaseâ€"Mechanisms and Therapeutic Implications. Endocrine Reviews, 2020, 41, 202-231.	8.9	77
494	Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism. Andrology, 2020, 8, 654-662.	1.9	24
495	Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease. Pharmacological Reviews, 2020, 72, 343-379.	7.1	100
496	Evaluation of kidney function throughout the heart failure trajectoryÂâ€“Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 584-603.	2.9	213
498	The use of sodiumâ€glucose coâ€transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 883-891.	0.7	30
499	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. Journal of the American Heart Association, 2020, 9, e012797.	1.6	28
500	Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes. Medical Journal of Australia, 2020, 212, 133-139.	0.8	14
502	Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovascular Diabetology, 2020, 19, 1.	2.7	121
503	A Multinational Real-World Study on the Clinical Characteristics of Patients with TypeÂ2 Diabetes Initiating Dapagliflozin in Southern Europe. Diabetes Therapy, 2020, 11, 423-436.	1.2	7
504	Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials. Diabetes Therapy, 2020, 11, 369-386.	1.2	48
505	Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. Journal of Pain and Symptom Management, 2020, 59, 1127-1146.e1.	0.6	5
506	The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?. CKJ: Clinical Kidney Journal, 2020, 13, 24-26.	1.4	18
507	Reinterpreting Cardiorenal Protection of Renal Sodiumâ€"Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming. Diabetes Care, 2020, 43, 501-507.	4.3	36
508	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2020, 63, 221-228.	2.9	368

#	Article	IF	Citations
509	Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 57-65.	2.6	24
511	Strategies of Unloading the Failing Heart from Metabolic Stress. American Journal of Medicine, 2020, 133, 290-296.	0.6	15
512	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes, Obesity and Metabolism, 2020, 22, 530-539.	2.2	14
513	Design and optimization strategies for the development of new drugs that treat chronic kidney disease. Expert Opinion on Drug Discovery, 2020, 15, 101-115.	2.5	13
514	Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study. Endocrinology, Diabetes and Metabolism, 2020, 3, e00096.	1.0	14
515	Sodium-Glucose Co-TransporterÂ2 Inhibitors and Fracture Risk. Diabetes Therapy, 2020, 11, 7-14.	1.2	18
516	Effect and possible mechanisms of dioscin on ameliorating metabolic glycolipid metabolic disorder in type-2-diabetes. Phytomedicine, 2020, 67, 153139.	2.3	39
517	SGLT2 inhibitors for primary prevention of cardiovascular events. Journal of Diabetes, 2020, 12, 5-7.	0.8	4
518	Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICTâ€5): 52â€week results from a randomized, openâ€label, phase III clinical trial. Diabetes, Obesity and Metabolism, 2020, 22, 540-548.	2.2	22
519	The effects of dapagliflozin on cardioâ€renal risk factors in patients with type 2 diabetes with or without reninâ€angiotensin system inhibitor treatment: a post hoc analysis. Diabetes, Obesity and Metabolism, 2020, 22, 549-556.	2.2	12
520	Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. American Journal of Physiology - Cell Physiology, 2020, 318, C328-C336.	2.1	34
521	The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. CardioRenal Medicine, 2020, 10, 1-10.	0.7	80
522	The year in cardiology: cardiovascular prevention. European Heart Journal, 2020, 41, 1157-1163.	1.0	13
523	The year in cardiology: heart failure. European Heart Journal, 2020, 41, 1232-1248.	1.0	11
525	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia, 2020, 40, 223-236.	0.2	21
526	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes, Obesity and Metabolism, 2020, 22, 442-451.	2.2	102
527	Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets. Diabetes, 2020, 69, 902-914.	0.3	42
528	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2020, 43, 487-493.	4.3	846

#	Article	IF	Citations
529	Preventing CKD in Developed Countries. Kidney International Reports, 2020, 5, 263-277.	0.4	72
530	An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opinion on Pharmacotherapy, 2020, 21, 275-285.	0.9	34
531	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLAREâ€"TIMI 58 Study. Diabetes Care, 2020, 43, 468-475.	4.3	72
532	For debate; pharmacological priorities in advanced type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107510.	1.2	2
533	SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes. Diabetes and Metabolism, 2020, 46, 203-209.	1.4	13
534	Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism: Clinical and Experimental, 2020, 104, 154045.	1.5	23
535	Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarctionâ€"The EMMY trial. American Heart Journal, 2020, 221, 39-47.	1.2	43
536	The landscape of diabetic kidney disease transformed. Nature Reviews Nephrology, 2020, 16, 67-68.	4.1	8
537	Renoprotection in diabetic kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 103-111.	1.0	0
538	Waiting List and Kidney Transplant Vascular Risk: An Ongoing Unmet Concern. Kidney and Blood Pressure Research, 2020, 45, 1-27.	0.9	12
539	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPAâ€REG OUTCOME trial. European Journal of Heart Failure, 2020, 22, 126-135.	2.9	67
540	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucoseâ€lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	2.9	131
541	Renal effects of SGLT2 inhibitors. Current Opinion in Nephrology and Hypertension, 2020, 29, 190-198.	1.0	65
542	Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge. Current Opinion in Cardiology, 2020, 35, 178-186.	0.8	8
543	SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function. Frontiers in Cardiovascular Medicine, 2019, 6, 186.	1.1	71
544	Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. Journal of Hypertension, 2020, 38, 377-386.	0.3	7
546	Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?. Trends in Endocrinology and Metabolism, 2020, 31, 150-164.	3.1	21
547	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care, 2020, 43, 446-452.	4.3	63

#	Article	IF	Citations
548	The right place for metformin today. Diabetes Research and Clinical Practice, 2020, 159, 107946.	1.1	29
549	High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment. Atherosclerosis, 2020, 292, 60-69.	0.4	31
550	Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study. Expert Opinion on Drug Safety, 2020, 19, 211-221.	1.0	21
551	A 12â€week, randomized, doubleâ€blind, placeboâ€controlled, fourâ€arm doseâ€finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 566-573.	2.2	16
552	Contemporary approach to treating heart failure. Trends in Cardiovascular Medicine, 2020, 30, 507-518.	2.3	9
553	Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway. Molecular and Cellular Endocrinology, 2020, 501, 110642.	1.6	67
554	Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment. Diabetes Therapy, 2020, 11, 15-35.	1.2	39
555	Review of the top 5 cardiology studies of 2017-18. Canadian Pharmacists Journal, 2020, 153, 32-36.	0.4	2
556	Cardiovascular Outcomes With the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease. Cardiology in Review, 2020, 28, 116-124.	0.6	14
557	SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?. Cardiology, 2020, 145, 311-320.	0.6	19
558	High Blood Pressure and Cardiovascular Disease. Hypertension, 2020, 75, 285-292.	1.3	728
559	Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologistâ€™s Perspective: Lessons Learned from Cardiovascular Outcome Trials. International Journal of Environmental Research and Public Health, 2020, 17, 155.	1.2	4
560	Efficacy of Ertugliflozin on Heart Failureâ€“Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation, 2020, 142, 2205-2215.	1.6	156
561	Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. Cardiovascular Diabetology, 2020, 19, 160.	2.7	20
562	Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure. Cardiovascular Diabetology, 2020, 19, 159.	2.7	28
563	SGLT2 Inhibitors across the Spectrum of Severity of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1386-1388.	2.2	1
564	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia, 2020, 40, 223-236.	0.2	7
565	Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research. Frontiers in Pharmacology, 2020, 11, 561494.	1.6	21

#	Article	IF	Citations
567	Secondary prevention after CABG: do new agents change the paradigm?. Current Opinion in Cardiology, 2020, 35, 664-672.	0.8	5
568	Glycaemic and nonâ€glycaemic efficacy of onceâ€weekly GLPâ€1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 28-42.	0.7	8
569	Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232095924.	1.1	10
570	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovascular Drugs and Therapy, 2021, 35, 1067-1076.	1.3	40
571	Sodiumâ€“glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells. Diabetes and Metabolism, 2020, 46, 353-361.	1.4	16
572	Heart Failure Trial Updateâ€”Analysis of Recent Data. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 2792-2800.	0.6	5
573	Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e265-e286.	1.6	107
574	Management of sodiumâ€“glucose cotransporter 2 inhibitors during the perioperative period: A retrospective comparative study. Journal of Perioperative Practice, 2020, 31, 175045892094869.	0.3	2
575	Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature. JRSM Cardiovascular Disease, 2020, 9, 204800402094932.	0.4	17
576	Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovascular Diabetology, 2020, 19, 148.	2.7	101
577	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2020, 98, S1-S115.	2.6	692
579	Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis. Cardiovascular Diabetology, 2020, 19, 154.	2.7	21
580	Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy. Metabolism: Clinical and Experimental, 2020, 113, 154405.	1.5	19
581	Randomized, â€œheadâ€toâ€headâ€•studies comparing different SGLT2 inhibitors are definitely needed. Journal of Clinical Hypertension, 2020, 22, 2391-2392.	1.0	1
582	Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes. Journal of Molecular Medicine, 2020, 98, 1689-1700.	1.7	10
583	Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes â€“ exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations. Current Medical Research and Opinion, 2020, 36, 1985-1989.	0.9	9
584	The influence of longâ€term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease. Journal of Clinical Hypertension, 2020, 22, 2306-2314.	1.0	5
585	Sodium-Glucose Co-Transporter 2 Inhibitors Correct Metabolic Maladaptation of Proximal Tubular Epithelial Cells in High-Glucose Conditions. International Journal of Molecular Sciences, 2020, 21, 7676.	1.8	21

#	Article	IF	Citations
586	Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both. Current Medical Research and Opinion, 2020, 36, 1927-1938.	0.9	3
587	Addressing Comorbidities in Heart Failure. Heart Failure Clinics, 2020, 16, 441-456.	1.0	13
588	Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with TypeÂ2 Diabetes (T2DM): Rationale and Design. Diabetes Therapy, 2020, 11, 2739-2755.	1.2	9
589	Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2020, 137, 130-132.	0.7	2
591	Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019. Heart Failure Clinics, 2020, 16, 433-440.	1.0	4
592	What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?. Current Diabetes Reports, 2020, 20, 63.	1.7	4
593	The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes. Diabetes Research and Clinical Practice, 2020, 170, 108462.	1.1	10
594	Chronic kidney disease as a cardiovascular risk factor. Journal of Hypertension, 2020, 38, 2110-2121.	0.3	21
595	Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells. Cardiovascular Drugs and Therapy, 2021, 35, 1083-1094.	1.3	44
596	A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress. Diabetes Research and Clinical Practice, 2020, 168, 108368.	1.1	28
598	The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation. Biochemical Pharmacology, 2020, 182, 114276.	2.0	19
599	Costâ€effectiveness of empagliflozin in the UK in an EMPAâ€REG OUTCOME subgroup with type 2 diabetes and heart failure. ESC Heart Failure, 2020, 7, 3910-3918.	1.4	17
600	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. European Journal of Heart Failure, 2020, 22, 2175-2186.	2.9	23
601	Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. Current Atherosclerosis Reports, 2020, 22, 72.	2.0	14
602	Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement. Diabetes Therapy, 2020, 11, 2791-2827.	1.2	14
603	Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke. Clinical Therapeutics, 2020, 42, e242-e249.	1.1	30
604	SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies. Pharmacological Research, 2020, 161, 105175.	3.1	14
606	Insuficiencia cardiaca y diabetes: la confrontaciÃ³n de dos grandes epidemias del siglo xxi. Revista Clinica Espanola, 2020, 220, 135-138.	0.2	10

#	Article	IF	Citations
607	Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study. American Journal of Kidney Diseases, 2020, 76, 471-479.e1.	2.1	39
608	Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 2020, 383, 1436-1446.	13.9	2,523
609	Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2020, 21, 2101-2114.	0.9	3
610	SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution. American Journal of Hypertension, 2020, 33, 1071-1074.	1.0	5
611	COVID-19 and the Heart and Vasculature. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2045-2053.	1.1	25
612	The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases. Biophysical Reviews, 2020, 12, 947-968.	1.5	47
613	SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology, 2020, 17, 761-772.	6.1	372
614	Bias and Loss to Followâ€Up in Cardiovascular Randomized Trials: A Systematic Review. Journal of the American Heart Association, 2020, 9, e015361.	1.6	7
615	Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovascular Diabetology, 2020, 19, 110.	2.7	30
616	A Call for a New Paradigm for Diabetes Care in the Era of Sodiumâ€“Glucose CotransporterÂ2 Inhibitors (SGLT2i). Cardiology and Therapy, 2020, 9, 219-225.	1.1	6
617	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. European Journal of Preventive Cardiology, 2021, 28, 975-982.	0.8	35
618	Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis. Diabetes Care, 2020, 43, 1958-1966.	4.3	12
619	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1926-1936.	1.1	7
621	Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance. Current Opinion in Pharmacology, 2020, 54, 11-17.	1.7	12
622	Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. American Heart Journal, 2020, 228, 47-56.	1.2	61
623	Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE. Diabetic Medicine, 2020, 37, 593-601.	1.2	3
626	Renal structure in type 2 diabetes: facts and misconceptions. Journal of Nephrology, 2020, 33, 901-907.	0.9	20
627	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal, 2021, 42, 2565-2573.	1.0	17

#	Article	IF	Citations
628	Blood Glucose Control Strategy for Type 2 Diabetes Patients With COVID-19. Frontiers in Cardiovascular Medicine, 2020, 7, 593061.	1.1	3
629	Effect of Empagliflozin on Hemodynamics in Patients WithÂHeartÂFailure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2020, 76, 2740-2751.	1.2	57
630	Sodium-glucose co-transporter-2 drugs: are we sure they are useful only in the treatment of diabetes?. European Heart Journal Supplements, 2020, 22, L66-L71.	0.0	1
631	Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis. Medical Sciences (Basel, Switzerland), 2020, 8, 47.	1.3	24
632	Standardized Definitions for EvaluationÂofÂHeart Failure Therapies: Scientific Expert Panel From the HeartÂFailure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972.	1.9	15
633	Contemporary Management of Heart Failure in Patients With Diabetes. Diabetes Care, 2020, 43, 2895-2903.	4.3	20
634	Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovascular Diabetology, 2020, 19, 196.	2.7	52
635	Acylated Aminooligosaccharides from the Yellow Sea Streptomyces sp. HO1518 as Both Î±-Glucosidase and Lipase Inhibitors. Marine Drugs, 2020, 18, 576.	2.2	5
636	SGLT-2 Inhibitorsâ€"a Culprit of Diabetic Ketoacidosis Postbariatric Surgery. Case Reports in Critical Care, 2020, 2020, 1-4.	0.2	7
637	Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad. Current Diabetes Reports, 2020, 20, 74.	1.7	20
638	Metformin: still the sweet spot for CV protection in diabetes?. Current Opinion in Pharmacology, 2020, 54, 202-208.	1.7	11
639	Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin. International Journal of Clinical Pharmacy, 2021, 43, 1015-1023.	1.0	3
640	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. Annals of Internal Medicine, 2020, 172, 541.	2.0	53
641	Sodiumâ€"Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis. Annals of Internal Medicine, 2020, 173, 417-425.	2.0	97
642	Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?. Diabetes and Metabolism, 2021, 47, 101209.	1.4	5
643	The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism. Frontiers in Endocrinology, 2020, 11, 599355.	1.5	12
644	Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?. Pharmaceuticals, 2020, 13, 427.	1.7	14
645	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodiumâ€"glucose coâ€transporter 2 inhibitor therapy in ‹scp›DECLAREâ€TIMI‹/scp› 58. European Journal of Heart Failure, 2021, 23, 1026-1036.	2.9	35

#	Article	IF	Citations
646	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPERORâ€Preserved trial. European Journal of Heart Failure, 2020, 22, 2383-2392.	2.9	93
647	How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?. Kidney and Blood Pressure Research, 2020, 45, 823-836.	0.9	1
648	Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study. BMJ Open Diabetes Research and Care, 2020, 8, e001856.	1.2	18
649	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. American Journal of Cardiology, 2020, 137, 133-135.	0.7	2
650	Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction. Frontiers in Cardiovascular Medicine, 2020, 7, 602251.	1.1	11
651	Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study. Cardiovascular Diabetology, 2020, 19, 189.	2.7	16
652	Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Annals of Internal Medicine, 2020, 173, 813-821.	2.0	60
653	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 949-959.	5.5	41
654	Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on â€˜Dapagliflozin in Patients with Chronic Kidney Diseaseâ€™. European Heart Journal, 2020, 41, 4231-4232.	1.0	1
655	Benefitâ€“Risk Tradeoffs in Assessment of New Drugs and Devices. Circulation, 2020, 142, 1974-1988.	1.6	7
656	Practical Strategy for Treating Chronic Kidney Disease (CKD)-Associated with Hypertension . International Journal of Nephrology and Renovascular Disease, 2020, Volume 13, 171-178.	0.8	4
657	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 2020, 76, 1117-1145.	1.2	276
658	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 2020, 142, 734-747.	1.6	44
659	Effectiveness and safety of sodiumâ€“glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study. Current Medical Research and Opinion, 2020, 36, 1601-1610.	0.9	5
660	Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process. American Journal of Health-System Pharmacy, 2020, 77, 1727-1738.	0.5	3
661	Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. Cardiology in Review, 2020, 28, 219-235.	0.6	6
662	Sodiumâ€“Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. Diabetes Care, 2020, 43, 2444-2452.	4.3	26
663	Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nature Reviews Drug Discovery, 2020, 19, 609-633.	21.5	441

#	Article	IF	Citations
664	Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. Diabetes Therapy, 2020, 11, 1925-1934.	1.2	15
665	Risk of de-novo heart failure and competing risk in asymptomatic patients with structural heart diseases. International Journal of Cardiology, 2020, 307, 87-93.	0.8	2
666	Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. Journal of the American Society of Nephrology: JASN, 2020, 31, 2446-2456.	3.0	15
667	Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. Diabetes Care, 2020, 43, 2519-2527.	4.3	3
669	SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. Cell Metabolism, 2020, 32, 404-419.e6.	7.2	197
670	Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice. Metabolism: Clinical and Experimental, 2020, 111, 154324.	1.5	40
671	Hematocrit, hemoglobin and red blood cells are associated with vascular function and vascular structure in men. Scientific Reports, 2020, 10, 11467.	1.6	28
672	Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study. Journal of Clinical Medicine, 2020, 9, 2275.	1.0	8
673	Antidiabetic drugs and blood pressure changes. Pharmacological Research, 2020, 161, 105108.	3.1	11
674	Diabetes is not a risk factor for myocardial infarction in patients without coronary artery disease: A study from the Western Denmark Heart Registry. Diabetes and Vascular Disease Research, 2020, 17, 147916412094180.	0.9	5
675	Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey. Diabetes and Vascular Disease Research, 2020, 17, 147916412094567.	0.9	3
676	Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation. Therapeutic Advances in Cardiovascular Disease, 2020, 14, 175394472093938.	1.0	11
677	Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus. Clinical Drug Investigation, 2020, 40, 991-1000.	1.1	3
678	Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE. Journal of Nephrology, 2020, 33, 977-983.	0.9	2
679	Dilemmas in diagnosising and managing of type 2 diabetes. Independent Nurse, 2020, 2020, 18-20.	0.0	0
680	Costâ€effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational healthâ€economic analysis of <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2020, 22, 2147-2156.	2.9	91
681	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and major adverse limb events: A trialâ€level metaâ€analysis including 51â€‰713 individuals. Diabetes, Obesity and Metabolism, 2020, 22, 2348-2355.	2.2	33
682	Assessing the costâ€effectiveness of sodiumâ€“glucose cotransporterâ€2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and realâ€world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 2364-2374.	2.2	33

#	Article	IF	Citations
683	Natriuresis, Diuresis, and Volume Changes in Diabetics With Heart Failure With Preserved Ejection Fraction: Impact of Sodiumâ€Glucose Cotransporter 2 Inhibitors on Natriuretic Peptides. Journal of the American Heart Association, 2020, 9, e017666.	1.6	1
684	Predictive values of ANGPTL8 on risk of all-cause mortality in diabetic patients: results from the REACTION Study. Cardiovascular Diabetology, 2020, 19, 121.	2.7	11
685	Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opinion on Pharmacotherapy, 2020, 21, 2125-2135.	0.9	18
687	Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits. Current Osteoporosis Reports, 2020, 18, 439-448.	1.5	11
688	Defragmenting Heart Failure Care. Heart Failure Clinics, 2020, 16, 467-477.	1.0	6
689	Randomized Trials Versus CommonÂSense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	1.2	50
690	Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies. Diabetes, Obesity and Metabolism, 2020, 22, 2276-2286.	2.2	12
691	Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. Current Opinion in Cardiology, 2020, 35, 517-523.	0.8	2
692	Quadruple Therapy Is the New Standard of Care for HFrEF. JACC: Heart Failure, 2020, 8, 819-821.	1.9	13
693	Sodiumâ€“glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. Current Opinion in Cardiology, 2020, 35, 589-601.	0.8	3
694	Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes. Journal of Hypertension, 2020, 38, 1811-1819.	0.3	17
695	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. Journal of Hypertension, 2020, 38, 1829-1840.	0.3	15
696	Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, .	1.8	6
697	Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. Journal of Biological Chemistry, 2020, 295, 14379-14390.	1.6	54
698	Importance de lâ€™Ã©valuation du risque cardiovasculaire pour une prÃ©conisation personnalisÃ©e des nouveaux traitements anti-hyperglycÃ©miants en prÃ©vention cardiovasculaire. Medecine Des Maladies Metaboliques, 2020, 14, 461-471.	0.1	0
699	Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovascular Diabetology, 2020, 19, 185.	2.7	83
700	Inhibidores de la SGLT2. Â¿CuÃ¡l es el lugar en terapÃ©utica?. FMC Formacion Medica Continuada En Atencion Primaria, 2020, 27, 419-427.	0.0	0
701	Evaluation and Management of PatientsÂWith Stable Angina: Beyond the Ischemia Paradigm. Journal of the American College of Cardiology, 2020, 76, 2252-2266.	1.2	52

#	Article	IF	Citations
702	Limitations of Natriuretic Peptide Levels in Establishing SGLT-2 Inhibitors for HeartÂFailure Care. Journal of the American College of Cardiology, 2020, 76, 2086-2088.	1.2	3
703	Diabetic Kidney Disease. Primary Care - Clinics in Office Practice, 2020, 47, 645-659.	0.7	74
704	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€"2020. Diabetes Care, 2020, 43, S111-S134.	4.3	421
705	Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. American Heart Journal, 2020, 229, 40-51.	1.2	4
706	New hypoglycaemic therapy in frail older people with diabetes mellitus-phenotypic status likely to be more important than functional status. Diabetes Research and Clinical Practice, 2020, 169, 108438.	1.1	3
707	Use of SGLT2 inhibitors during Ramadan: An expert panel statement. Diabetes Research and Clinical Practice, 2020, 169, 108465.	1.1	16
708	Costâ€effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. ESC Heart Failure, 2020, 7, 3582-3592.	1.4	31
709	Practical Considerations and Opportunities for SGLT2 Inhibitor Prescription in Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	2
710	The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Annals of Medicine, 2021, 53, 2072-2089.	1.5	27
711	Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. BMJ Open, 2020, 10, e034883.	0.8	2
712	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE. Nephrology, 2020, 25, 12-45.	0.7	17
713	Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. International Journal of Molecular Sciences, 2020, 21, 7833.	1.8	46
714	Comprehensive Investigation of Circulating Biomarkers and Their Causal Role in Atherosclerosis-Related Risk Factors and Clinical Events. Circulation Genomic and Precision Medicine, 2020, 13, e002996.	1.6	15
715	SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients . International Journal of Nephrology and Renovascular Disease, 2020, Volume 13, 281-296.	0.8	16
716	Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease. Drug Safety, 2020, 43, 1211-1221.	1.4	24
717	SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes and Metabolism, 2020, 47, 101196.	1.4	7
719	Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db/db mice. BMJ Open Diabetes Research and Care, 2020, 8, e001303.	1.2	9
720	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 2020, 35, 1700-1711.	0.4	107

#	Article	IF	Citations
721	Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study. Journal of Clinical Hypertension, 2020, 22, 1585-1593.	1.0	29
722	SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease. Journal of Clinical Medicine, 2020, 9, 2723.	1.0	13
723	Level of glycemic control among US type 2 diabetes mellitus patients on dual therapy of metformin and sodiumâ€"glucose cotransporter 2 inhibitor: a retrospective database study. Current Medical Research and Opinion, 2020, 36, 1583-1589.	0.9	0
724	Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012â€"2018. BMJ Open Diabetes Research and Care, 2020, 8, e001279.	1.2	41
725	Improved Erythrocyte Deformability Induced by Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients. Cardiovascular Drugs and Therapy, 2022, 36, 59-67.	1.3	0
726	Tubular effects of sodiumâ€"glucose cotransporter 2 inhibitors: intended and unintended consequences. Current Opinion in Nephrology and Hypertension, 2020, 29, 523-530.	1.0	9
727	Interpreting the results of the VERTISâ€CV trial: Is this the end of the â€œclass effectâ€•perspective?. Journal of Diabetes, 2020, 12, 942-945.	0.8	10
728	Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials. Diabetes Care, 2020, 43, 2614-2623.	4.3	9
729	Ertugliflozin and VERTISâ€CV : will the wheels come off the SGLT2 inhibitor bandwagon?. Practical Diabetes, 2020, 37, 112.	0.1	0
730	Cardiovascular safety outcomes of onceâ€weekly GLPâ€1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 61-72.	0.7	9
731	Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. Value in Health, 2020, 23, 1163-1170.	0.1	32
732	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine, 2020, 383, 1425-1435.	13.9	927
733	Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ, The, 2020, 370, m3342.	3.0	70
734	Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis. Vascular Pharmacology, 2020, 133-134, 106779.	1.0	21
735	Association of glucose uptake of visceral fat and acute myocardial infarction: a pilot 18F-FDG PET/CT study. Cardiovascular Diabetology, 2020, 19, 145.	2.7	14
736	Micro RNA-126 promoting angiogenesis in diabetic heart by VEGF/Spred-1/Raf-1 pathway: effects of high-intensity interval training. Journal of Diabetes and Metabolic Disorders, 2020, 19, 1089-1096.	0.8	9
737	Glyphozines and treatment of cardiac disease. Geriatric Care, 2020, 6, .	0.2	0
738	Diabetes, pre-diabetes and cardiovascular diseases in light of the 2019 ESC Guidelines. Studia Medyczne, 2020, 36, 148-155.	0.0	0

#	Article	IF	Citations
739	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. Circulation, 2020, 142, 1205-1218.	1.6	63
740	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3613-3682.	1.8	63
741	Clinical Adverse Events of High-Dose vs Low-Dose Sodiumâ€“Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials. Journal of Clinical Endocrinology and Metabolism, 2020, 105, .	1.8	10
742	Impact of Intensive Glucose Control in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: 3-Year Clinical Outcomes. Journal of Clinical Medicine, 2020, 9, 2464.	1.0	2
743	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane Library, 0, , .	1.5	2
744	Home Therapies in Advanced Heart Failure: Inotropes and Diuretics. Current Heart Failure Reports, 2020, 17, 314-323.	1.3	5
745	Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials. Scientific Reports, 2020, 10, 12837.	1.6	4
746	Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. Scientific Reports, 2020, 10, 13553.	1.6	21
748	New and emerging cardiovascular and antihypertensive drugs. Expert Opinion on Drug Safety, 2020, 19, 1315-1327.	1.0	5
749	Cardiometabolic medicine â€“ the US perspective on a new subspecialty. Cardiovascular Endocrinology and Metabolism, 2020, 9, 70-80.	0.5	12
750	Sodiumâ€“glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology, 2020, 16, 556-577.	4.3	169
751	More Evidence for SGLT2 Inhibitors in Heart Failure. New England Journal of Medicine, 2020, 383, 1481-1482.	13.9	14
752	Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?. Diabetes Therapy, 2020, 11, 2207-2219.	1.2	41
753	GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression. Diabetes Therapy, 2020, 11, 2429-2440.	1.2	13
754	Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure. Circulation, 2020, 142, 1713-1724.	1.6	144
755	Dapagliflozin Promotes Neovascularization by Improving Paracrine Function of Skeletal Muscle Cells in Diabetic Hindlimb Ischemia Mice Through PHD2/HIF-1Î± Axis. Frontiers in Pharmacology, 2020, 11, 1104.	1.6	15
756	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, The, 2020, 396, 819-829.	6.3	816
757	Diabetes in ageing: pathways for developing the evidence base for clinical guidance. Lancet Diabetes and Endocrinology,the, 2020, 8, 855-867.	5.5	47

#	Article	IF	Citations
758	Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. Drugs, 2020, 80, 1763-1781.	4.9	39
759	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane Library, 2020, 2020, CD009966.	1.5	9
760	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. Canadian Journal of Diabetes, 2020, 44, 575-591.	0.4	98
761	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update â€“ The Userâ€™s Guide. Canadian Journal of Diabetes, 2020, 44, 592-596.	0.4	12
762	Nonâ€insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. ESC Heart Failure, 2020, 7, 3438-3451.	1.4	13
763	Totality of evidence in trials of sodiumâ€“glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. European Heart Journal, 2020, 41, 3398-3401.	1.0	20
764	In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes. Pharmaceutics, 2020, 12, 865.	2.0	16
765	Diabetes and CVD Risk: Special Considerations in African Americans Related to Care. Current Cardiovascular Risk Reports, 2020, 14, 1.	0.8	8
767	Acute Cardiorenal Syndrome in Heart Failure: from Dogmas to Advances. Current Cardiology Reports, 2020, 22, 143.	1.3	9
768	Repurposing Antidiabetic Drugs for Cardiovascular Disease. Frontiers in Physiology, 2020, 11, 568632.	1.3	25
769	Response by Zelniker et al to Letter Regarding Article, â€œEffect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trialâ€• Circulation, 2020, 142, e129-e130.	1.6	6
771	Novel therapeutic agents for the treatment of diabetic kidney disease. Expert Opinion on Investigational Drugs, 2020, 29, 1277-1293.	1.9	11
772	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1236-1245.	1.6	81
774	Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors. Renal Failure, 2020, 42, 836-844.	0.8	19
775	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. European Heart Journal, 2020, 41, 3998-4007.	1.0	68
776	Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. Journal of the American Heart Association, 2020, 9, e015103.	1.6	37
777	Prescribing Paradigm Shift? Damned If You Do, Damned If You Donâ€™t. Diabetes Care, 2020, 43, 1991-1993.	4.3	0
778	Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes. Medicine (United States), 2020, 99, e21409.	0.4	3

#	Article	IF	Citations
779	Effects of Epeleuton, a Novel Synthetic Secondâ€Generation nâ€3 Fatty Acid, on Nonâ€Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers. Journal of the American Heart Association, 2020, 9, e016334.	1.6	17
780	Prescription trends and costs of diabetes medications in Australia between 2003 and 2019: an analysis and review of the literature. Internal Medicine Journal, 2022, 52, 841-847.	0.5	5
781	Chronic Lower Extremity Ischemia and Its Association with the Frailty Syndrome in Patients with Diabetes. International Journal of Environmental Research and Public Health, 2020, 17, 9339.	1.2	28
782	Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry. Diabetes and Vascular Disease Research, 2020, 17, 147916412097367.	0.9	9
783	Two Japanese patients with stage G3b chronic kidney disease and impaired glucose metabolism after renal transplantation successfully treated with empagliflozin. Renal Replacement Therapy, 2020, 6, .	0.3	4
784	The role of intracoronary imaging in translational research. Cardiovascular Diagnosis and Therapy, 2020, 10, 1480-1507.	0.7	3
785	The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy. Frontiers in Physiology, 2020, 11, 603247.	1.3	11
787	An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 1799-1803.	0.9	4
788	Nephroprotection by SGLT2i in CKD Patients: May It Be Modulated by Low-Protein Plant-Based Diets?. Frontiers in Medicine, 2020, 7, 622593.	1.2	11
789	Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations. American Journal of Preventive Cardiology, 2020, 4, 100117.	1.3	2
790	169 Sodium-glucose Co-transporter-2 (SGLT2) Inhibitor Usage in Heart Failure Patients With Type Two Diabetes. Heart Lung and Circulation, 2020, 29, S111.	0.2	0
793	Cardioprotective effects of short-term empagliflozin treatment in db/db mice. Scientific Reports, 2020, 10, 19686.	1.6	13
794	Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors?. European Heart Journal, 2020, 41, 4232-4233.	1.0	4
795	Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region. Medicine (United States), 2020, 99, e23489.	0.4	7
796	Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation, 2021, 143, 770-779.	1.6	47
797	VERTIS-CV. Circulation, 2020, 142, 2216-2218.	1.6	4
798	Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective. Frontiers in Pharmacology, 2020, 11, 582680.	1.6	146
799	Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance. International Journal of Molecular Sciences, 2020, 21, 9216.	1.8	4

#	Article	IF	Citations
800	SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, â€˜diabetic nephropathyâ€™, IgA nephropathy and podocytopathies with FSGS lesions. Nephrology Dialysis Transplantation, 2022, 37, 1609-1615.	0.4	30
801	Interactions Between Therapeutics for Metabolic Disease, Cardiovascular Risk Factors, and Gut Microbiota. Frontiers in Cellular and Infection Microbiology, 2020, 10, 530160.	1.8	10
803	SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy . Drug Design, Development and Therapy, 2020, Volume 14, 4775-4788.	2.0	32
804	Nurse Practitionerâ€“Directed Cardio-Diabetes Pilot Program. Journal for Nurse Practitioners, 2020, 16, e123-e128.	0.4	1
805	The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovascular Diabetology, 2020, 19, 188.	2.7	39
806	The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now. Clinical Cardiology, 2020, 43, 1376-1387.	0.7	22
807	Nitrates in combination with hydralazine in cardiorenal syndrome: a randomized controlled proofâ€ofâ€concept study. ESC Heart Failure, 2020, 7, 4267-4276.	1.4	3
808	Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodiumâ€“Glucose Transporter 2 Inhibitors. Diabetes Care, 2020, 43, 1530-1536.	4.3	16
809	Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. Advances in Therapy, 2020, 37, 2620-2645.	1.3	5
811	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 1619-1627.	2.2	95
812	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care, 2020, 43, 1546-1552.	4.3	92
813	Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt. Journal of Medical Economics, 2020, 23, 908-914.	1.0	3
814	The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The <scp>CANAâ€HF</scp> study. Diabetes/Metabolism Research and Reviews, 2020, 36, e3335.	1.7	27
815	Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus. Advances in Therapy, 2020, 37, 3463-3484.	1.3	24
816	Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials. American Journal of Medicine, 2020, 133, e625-e630.	0.6	23
817	Weight-centric pharmacological management of type 2 diabetes mellitus â€“ An essential component of cardiovascular disease prevention. Journal of Diabetes and Its Complications, 2020, 34, 107619.	1.2	11
818	Stroke in the patient with diabetes (Part 2) â€“ Prevention and the effects of glucose lowering therapies. Diabetes Research and Clinical Practice, 2020, 164, 108199.	1.1	5
819	The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-29.	1.9	149

#	Article	IF	Citations
820	Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. Diabetes Care, 2020, 43, 1843-1850.	4.3	27
821	What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient. Diabetes Therapy, 2020, 11, 1381-1395.	1.2	4
822	Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Therapy, 2020, 11, 1347-1367.	1.2	14
823	Maintaining Myocardial Glucose Utilization in Diabetic Cardiomyopathy Accelerates Mitochondrial Dysfunction. Diabetes, 2020, 69, 2094-2111.	0.3	41
824	Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut, 2020, 69, 1877-1884.	6.1	127
825	Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes, Obesity and Metabolism, 2020, 22, 1607-1618.	2.2	118
826	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1128-1139.	3.0	106
827	Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report. American Journal of Kidney Diseases, 2020, 76, 144-147.	2.1	21
828	Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus. BMJ Open Diabetes Research and Care, 2020, 8, e001248.	1.2	65
829	Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovascular Diabetology, 2020, 19, 55.	2.7	27
830	The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT). Trials, 2020, 21, 379.	0.7	5
831	Should Baseline Hemoglobin A 1c or Dose of SGLTâ€2i Guide Treatment With SGLTâ€2i Versus DPPâ€4i in People With Type 2 Diabetes? A Metaâ€Analysis and Systematic Review. Journal of Clinical Pharmacology, 2020, 60, 980-991.	1.0	1
832	Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism. Annals of Medicine, 2020, 52, 178-190.	1.5	1
833	Trends in diabetes-related complications in Hong Kong, 2001â€“2016: a retrospective cohort study. Cardiovascular Diabetology, 2020, 19, 60.	2.7	24
834	Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis. Endocrine, 2020, 69, 688-691.	1.1	6
835	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Frontiers in Cardiovascular Medicine, 2020, 7, 88.	1.1	82
836	Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodiumâ€“Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes. Diabetes Spectrum, 2020, 33, 165-174.	0.4	12
837	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 394-404.	1.4	16

#	Article	IF	Citations
838	Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials. Cardiovascular Diabetology, 2020, 19, 65.	2.7	15
839	SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?. Diseases (Basel, Switzerland), 2020, 8, 14.	1.0	56
840	Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review. Diabetes Therapy, 2020, 11, 1237-1250.	1.2	6
841	Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. Progress in Cardiovascular Diseases, 2020, 63, 570-584.	1.6	53
842	Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgraduate Medicine, 2020, 132, 337-345.	0.9	13
843	Empagliflozin in Heart Failure. Circulation, 2020, 142, 1028-1039.	1.6	252
844	Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity. Frontiers in Cardiovascular Medicine, 2020, 7, 64.	1.1	39
845	Bioanalytical methods for quantification of novel sodium-glucose cotransporter 2 inhibitors: toward greener approach in separation science. Bioanalysis, 2020, 12, 565-568.	0.6	0
846	Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiology, 2020, 5, 948.	3.0	77
847	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 418-435.	5.5	105
848	Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes. Lancet Diabetes and Endocrinology,the, 2020, 8, 436-446.	5.5	51
849	Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacological Research, 2020, 157, 104781.	3.1	74
850	Cardiovascular outcome trials of glucose-lowering therapies. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 237-249.	0.7	5
851	Diuretic and renal effects of spironolactone and heart failure hospitalizations: a <scp>TOPCAT</scp> Americas analysis. European Journal of Heart Failure, 2020, 22, 1600-1610.	2.9	15
852	SGLT2 Inhibitors in Liver Patients. Clinical Gastroenterology and Hepatology, 2020, 18, 2168-2172.e2.	2.4	19
853	Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 715-722.	1.8	16
854	CREDENCE: Significant Victory for Diabetic Kidney Disease. Trends in Endocrinology and Metabolism, 2020, 31, 391-393.	3.1	5
855	Advances in the management of diabetes: therapies for type 2 diabetes. Postgraduate Medical Journal, 2020, 96, 610-618.	0.9	11

#	Article	IF	Citations
856	Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovascular Diabetology, 2020, 19, 69.	2.7	36
857	Sodiumâ€“Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?. Journal of Clinical Medicine, 2020, 9, 1603.	1.0	12
858	Dapagliflozin, a sodium glucose cotransporter 2 inhibitors, protects cardiovascular function in type-2 diabetic murine model. Journal of Genetics, 2020, 99, 1.	0.4	8
859	Subclinical diastolic dysfunction in diabetes: how to detect, how to manage?. European Heart Journal Cardiovascular Imaging, 2020, 21, 885-886.	0.5	2
860	The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1753-1766.	2.2	31
861	Basic Mechanisms of Diabetic Heart Disease. Circulation Research, 2020, 126, 1501-1525.	2.0	279
862	Clinical evidence and treatment requirements related to heart failure in type 2 diabetes mellitus. Chinese Medical Journal, 2020, 133, 1135-1137.	0.9	2
863	Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment. Expert Opinion on Drug Safety, 2020, 19, 673-682.	1.0	8
864	The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model. Diabetes Care, 2020, 43, 1910-1919.	4.3	30
865	Sodiumâ€“glucose coâ€transporter 2 inhibitors: â€˜a tale of two sistersâ€™, diabetes and heart failure. European Journal of Heart Failure, 2020, 22, 1259-1262.	2.9	2
866	Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 582-593.	5.5	155
867	Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial. Cardiovascular Diabetology, 2020, 19, 85.	2.7	11
868	Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. Cardiovascular Diabetology, 2020, 19, 87.	2.7	23
869	Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials. International Urology and Nephrology, 2020, 52, 1733-1745.	0.6	3
870	Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Therapy, 2020, 11, 1891-1905.	1.2	5
871	New pharmacotherapy for heart failure with reduced ejection fraction. Expert Review of Cardiovascular Therapy, 2020, 18, 405-414.	0.6	4
872	Adjunct therapies in treatment of type 1 diabetes. Journal of Diabetes, 2020, 12, 742-753.	0.8	17
873	Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with typeÂ2 diabetes and established cardiovascular diseases: The placeboâ€controlled doubleâ€blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multiâ€center placeboâ€controlled doubleâ€blind randomized trial. Journal of Diabetes Investigation, 2020, 11, 1551-1563.	1.1	14

#	Article	IF	Citations
874	Consenso de expertos sobre la insuficiencia cardiaca con fracciÃ³n de eyecciÃ³n reducida: mÃ¡s allÃ¡ de las guÃas. Revista Espanola De Cardiologia Suplementos, 2020, 20, 1-46.	0.2	2
875	Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors. JACC Basic To Translational Science, 2020, 5, 632-644.	1.9	419
876	Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006260.	0.9	28
877	Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. Cardiovascular Diabetology, 2020, 19, 95.	2.7	16
878	Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy . Drug Design, Development and Therapy, 2020, Volume 14, 2487-2501.	2.0	22
879	Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus. Diabetology and Metabolic Syndrome, 2020, 12, 45.	1.2	10
880	Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options. Drugs and Aging, 2020, 37, 567-584.	1.3	9
881	Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - A focus on the new hypoglycaemic therapy. Journal of Diabetes and Its Complications, 2020, 34, 107639.	1.2	17
882	Diabetes and coronary artery disease: not just a risk factor. Heart, 2020, 106, 1357-1364.	1.2	13
883	SGLT inhibitors for type 1 diabetes: a finely balanced matter?. Independent Nurse, 2020, 2020, 14-17.	0.0	0
884	Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0234065.	1.1	59
885	Baseline Characteristics of Patients with TypeÂ2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study. Diabetes Therapy, 2020, 11, 1563-1578.	1.2	8
887	Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. Cardiovascular Endocrinology and Metabolism, 2020, 9, 56-59.	0.5	20
888	Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTerold) Tj ETQq1 1 0.784314 rgBT /Over empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment. BMC Endocrine Disorders, 2020, 20, 86.	0.9	10
889	Recent advances in the management of secondary hypertension: chronic kidney disease. Hypertension Research, 2020, 43, 869-875.	1.5	9
890	The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i. Molecules, 2020, 25, 2757.	1.7	16
891	Rationale for Timely Insulin Therapy in TypeÂ2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. Diabetes Therapy, 2020, 11, 1645-1666.	1.2	27
892	Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. Diabetology International, 2020, 11, 245-251.	0.7	13

#	Article	IF	Citations
893	The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovascular Diabetology, 2020, 19, 73.	2.7	58
894	The year in cardiology: heart failure. The year in cardiology 2019.. SA Heart Journal, 2020, 17, .	0.0	0
895	Current understanding of the effect of sodiumâ€“glucose co-transporter-2 inhibitors in Asian patients with diabetes mellitus. Diabetology International, 2020, 11, 242-244.	0.7	5
896	Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1678-1688.	2.2	34
897	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 606-615.	5.5	67
898	Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Diseaseâ€™s â€˜ABCâ€™s Approach. American Journal of Preventive Cardiology, 2020, 2, 100027.	1.3	6
899	An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective. Expert Opinion on Pharmacotherapy, 2020, 21, 1565-1577.	0.9	13
900	Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes. Future Cardiology, 2020, 16, 77-88.	0.5	6
901	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences, 2020, 21, 1907.	1.8	42
902	Effects of Sodiumâ€“Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. Cardiovascular Drugs and Therapy, 2020, 34, 311-321.	1.3	10
903	Invited review. Series: Implications of the recent CVOTs in type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 162, 108112.	1.1	21
904	Role of the Gut in Diabetic Dyslipidemia. Frontiers in Endocrinology, 2020, 11, 116.	1.5	16
905	Toxicity of Metformin and Hypoglycemic Therapies. Advances in Chronic Kidney Disease, 2020, 27, 18-30.	0.6	16
906	Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Research and Clinical Practice, 2020, 162, 108114.	1.1	29
907	Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism: Clinical and Experimental, 2020, 111, 154203.	1.5	88
908	A randomized, openâ€label, active comparator trial assessing the effects of 26â€‰weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1187-1196.	2.2	13
909	SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review. International Journal of Endocrinology, 2020, 2020, 1-11.	0.6	29
910	Noninsulin Therapy for Diabetes. Physician Assistant Clinics, 2020, 5, 153-165.	0.1	0

#	Article	IF	Citations
911	Effects of Liraglutide on CardiovascularÂOutcomes in Patients With Diabetes With or Without HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1128-1141.	1.2	53
912	Diabetes mellitus and chronic kidney disease: A neglected and dangerous liaison. European Journal of Preventive Cardiology, 2020, 27, 1920-1921.	0.8	0
913	Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney. Cardiovascular Diabetology, 2020, 19, 35.	2.7	24
914	SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165770.	1.8	62
915	Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors inÂhyperfiltering people with type 1 diabetes andÂpeople with type 2 diabetes and normal kidney function. Kidney International, 2020, 97, 631-635.	2.6	29
916	Sodiumâ€“glucose cotransporters: Functional properties and pharmaceutical potential. Journal of Diabetes Investigation, 2020, 11, 770-782.	1.1	67
917	SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes. Internal Medicine, 2020, 59, 1535-1539.	0.3	4
918	Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacokinetics, 2020, 59, 981-994.	1.6	13
919	Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes. Hypertension Research, 2020, 43, 876-883.	1.5	13
920	New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. Metabolism: Clinical and Experimental, 2020, 107, 154218.	1.5	10
921	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	3.8	340
922	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation, 2020, 141, 1841-1854.	1.6	96
923	The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial. Journal of Atherosclerosis and Thrombosis, 2020, 27, 1348-1358.	0.9	31
924	The future of diabetic kidney disease management: what to expect from the experimental studies?. Journal of Nephrology, 2020, 33, 1151-1161.	0.9	6
925	Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure. Cardiology, 2020, 145, 321-323.	0.6	1
926	Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine, 2020, 9, 912.	1.0	27
928	Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users. Diabetes Care, 2020, 43, 1209-1218.	4.3	28
929	Heart failure with midâ€range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. ESC Heart Failure, 2020, 7, 381-399.	1.4	31

#	Article	IF	Citations
930	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. Diabetes, Obesity and Metabolism, 2020, 22, 1243-1262.	2.2	13
932	Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial. Postgraduate Medicine, 2020, 132, 314-319.	0.9	0
933	Effectiveness of sodiumâ€glucose coâ€transporterâ€2 inhibitors on ischaemic heart disease. Diabetes, Obesity and Metabolism, 2020, 22, 1197-1206.	2.2	6
934	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. American Journal of Nephrology, 2020, 51, 276-288.	1.4	9
935	The variability of glycated hemoglobin is associated with renal function decline in patients with type 2 diabetes. Therapeutic Advances in Chronic Disease, 2020, 11, 204062231989837.	1.1	20
936	Can the cardiovascular risk reductions observed with empagliflozin in the EMPAâ€REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. Diabetes, Obesity and Metabolism, 2020, 22, 1151-1156.	2.2	8
937	A metabolomicsâ€based molecular pathway analysis of how the sodiumâ€glucose coâ€transporterâ€2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1157-1166.	2.2	40
938	Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney. American Journal of Physiology - Renal Physiology, 2020, 318, F1017-F1029.	1.3	30
939	Gene knockout of the Na⁺-glucose cotransporter SGLT2 in a murine model of acute kidney injury induced by ischemia-reperfusion. American Journal of Physiology - Renal Physiology, 2020, 318, F1100-F1112.	1.3	27
940	Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature. Case Reports in Endocrinology, 2020, 2020, 1-4.	0.2	13
941	Sodiumâ€“glucose coâ€transporterâ€2 inhibitor cardiovascular outcome trials and generalizability to English primary care. Diabetic Medicine, 2020, 37, 1499-1508.	1.2	5
942	Sodiumâ€“glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis. Medical Journal of Australia, 2020, 212, 294.	0.8	3
943	Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update. Diabetes Therapy, 2020, 11, 813-833.	1.2	10
944	Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1152, 122257.	1.2	16
945	SGLT2i: beyond the glucose-lowering effect. Cardiovascular Diabetology, 2020, 19, 98.	2.7	106
946	Promising roles of sodiumâ€“glucose cotransporter 2 inhibitors in heart failure prevention and treatment. Diabetology International, 2020, 11, 252-260.	0.7	4
947	Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. Current Hepatology Reports, 2020, 19, 315-326.	0.4	11
948	A Paradigm Shift in the Treatment of Type 2 Diabetes and Heart Failure. Journal of Atherosclerosis and Thrombosis, 2020, 27, 727-731.	0.9	4

#	Article	IF	Citations
949	Pharmacological therapies to address obesity in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 194-206.	1.2	7
950	Pleiotropic effects of anti-diabetic drugs: A comprehensive review. European Journal of Pharmacology, 2020, 884, 173349.	1.7	19
951	A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882093830.	1.4	55
952	Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812093570.	0.6	9
953	Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovascular Diabetology, 2020, 19, 107.	2.7	18
954	Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. Pharmacological Research, 2020, 160, 105068.	3.1	56
955	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. Journal of the Chinese Medical Association, 2020, 83, 587-621.	0.6	7
956	Review article: the impact of liverâ€directed therapies on the atherogenic risk profile in nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2020, 52, 619-636.	1.9	6
957	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 811-818.	1.9	87
958	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney International, 2020, 98, 839-848.	2.6	193
959	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metabolism Open, 2020, 7, 100039.	1.4	14
960	A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. European Heart Journal, 2020, 41, 3421-3432.	1.0	138
961	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiologyâ€“Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodiumâ€“Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQq0 0 0 rgBT /Overlock 10	4.3	13
962	Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Research and Care, 2020, 8, e001451.	1.2	48
964	Cross talk between exosomes and pancreatic Î²-cells in diabetes. Archives of Physiology and Biochemistry, 2022, 128, 1140-1149.	1.0	2
966	Sodium-glucose co-transporter-2 inhibitors: peculiar â€œhybridâ€•diuretics that protect from target organ damage and cardiovascular events. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1622-1632.	1.1	14
967	Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. Pharmacological Research, 2020, 160, 105052.	3.1	34
968	Sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	2.9	100

#	Article	IF	Citations
969	Diabetes and Heart Failure. Clinics in Geriatric Medicine, 2020, 36, 447-455.	1.0	5
971	Primary Care Physiciansâ€™ Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey. Advances in Therapy, 2020, 37, 3630-3639.	1.3	5
972	Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes. Endocrinology, Diabetes and Metabolism, 2020, 3, e00129.	1.0	6
973	Sodium glucose cotransporterâ€2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function. ESC Heart Failure, 2020, 7, 2784-2796.	1.4	6
974	Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature. Advances in Therapy, 2020, 37, 3450-3462.	1.3	6
975	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology Dialysis Transplantation, 2020, 35, 274-282.	0.4	168
976	The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and wellâ€controlled plasma LDL cholesterol. Diabetes, Obesity and Metabolism, 2020, 22, 988-996.	2.2	11
977	Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry. European Journal of Preventive Cardiology, 2020, 27, 1890-1901.	0.8	24
978	Major Influence of Diabetes on Hospitalization for Heart Failure in Patients With Ischemic Heart Diseases. Circulation Journal, 2020, 84, 382-383.	0.7	0
979	GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection. Advances in Experimental Medicine and Biology, 2020, 1307, 193-212.	0.8	24
980	Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. Diabetes Research and Clinical Practice, 2020, 161, 108054.	1.1	10
981	Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo. Cardiology, 2020, 145, 370-374.	0.6	9
982	Impact on guidelines: The general practitioner point of view. Diabetes Research and Clinical Practice, 2020, 166, 108091.	1.1	4
984	Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 181-187.	1.8	63
985	Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance. Diabetic Medicine, 2020, 37, 1316-1325.	1.2	8
986	Evaluating glucoseâ€lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial. Diabetes, Obesity and Metabolism, 2020, 22, 1231-1242.	2.2	13
987	Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy. Circulation, 2020, 141, 1704-1719.	1.6	127
988	Post-Transplantation Diabetes Mellitus. Diabetes Therapy, 2020, 11, 779-801.	1.2	29

#	Article	IF	Citations
990	Link between body weight changes and metabolic parameters in drugs naÃ¨ve subjects with type 2 diabetes treated with canagliflozin monotherapy. Hospital Practice (1995), 2020, 48, 68-74.	0.5	3
991	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodiumâ€glucose coâ€transporterâ€2 inhibitors. Journal of Clinical Hypertension, 2020, 22, 562-571.	1.0	24
992	SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?. Journal of Nephrology, 2020, 33, 985-994.	0.9	13
993	Treatment strategies for hypertension in patients with type 1 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 1241-1252.	0.9	9
994	Effects of the dual sodiumâ€“glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. British Journal of Clinical Pharmacology, 2020, 86, 1346-1356.	1.1	35
995	Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1câ€‰<â€‰6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study. Cardiovascular Diabetology, 2020, 19, 21.	2.7	12
996	Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovascular Diabetology, 2020, 19, 19.	2.7	90
997	Differentiating the Sodiumâ€Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 222-229.	1.3	19
998	Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. Lancet Diabetes and Endocrinology,the, 2020, 8, 192-205.	5.5	100
999	Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nature Reviews Cardiology, 2020, 17, 585-607.	6.1	353
1000	Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Expert Opinion on Drug Safety, 2020, 19, 243-256.	1.0	19
1001	Cardiovascular and renal benefits of dapagliflozin in patients with short and longâ€standing type 2 diabetes: Analysis from the DECLAREâ€TIMI 58 trial. Diabetes, Obesity and Metabolism, 2020, 22, 1122-1131.	2.2	16
1002	GangrÃ¨ne de Fournier. RÃ1e du diabÃ¨te. Quelle responsabilitÃ© pour les inhibiteurs de SGLT2Â?. Medecine Des Maladies Metaboliques, 2020, 14, 21-28.	0.1	1
1003	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circulation Research, 2020, 126, 679-704.	2.0	121
1004	Dapagliflozin in patients with heart failure and reduced ejection fraction. Internal and Emergency Medicine, 2020, 15, 515-517.	1.0	8
1005	MÃ©dicaments hypoglycÃ©miants dans le diabÃ¨te de typeÂ2 et nÃ©phroprotectionÂ: un nouvel axe thÃ©rapeutiqueÂ?. Medecine Des Maladies Metaboliques, 2020, 14, 77-84.	0.1	0
1007	Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention. American Journal of Cardiovascular Drugs, 2020, 20, 419-429.	1.0	3
1008	Costâ€effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Diabetes, Obesity and Metabolism, 2020, 22, 1047-1055.	2.2	6

#	Article	IF	Citations
1009	Sodiumâ€glucose linked transporterâ€2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk. Diabetes, Obesity and Metabolism, 2020, 22, 1024-1034.	2.2	6
1010	Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovascular Diabetology, 2020, 19, 13.	2.7	42
1011	Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodiumâ€“glucose cotransporter 2 inhibitors. European Journal of Heart Failure, 2020, 22, 618-628.	2.9	76
1012	Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Classes of Glucose-Lowering Medications on Renal Outcome in Type 2 Diabetes. Mayo Clinic Proceedings, 2020, 95, 265-273.	1.4	24
1013	SGLT2 Inhibitors and the Risk of Hospitalization for Fournierâ€™s Gangrene: A Nested Caseâ€“Control Study. Diabetes Therapy, 2020, 11, 711-723.	1.2	15
1014	Innate immunity in diabetic kidney disease. Nature Reviews Nephrology, 2020, 16, 206-222.	4.1	273
1015	Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel. Indian Heart Journal, 2020, 72, 7-13.	0.2	2
1016	Comparative effects of sulphonylureas, dipeptidyl peptidaseâ€4 inhibitors and sodiumâ€glucose coâ€transporterâ€2 inhibitors added to metformin monotherapy: a propensityâ€score matched cohort study in UK primary care. Diabetes, Obesity and Metabolism, 2020, 22, 847-856.	2.2	6
1017	Impact of sodiumâ€“glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria. Diabetology and Metabolic Syndrome, 2020, 12, 4.	1.2	8
1018	Mechanisms of Cardiorenal Effects of Sodium-Glucose CotransporterÂ2ÂInhibitors. Journal of the American College of Cardiology, 2020, 75, 422-434.	1.2	302
1019	Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2ÂInhibitors. Journal of the American College of Cardiology, 2020, 75, 435-447.	1.2	65
1020	Nanotherapeutic Shots through the Heart of Plaque. ACS Nano, 2020, 14, 1236-1242.	7.3	24
1021	Effect of hyperglycaemia and diabetes on acute myocardial ischaemiaâ€“reperfusion injury and cardioprotection by ischaemic conditioning protocols. British Journal of Pharmacology, 2020, 177, 5312-5335.	2.7	68
1022	Liraglutide as addâ€on to sodiumâ€glucose coâ€transporterâ€2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRAâ€ADD2SGLT2i, a 26â€week, randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 929-937.	2.2	29
1023	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation, 2020, 141, 1227-1234.	1.6	241
1024	Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 161-174.	1.1	105
1025	Association of blood glucose and renal end points in advanced diabetic kidney disease. Diabetes Research and Clinical Practice, 2020, 161, 108011.	1.1	4
1026	Exposureâ€“response relationships for the sodiumâ€glucose coâ€transporterâ€2 inhibitor dapagliflozin with regard to renal risk markers. Diabetes, Obesity and Metabolism, 2020, 22, 916-921.	2.2	5

#	Article	IF	Citations
1027	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. Circulation, 2020, 141, 843-862.	1.6	62
1028	Sodiumâ€Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e014908.	1.6	161
1029	Osmotic diuresis by SGLT2 inhibition stimulates vasopressinâ€induced water reabsorption to maintain body fluid volume. Physiological Reports, 2020, 8, e14360.	0.7	70
1030	Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction. ESC Heart Failure, 2020, 7, 604-615.	1.4	6
1031	Dulaglutide: A Review in Type 2 Diabetes. Drugs, 2020, 80, 197-208.	4.9	19
1032	Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52â€‰weeks as addâ€on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallelâ€design, openâ€label, Phase 3 trial. Diabetes, Obesity and Metabolism, 2020, 22, 957-968.	2.2	4
1033	Association of Prediabetes With CKD Progression and Adverse Cardiovascular Outcomes: An Analysis of the CRIC Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1772-e1780.	1.8	23
1034	Use of sodiumâ€“glucose coâ€transporterâ€2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. European Journal of Heart Failure, 2020, 22, 604-617.	2.9	33
1035	Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult. American Journal of Medicine, 2020, 133, e422-e424.	0.6	3
1036	Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Advances in Experimental Medicine and Biology, 2020, 1307, 213-230.	0.8	13
1037	GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice. Clinical Therapeutics, 2020, 42, e1-e12.	1.1	15
1038	Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps. Journal of the American College of Cardiology, 2020, 75, 539-555.	1.2	58
1039	Prevention of cardiac allograft vasculopathy â€“ A new possible indication for SGLT-2 inhibitors?. Medical Hypotheses, 2020, 137, 109594.	0.8	6
1040	Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, i13-i23.	0.4	26
1041	Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Cardiovascular Diabetology, 2020, 19, 6.	2.7	65
1042	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. Current Vascular Pharmacology, 2020, 18, 125-138.	0.8	9
1043	Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor. Endocrine Journal, 2020, 67, 501-507.	0.7	22
1045	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Canadian Journal of Cardiology, 2020, 36, 159-169.	0.8	89

#	Article	IF	Citations
1047	Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM. Journal of the Endocrine Society, 2020, 4, bvaa037.	0.1	18
1048	Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naÃ¯ve patients with type 2 diabetes: initial triple study. BMJ Open Diabetes Research and Care, 2020, 8, e000807.	1.2	13
1049	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. CJC Open, 2020, 2, 402-415.	0.7	6
1050	Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria â€“ A double blind randomized placebo-controlled crossover trial. Journal of Diabetes and Its Complications, 2020, 34, 107590.	1.2	24
1051	Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats. Scientific Reports, 2020, 10, 7238.	1.6	23
1052	Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 610-618.	0.5	17
1053	Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential. Cardiovascular Drugs and Therapy, 2020, 34, 419-436.	1.3	16
1054	Diabetic Agents, From Metformin toÂSGLT2 Inhibitors and GLP1ÂReceptorÂAgonists. Journal of the American College of Cardiology, 2020, 75, 1956-1974.	1.2	48
1055	Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2. Advances in Experimental Medicine and Biology, 2020, 1307, 129-152.	0.8	31
1057	Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. ESC Heart Failure, 2020, 7, 1168-1177.	1.4	14
1058	Effects of ertugliflozin on renal function over 104Âweeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia, 2020, 63, 1128-1140.	2.9	33
1059	Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus. Heart and Vessels, 2020, 35, 1218-1226.	0.5	8
1061	Adverse Changes in HbA1c, Body Weight and Insulin Use in People with TypeÂ1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme. Diabetes Therapy, 2020, 11, 1135-1146.	1.2	3
1062	Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects. Drugs and Aging, 2020, 37, 399-409.	1.3	20
1063	Relationship between renal capacity to reabsorb glucose and renal status in patients with diabetes. Diabetes and Metabolism, 2020, 46, 488-495.	1.4	1
1064	Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 237-239.	1.8	3
1065	Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Progress in Cardiovascular Diseases, 2020, 63, 249-262.	1.6	41
1066	Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1. Redox Biology, 2020, 32, 101527.	3.9	47

#	Article	IF	Citations
1067	The present and future scope of realâ€world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?. Diabetes, Obesity and Metabolism, 2020, 22, 21-34.	2.2	16
1068	Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. Diabetes, Obesity and Metabolism, 2020, 22, 32-45.	2.2	29
1069	What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?. Diabetes, Obesity and Metabolism, 2020, 22, 55-68.	2.2	20
1070	ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release. Diabetes, Obesity and Metabolism, 2020, 22, 5-11.	2.2	12
1071	Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines. Diabetes, Obesity and Metabolism, 2020, 22, 33-42.	2.2	7
1072	Dedicated kidney diseaseâ€focused outcome trials with sodiumâ€glucose cotransporterâ€2 inhibitors: Lessons from CREDENCE and expectations from DAPAâ€HF, DAPAâ€CKD, and EMPAâ€KIDNEY. Diabetes, Obesity and Metabolism, 2020, 22, 46-54.	2.2	36
1073	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLAREâ€TIMI 58 study. Diabetes, Obesity and Metabolism, 2020, 22, 1357-1368.	2.2	26
1074	Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A metaâ€analysis with metaâ€regression. Diabetes, Obesity and Metabolism, 2020, 22, 1397-1405.	2.2	27
1075	Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis. Diabetes Care, 2020, 43, 1157-1163.	4.3	38
1076	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€“ 2020 Executive Summary. Endocrine Practice, 2020, 26, 107-139.	1.1	410
1077	Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice. Expert Review of Clinical Pharmacology, 2020, 13, 545-551.	1.3	1
1078	The Place of Sulfonylureas in Guidelines: Why Are There Differences?. Diabetes Therapy, 2020, 11, 5-14.	1.2	9
1079	Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPKâ€“mTOR Interplay. Cardiovascular Drugs and Therapy, 2020, 34, 443-461.	1.3	59
1080	Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study. Journal of Diabetes Research, 2020, 2020, 1-7.	1.0	3
1081	Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. Clinical Pharmacokinetics, 2020, 59, 949-965.	1.6	32
1082	Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients. Journal of Cardiology, 2020, 76, 123-131.	0.8	27
1083	Cardiovascular protection with sodiumâ€glucose coâ€transporterâ€2 inhibitors in type 2 diabetes: Does it apply to all patients?. Diabetes, Obesity and Metabolism, 2020, 22, 1481-1495.	2.2	17
1084	Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline. Cardiovascular Diabetology, 2020, 19, 38.	2.7	9

#	Article	IF	Citations
1085	Albuminuriaâ€lowering effect of sodiumâ€glucose cotransporter 2 inhibitors could be partly attributable to the attenuation of tubular damage in type 2 diabetic patients. Diabetes/Metabolism Research and Reviews, 2020, 36, e3327.	1.7	2
1088	Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis. International Journal of Cardiology, 2020, 310, 147-154.	0.8	5
1089	Exposureâ€“response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials. British Journal of Clinical Pharmacology, 2020, 86, 2192-2203.	1.1	7
1090	Myocardium Metabolism in Physiological and Pathophysiological States: Implications of Epicardial Adipose Tissue and Potential Therapeutic Targets. International Journal of Molecular Sciences, 2020, 21, 2641.	1.8	20
1091	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Failure Reviews, 2021, 26, 1421-1435.	1.7	26
1092	Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. American Heart Journal, 2020, 224, 47-53.	1.2	44
1093	Risk stratification tools for heart failure in the diabetes clinic. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1070-1079.	1.1	7
1094	An evaluation of empagliflozin and itâ€™s applicability to hypertension as a therapeutic option. Expert Opinion on Pharmacotherapy, 2020, 21, 1157-1166.	0.9	4
1095	Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes. Expert Review of Cardiovascular Therapy, 2020, 18, 187-199.	0.6	1
1096	Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2020, 15, 147-157.	1.2	12
1097	Second revolution in cardiovascular prevention. Journal of the Chinese Medical Association, 2020, 83, 327-336.	0.6	6
1098	Selected Abstracts from Pharmacology 2019. British Journal of Pharmacology, 2020, 177, 2487-2654.	2.7	1
1099	Prognosis of patients eligible for dapagliflozin in acute heart failure. European Journal of Clinical Investigation, 2020, 50, e13245.	1.7	3
1100	Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2475-2486.	1.8	23
1101	The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1342-1351.	2.2	5
1102	Acute Effects of Insulin on Cardiac Function in Patients with Diabetes Mellitus: Clinical Applicability and Feasibility. International Journal of Endocrinology, 2020, 2020, 1-8.	0.6	0
1103	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation, 2020, 141, e779-e806.	1.6	157
1104	Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagonâ€Like Peptideâ€1 Receptor Agonist and Sodiumâ€Glucose Cotransporterâ€2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e015323.	1.6	22

#	Article	IF	Citations
1105	Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovascular Diabetology, 2020, 19, 46.	2.7	43
1106	Use of sodiumâ€“glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. Cmaj, 2020, 192, E351-E360.	0.9	53
1107	Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 285-288.	2.2	23
1108	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. Journal of Clinical Medicine, 2020, 9, 947.	1.0	85
1109	Time to Rethink Reducing Cardiovascular Risk: Are We Ready?. Canadian Journal of Diabetes, 2020, 44, 1-3.	0.4	2
1110	Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress. Antioxidants and Redox Signaling, 2021, 34, 551-571.	2.5	44
1111	Improving exercise capacity and quality of life using nonâ€invasive heart failure treatments: evidence from clinical trials. European Journal of Heart Failure, 2021, 23, 92-113.	2.9	67
1112	Empagliflozin improves endothelial and cardiomyocyte functionÂin human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gǐ± oxidation. Cardiovascular Research, 2021, 117, 495-507.	1.8	167
1113	Rodent models of diabetic kidney disease: human translatability and preclinical validity. Drug Discovery Today, 2021, 26, 200-217.	3.2	5
1114	Comparative effectiveness of dapagliflozin vs <scp>DPP</scp>â€4 inhibitors on a composite endpoint of <scp>HbA1c</scp>, body weight and blood pressure reduction in the real world. Diabetes/Metabolism Research and Reviews, 2021, 37, e3353.	1.7	17
1115	Sodiumâ€“glucose cotransporterÂ2 inhibitors represent a paradigm shift in the prevention of heart failure in typeÂ2 diabetes patients. Journal of Diabetes Investigation, 2021, 12, 6-20.	1.1	17
1116	A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Annals of Pharmacotherapy, 2021, 55, 65-79.	0.9	54
1117	Sodiumâ€“glucose cotransporterÂ2 inhibitors compared with other glucoseâ€lowering drugs in Japan: Subanalyses of the CVDâ€REAL 2 Study. Journal of Diabetes Investigation, 2021, 12, 67-73.	1.1	7
1118	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. Primary Care Diabetes, 2021, 15, 31-51.	0.9	27
1119	Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease. Annals of Pharmacotherapy, 2021, 55, 252-260.	0.9	1
1120	Blood pressure after treatment with sodiumâ€“glucose cotransporterÂ2 inhibitors influences renal composite outcome: Analysis using propensity scoreâ€matched models. Journal of Diabetes Investigation, 2021, 12, 74-81.	1.1	8
1121	Sodium-glucose co-transporter 2 inhibitors and heart failureâ€”the present and the future. Heart Failure Reviews, 2021, 26, 953-960.	1.7	1
1122	Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with typeÂ2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIMEâ€V study). Journal of Diabetes Investigation, 2021, 12, 200-206.	1.1	14

#	Article	IF	Citations
1123	Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 1839-1859.	0.6	30
1124	A Review of the Renoprotective Effects of Novel Antidiabetic Agents. Journal of Pharmacy Practice, 2021, 34, 141-148.	0.5	6
1125	Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus. Diabetology International, 2021, 12, 247-253.	0.7	8
1126	Changing Fields-Diabetes Medications Invading the Cardiovascular Space. Current Problems in Cardiology, 2021, 46, 100736.	1.1	1
1127	Realâ€world use of cardioprotective glucoseâ€lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019. Diabetes, Obesity and Metabolism, 2021, 23, 520-529.	2.2	19
1128	Management of postâ€transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transplant International, 2021, 34, 27-48.	0.8	57
1129	Organ protection beyond glycaemic control with SGLT2 inhibitors. Nature Reviews Nephrology, 2021, 17, 223-224.	4.1	4
1130	Use of sodiumâ€glucose coâ€transporterâ€2 inhibitors in <scp>Asian</scp> patients with type 2 diabetes and kidney disease: An <scp>Asian</scp> perspective and expert recommendations. Diabetes, Obesity and Metabolism, 2021, 23, 299-317.	2.2	20
1131	Sodiumâ€“Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Breast Cancer Among Women With Type 2 Diabetes. Diabetes Care, 2021, 44, e9-e11.	4.3	6
1132	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes and Endocrinology,the, 2021, 9, 46-52.	5.5	103
1133	Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors. Heart Failure Reviews, 2021, 26, 643-652.	1.7	6
1134	Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor) Tj ETQq1 1 0.784314 rgBT /O	1.0	23
1135	Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 322, 183-190.	0.8	31
1136	Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications. International Urology and Nephrology, 2021, 53, 291-299.	0.6	6
1137	SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. Journal of Human Hypertension, 2021, 35, 12-25.	1.0	30
1138	Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Diseaseâ€”Pathogenesis and Pharmacological Treatment Options. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 25-39.	1.0	13
1139	Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis. American Journal of Cardiovascular Drugs, 2021, 21, 321-330.	1.0	10
1140	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. International Journal of Cardiology, 2021, 324, 165-172.	0.8	6

#	Article	IF	Citations
1141	Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis. Primary Care Diabetes, 2021, 15, 227-233.	0.9	0
1142	PrevenciÃ³n de ictus en pacientes con diabetes mellitus tipo 2 o prediabetes. Recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad EspaÃ±ola de NeurologÃa. NeurologÃa, 2021, 36, 305-323.	0.3	5
1143	Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nature Reviews Nephrology, 2021, 17, 65-77.	4.1	86
1144	Efficacy and safety of a sodiumâ€glucose coâ€transporterâ€2 inhibitor versus placebo as an addâ€on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidaseâ€4 inhibitor: a systematic review and metaâ€analysis of randomised controlled trials. Diabetic Medicine, 2021, 38, e14409.	1.2	2
1145	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. Diabetes, Obesity and Metabolism, 2021, 23, 276-280.	2.2	65
1146	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 148.	3.0	625
1147	Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	12
1148	GLP-1 receptor agonists in the treatment of type 2 diabetes â€“ state-of-the-art. Molecular Metabolism, 2021, 46, 101102.	3.0	518
1149	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. Circulation, 2021, 143, 310-321.	1.6	168
1150	Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study. Internal and Emergency Medicine, 2021, 16, 895-903.	1.0	6
1151	SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis. Journal of Diabetes and Its Complications, 2021, 35, 107761.	1.2	3
1152	Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials. Primary Care Diabetes, 2021, 15, 208-211.	0.9	29
1153	Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes. JACC: Cardiovascular Imaging, 2021, 14, 503-504.	2.3	9
1154	<scp>Sodiumâ€glucose coâ€transporterâ€2</scp> inhibitors with and without metformin: A metaâ€analysis of cardiovascular, kidney and mortality outcomes. Diabetes, Obesity and Metabolism, 2021, 23, 382-390.	2.2	40
1155	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 298-309.	1.6	193
1156	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	13.9	1,080
1157	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	13.9	662
1158	Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. Canadian Journal of Diabetes, 2021, 45, 291-302.	0.4	9

#	Article	IF	Citations
1159	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation, 2021, 143, 438-448.	1.6	85
1160	The Association between Urinary Glucose and Renal Uric Acid Excretion in Non-diabetic Patients with Stage 1-2 Chronic Kidney Disease. Endocrine Research, 2021, 46, 28-36.	0.6	2
1161	Effectiveness and safety of sodiumâ€glucose coâ€transporterâ€2 inhibitors compared with dipeptidyl peptidaseâ€4 inhibitors in older adults with type 2 diabetes: A nationwide populationâ€based study. Diabetes, Obesity and Metabolism, 2021, 23, 682-691.	2.2	46
1162	Targeting Mitochondria-Inflammation Circuit by Î²-Hydroxybutyrate Mitigates HFpEF. Circulation Research, 2021, 128, 232-245.	2.0	190
1163	Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital. Hormones, 2021, 20, 369-376.	0.9	5
1164	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. European Journal of Heart Failure, 2021, 23, 68-78.	2.9	79
1165	Impact of diabetes mellitus on mortality rates and outcomes in myocardial infarction. Diabetes and Metabolism, 2021, 47, 101211.	1.4	24
1166	SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Failure Reviews, 2021, 26, 623-642.	1.7	41
1167	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. American Journal of Kidney Diseases, 2021, 77, 23-34.e1.	2.1	38
1168	Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus. American Journal of Hypertension, 2021, 34, 404-413.	1.0	7
1169	Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (<scp>TRSâ€HF_{DM}</scp>) in patients in the <scp>ACCORD</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 782-790.	2.2	19
1170	Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. Nephrology, 2021, 26, 377-390.	0.7	10
1171	Mitochondrial Ca2+, redox environment and ROS emission in heart failure: Two sides of the same coin?. Journal of Molecular and Cellular Cardiology, 2021, 151, 113-125.	0.9	24
1172	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. Postgraduate Medicine, 2021, 133, 125-139.	0.9	8
1173	Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel. Diabetes Research and Clinical Practice, 2021, 172, 108535.	1.1	14
1174	Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications. Diabetes Therapy, 2021, 12, 87-105.	1.2	17
1175	Characterization and implications of the initial estimated glomerular filtration rate â€˜dipâ€™ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney International, 2021, 99, 750-762.	2.6	111
1176	Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. Nature Reviews Cardiology, 2021, 18, 291-304.	6.1	141

#	Article	IF	Citations
1177	Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annual Review of Physiology, 2021, 83, 503-528.	5.6	170
1178	Sodium-Glucose Co-TransporterÂ2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials. Diabetes Therapy, 2021, 12, 55-70.	1.2	22
1179	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 385-394.	2.0	110
1180	Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States. Advances in Therapy, 2021, 38, 594-606.	1.3	5
1181	Randomized Trial of Empagliflozin in Nondiabetic Patients With HeartÂFailure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 243-255.	1.2	280
1182	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2021, 77, 94-109.	2.1	88
1183	Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus. Circulation, 2021, 143, 510-512.	1.6	46
1184	Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study. American Journal of Medicine, 2021, 134, 606-613.e6.	0.6	6
1185	Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area: A retrospective cohort study. Diabetes Research and Clinical Practice, 2021, 171, 108616.	1.1	2
1186	The role of sodium glucose co-transporter inhibitors in heart failure prevention. Journal of Diabetes and Its Complications, 2021, 35, 107811.	1.2	3
1187	Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes. Value in Health, 2021, 24, 227-235.	0.1	0
1188	The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study. European Heart Journal, 2021, 42, 1728-1738.	1.0	53
1189	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and allâ€cause mortality: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 1052-1056.	2.2	32
1190	Evaluation of dapagliflozin in the treatment of heart failure. Future Cardiology, 2021, 17, 415-425.	0.5	3
1191	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2021. Diabetes Care, 2021, 44, S125-S150.	4.3	359
1192	Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVIDâ€19: Design and rationale for the DAREâ€19 study. Diabetes, Obesity and Metabolism, 2021, 23, 886-896.	2.2	40
1193	Development and Internal Validation of A Prediction Tool To Assist Clinicians Selecting Second-Line Therapy Following Metformin Monotherapy For Type 2 Diabetes. Endocrine Practice, 2021, 27, 334-341.	1.1	2
1194	Novel management of diabetes in kidney transplantation. Current Opinion in Nephrology and Hypertension, 2021, 30, 5-13.	1.0	6

#	Article	IF	Citations
1195	Updated metaâ€analysis assessing the risk of amputation with sodiumâ€glucose coâ€transporterâ€2 inhibitors in the hallmark cardiovascular and renal outcome trials. Diabetes, Obesity and Metabolism, 2021, 23, 1063-1065.	2.2	6
1196	Do sodiumâ€“glucose cotransporterÂ2 inhibitors lead to fracture risk? A pharmacovigilance realâ€world study. Journal of Diabetes Investigation, 2021, 12, 1400-1407.	1.1	10
1197	Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2021, 44, 595-603.	4.3	5
1198	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. Circulation, 2021, 143, 1002-1013.	1.6	174
1199	External validity of type 2 diabetes clinical trials on cardiovascular outcomes for a multimorbid population. Diabetes, Obesity and Metabolism, 2021, 23, 971-979.	2.2	2
1200	Incidence of adverse cardiovascular events in typeÂ2 diabetes mellitus patients after initiation of glucoseâ€lowering agents: A populationâ€based community study from the Shizuoka Kokuho database. Journal of Diabetes Investigation, 2021, 12, 1452-1461.	1.1	9
1201	Latin American Expert Consensus for Comprehensive Management of Type 2 Diabetes from a Metabolicâ€“Cardioâ€“Renal Perspective for the Primary Care Physician. Diabetes Therapy, 2021, 12, 1-20.	1.2	2
1202	The Predicament of Large Numbers of Observations and How We Got There: Critical Review. journal of applied laboratory medicine, The, 2021, 6, 496-509.	0.6	1
1203	Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPAâ€HF Study Population: A Mathematical Modeling Analysis. Journal of Clinical Pharmacology, 2021, 61, 636-648.	1.0	9
1204	Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomesâ€”Systematic review and meta-analysis of randomized placebo-controlled trials. American Heart Journal, 2021, 232, 10-22.	1.2	75
1205	Safety and effectiveness of tofogliflozin in Japanese patients with typeÂ2 diabetes mellitus treated in realâ€world clinical practice: Results of a 36â€month postâ€marketing surveillance study (Jâ€STEP/LT). Journal of Diabetes Investigation, 2021, 12, 184-199.	1.1	8
1206	Glucoseâ€lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology. Diabetes/Metabolism Research and Reviews, 2021, 37, e3416.	1.7	7
1207	Renal outcomes and allâ€cause death associated with sodiumâ€glucose coâ€transporterâ€2 inhibitors versus other glucoseâ€lowering drugs (<scp>CVDâ€REAL</scp> 3 <scp>Korea</scp>). Diabetes, Obesity and Metabolism, 2021, 23, 455-466.	2.2	15
1208	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Diabetes, 2021, 70, 1-16.	0.3	53
1209	Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes. International Journal of Cardiovascular Imaging, 2021, 37, 517-527.	0.7	18
1210	A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor. Diabetes Therapy, 2021, 12, 431-440.	1.2	2
1211	Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease. Journal of Diabetes and Its Complications, 2021, 35, 107774.	1.2	6
1212	Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience. Primary Care Diabetes, 2021, 15, 283-288.	0.9	7

#	Article	IF	Citations
1213	Asymptomatic left ventricular dysfunction in patients with type 2 diabetes free of cardiovascular disease and its relationship with clinical characteristics: The <scp>DIACAR</scp> cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 434-443.	2.2	7
1214	Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes. Drug and Therapeutics Bulletin, 2021, 59, 22-23.	0.3	2
1215	Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients. Annals of Pharmacotherapy, 2021, 55, 496-508.	0.9	17
1216	Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodiumâ€“Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Diabetes Technology and Therapeutics, 2021, 23, 110-119.	2.4	11
1217	Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure. Clinical Diabetes, 2021, 39, 105-116.	1.2	0
1218	Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study. Endocrinology, Diabetes and Metabolism, 2021, 4, e00183.	1.0	23
1219	Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. CKJ: Clinical Kidney Journal, 2021, 14, 1396-1402.	1.4	18
1220	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	1.0	3,048
1221	SGLT2 inhibitors, sodium and off-target effects: an overview. Journal of Nephrology, 2021, 34, 673-680.	0.9	18
1222	Canagliflozin and cardiovascular outcomes in Type 2 diabetes. Future Cardiology, 2021, 17, 39-48.	0.5	1
1223	Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney International, 2021, 99, 256-266.	2.6	46
1224	Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?. Expert Opinion on Pharmacotherapy, 2021, 22, 163-165.	0.9	3
1225	Sodiumâ€glucose coâ€transporterâ€2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 252-257.	2.2	12
1226	Pharmacotherapeutic options for prediabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 45-54.	0.9	3
1227	Lower cardiorenal risk with <scp>sodiumâ€glucose</scp> cotransporterâ€2 inhibitors versus dipeptidyl peptidaseâ€4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes, Obesity and Metabolism, 2021, 23, 75-85.	2.2	43
1228	Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. Heart Failure Reviews, 2021, 26, 337-345.	1.7	23
1229	Potential unrealized mortality benefit of glucagonâ€like peptideâ€1 receptor agonists and sodiumâ€glucose coâ€transportâ€2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program. Diabetes, Obesity and Metabolism, 2021, 23, 97-105.	2.2	1
1230	Cardiorenal outcomes with dapagliflozin by baseline glucoseâ€lowering agents: Post hoc analyses from <scp>DECLAREâ€TIMI</scp> 58. Diabetes, Obesity and Metabolism, 2021, 23, 29-38.	2.2	28

#	Article	IF	Citations
1231	A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease. Journal of Pharmacy Practice, 2021, 34, 428-437.	0.5	11
1232	The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 2021, 42, 1199-1202.	1.0	24
1233	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. Trends in Cardiovascular Medicine, 2021, 31, 49-56.	2.3	12
1234	Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. Trends in Cardiovascular Medicine, 2021, 31, 101-108.	2.3	5
1235	Urinary chloride concentration and progression of chronic kidney disease: results from the KoreaN cohort study for Outcomes in patients With Chronic Kidney Disease. Nephrology Dialysis Transplantation, 2021, 36, 673-680.	0.4	6
1236	Chronic complications of diabetes. , 2021, , 71-90.		0
1237	To Heart â€œFailâ€•or Not? The Expanding Role of SGLT2 Inhibitors. ADCES in Practice, 2021, 9, 28-33.	0.2	1
1238	Peripheral artery disease, lower limb revascularization, and amputation in diabetes patients with and without coronary artery disease: a cohort study from the Western Denmark Heart Registry. BMJ Open Diabetes Research and Care, 2021, 9, e001803.	1.2	16
1239	Novel Insights Into Molecular Mechanism of Mitochondria in Diabetic Cardiomyopathy. Frontiers in Physiology, 2020, 11, 609157.	1.3	13
1240	Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom. International Journal of Heart Failure, 2021, 3, 205.	0.9	4
1241	A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodiumâ€glucose coâ€transporterâ€2 inhibitor tofogliflozin. Diabetes, Obesity and Metabolism, 2021, 23, 1092-1100.	2.2	2
1242	Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics, 2021, 11, 4502-4515.	4.6	61
1243	Reverse Cardiac Remodeling and ARNI Therapy. Current Heart Failure Reports, 2021, 18, 71-83.	1.3	19
1244	NLRP3 inflammasome as a key driver of vascular disease. Cardiovascular Research, 2022, 118, 372-385.	1.8	84
1245	The Pleiotropic Effects of SGLT2ÂInhibitors. Journal of the American College of Cardiology, 2021, 77, 256-258.	1.2	6
1246	Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review. Nutrients, 2021, 13, 257.	1.7	24
1247	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease. Annals of Pharmacotherapy, 2021, 55, 1267-1275.	0.9	3
1249	Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease. Scientific Reports, 2021, 11, 951.	1.6	4

#	Article	IF	Citations
1250	Prevention of Cardiovascular Disease. , 2021, , 33-54.		0
1251	Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure. British Journal of Cardiology, 2021, , .	0.7	1
1252	Diabetes care. , 2021, , 19-66.		1
1253	Sodium–glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. Journal of Hypertension, 2021, 39, 1090-1097.	0.3	22
1254	Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein and Cell, 2022, 13, 336-359.	4.8	74
1255	SGLT2 inhibitors: a narrative review of efficacy and safety. Journal of Osteopathic Medicine, 2021, 121, 229-239.	0.4	18
1256	Treatment of Diabetic Kidney Disease: Current and Future. Diabetes and Metabolism Journal, 2021, 45, 11-26.	1.8	98
1257	Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis. Journal of Cardiovascular Pharmacology, 2021, 77, 34-37.	0.8	11
1258	Sodiumâ€“glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 17.	2.7	27
1259	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy. Frontiers in Physiology, 2020, 11, 612722.	1.3	11
1260	A 52â€week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The <scp>Nâ€ISM</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 811-821.	2.2	12
1261	Association between sodiumâ€“glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace, 2022, 24, 20-30.	0.7	39
1262	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2022, 29, 275-300.	0.8	11
1263	Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 351-359.	1.8	13
1264	Effect of sodiumâ€“glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovascular Diabetology, 2021, 20, 25.	2.7	27
1265	Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes. Therapeutic Advances in Drug Safety, 2021, 12, 204209862199770.	1.0	9
1266	Diabetes, Lipids, and CV Risk. Current Atherosclerosis Reports, 2021, 23, 8.	2.0	6
1267	Empagliflozin in Patients with Type 2 Diabetes: A Meta-Analysis of Cardiovascular Remodeling. Advances in Clinical Medicine, 2021, 11, 469-475.	0.0	0

#	Article	IF	Citations
1268	DNA aptamer raised against receptor for advanced glycation end products suppresses renal tubular damage and improves insulin resistance in diabetic mice. Diabetes and Vascular Disease Research, 2021, 18, 147916412199053.	0.9	5
1269	SGLT â€2 inhibitors and the risk of hospitalization for communityâ€acquired pneumonia: A populationâ€based cohort study. Pharmacoepidemiology and Drug Safety, 2021, 30, 740-748.	0.9	6
1270	Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovascular Diabetology, 2021, 20, 14.	2.7	74
1271	Sodiumâ€“glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemiaâ€“reperfusion injury: a meta-analysis. Diabetologia, 2021, 64, 737-748.	2.9	20
1272	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. European Heart Journal, 2021, 42, 4887-4890.	1.0	11
1273	Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. International Journal of Molecular Sciences, 2021, 22, 660.	1.8	15
1274	SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study. Current Cardiology Reviews, 2021, 16, 258-265.	0.6	7
1275	Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction. Korean Circulation Journal, 2021, 51, 251.	0.7	16
1276	SGLT2 inhibitors â€“ A new silver bullet. Hellenic Journal of Cardiology, 2021, 62, 99-100.	0.4	0
1277	Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2021, 33, 33-40.	0.1	1
1278	Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity. Lipids in Health and Disease, 2021, 20, 5.	1.2	31
1279	Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model. Journal of the American Heart Association, 2021, 10, e017483.	1.6	32
1280	The costâ€effectiveness of dapagliflozin in treating highâ€risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLAREâ€TIMI 58 trial. Diabetes, Obesity and Metabolism, 2021, 23, 1020-1029.	2.2	19
1282	Comparative Effectiveness and Safety of Sodiumâ€“Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care, 2021, 44, 826-835.	4.3	66
1283	Device-based treatment options for heart failure with preserved ejection fraction. Heart Failure Reviews, 2021, 26, 749-762.	1.7	16
1284	Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Therapeutic Advances in Drug Safety, 2021, 12, 204209862198913.	1.0	46
1285	Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110449.	1.4	0
1286	Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study. BMJ Open Diabetes Research and Care, 2021, 9, e001765.	1.2	9

#	Article	IF	Citations
1287	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ, The, 2021, 372, m4573.	3.0	322
1288	New-onset Diabetes Mellitus After Adult Heart Transplantation and the Risk of Renal Dysfunction or Mortality. Transplantation, 2022, 106, 178-187.	0.5	17
1289	Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination. European Endocrinology, 2021, 1, 12.	0.8	0
1290	Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review. Advances in Therapy, 2021, 38, 994-1010.	1.3	22
1291	The year in cardiovascular medicine 2020: epidemiology and prevention. European Heart Journal, 2021, 42, 813-821.	1.0	18
1292	Empagliflozin in Heart Failure. New England Journal of Medicine, 2021, 384, 384-388.	13.9	3
1293	Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors. International Journal of Cardiovascular Imaging, 2021, 37, 1333-1341.	0.7	5
1294	Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial. Endocrine Journal, 2021, 68, 329-343.	0.7	7
1296	Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. JAMA Network Open, 2021, 4, e2035792.	2.8	46
1297	Medical treatment of type 2 diabetes mellitus: Recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine. Revista Clínica Espanõla, 2021, 221, 101-108.	0.3	4
1298	Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials. Diabetes Research and Clinical Practice, 2021, 172, 108648.	1.1	1
1300	Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nature Reviews Nephrology, 2021, 17, 319-334.	4.1	244
1301	New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H838-H853.	1.5	18
1302	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia, 2021, 64, 1226-1234.	2.9	15
1303	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Failure, 2021, 8, 1482-1493.	1.4	16
1304	Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1269-1283.	1.8	24
1305	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation, 2021, 143, 685-695.	1.6	22
1306	Dietary Phosphorus as a Marker of Mineral Metabolism and Progression of Diabetic Kidney Disease. Nutrients, 2021, 13, 789.	1.7	7

#	Article	IF	Citations
1307	Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. Endocrine, 2021, 73, 31-36.	1.1	19
1308	Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 636152.	1.1	11
1309	Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2) Inhibition-Induced Relaxation in Arteries From Human Visceral Adipose Tissue. Hypertension, 2021, 77, 729-738.	1.3	20
1310	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 384-395.	2.2	37
1311	Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study. Journal of Clinical Medicine, 2021, 10, 505.	1.0	6
1312	Beyond the myocardium: Sodiumâ€glucose coâ€transporterâ€2 inhibitors in heart failure. Diabetes, Obesity and Metabolism, 2021, 23, 1215-1218.	2.2	0
1313	The Effects of SGLT2 Inhibitors on Lipid Metabolism. Metabolites, 2021, 11, 87.	1.3	72
1314	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the <scp>EXSCEL</scp> and <scp>SAVORâ€TIMI</scp> 53 cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2021, 23, 1101-1110.	2.2	4
1315	Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2. Journal of Clinical Medicine, 2021, 10, 571.	1.0	3
1316	Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics. Kidney360, 2021, 2, 742-746.	0.9	18
1317	Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis. Diabetes and Metabolism, 2021, 47, 101160.	1.4	6
1318	Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. PLoS ONE, 2021, 16, e0244689.	1.1	41
1319	Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Medicine (United States), 2021, 100, e24655.	0.4	12
1320	Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective. Frontiers in Cardiovascular Medicine, 2021, 8, 644189.	1.1	34
1321	SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Heart Failure Reviews, 2022, 27, 935-949.	1.7	19
1322	Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. Canadian Journal of Diabetes, 2021, , .	0.4	1
1323	Quantifying Variation in Treatment Utilization for Type 2 Diabetes Across Five Major University of California Health Systems. Diabetes Care, 2021, 44, 908-914.	4.3	9
1324	Effects and Issues of Diet Fat on Cardiovascular Metabolism. , 0, , .		0

#	Article	IF	Citations
1325	Sodiumâ€“glucose cotransporterÂ2 inhibitorâ€induced reduction in the mean arterial pressure improved renal composite outcomes in typeÂ2 diabetes mellitus patients with chronic kidney disease: A propensity scoreâ€matched model analysis in Japan. Journal of Diabetes Investigation, 2021, 12, 1408-1416.	1.1	9
1326	SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Failure Reviews, 2022, 27, 951-960.	1.7	16
1327	Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology, 2021, 26, 491-500.	0.7	63
1328	Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart, 2021, 107, 1032-1038.	1.2	90
1329	Sodiumâ€“glucose cotransporterÂ2 inhibitors in typeÂ2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice. Journal of Diabetes Investigation, 2021, 12, 1577-1585.	1.1	6
1330	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. European Journal of Preventive Cardiology, 2022, 29, 1352-1360.	0.8	26
1331	Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK. Cell and Bioscience, 2021, 11, 44.	2.1	20
1332	A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study. ADCES in Practice, 2021, 9, 16-23.	0.2	0
1333	Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications. Journal of Clinical Medicine, 2021, 10, 721.	1.0	19
1334	Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis. Journal of Diabetes and Its Complications, 2021, 35, 107803.	1.2	7
1335	Gliflozins for the treatment of congestive heart failure and renal failure in type 2 diabetes. Deutsches Ärzteblatt International, 2021, 118, .	0.6	5
1336	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 772-810.	1.2	612
1337	Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020. Endocrinology and Metabolism, 2021, 36, 41-50.	1.3	4
1339	Double Diabetes: A Growing Problem Requiring Solutions. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, 268-274.	0.6	5
1340	Macrovascular Risk Equations Based on the CANVAS Program. Pharmacoeconomics, 2021, 39, 447-461.	1.7	4
1341	TÃ³picos Emergentes em InsuficiÃªncia CardÃaca: Inibidores do Cotransportador SÃ³dio-Glicose 2 (iSGLT2) na IC. Arquivos Brasileiros De Cardiologia, 2021, 116, 355-358.	0.3	3
1342	Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?. Cardiology, 2021, 146, 201-206.	0.6	10
1343	Tratamiento mÃ©dico de la diabetes mellitus tipo 2: recomendaciones del Grupo de Diabetes, Obesidad y NutriciÃ³n de la Sociedad EspaÃ±ola de Medicina Interna. Revista Clinica Espanola, 2021, 221, 101-108.	0.2	4

#	Article	IF	Citations
1344	Fournierâ€™s gangrene with dapagliflozin in a rural hospital: a case report. BMJ Case Reports, 2021, 14, e237784.	0.2	4
1345	Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?. Diabetes Care, 2021, 44, 641-646.	4.3	10
1346	Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: AÂDescriptive Analysis in the UK CPRD. Clinical Therapeutics, 2021, 43, 320-335.	1.1	26
1347	Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects. Diagnostics, 2021, 11, 290.	1.3	16
1348	SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. Heart Failure Reviews, 2022, 27, 961-980.	1.7	18
1349	The â€œEarly Treatmentâ€•Approach Reducing Cardiovascular Risk in Patients with TypeÂ2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique. Diabetes Therapy, 2021, 12, 1445-1461.	1.2	5
1350	Sirtuin-7 as a Novel Therapeutic Target in Vascular Smooth Muscle Cell Proliferation and Remodeling. Circulation Journal, 2021, 85, 2241-2242.	0.7	3
1351	Diabetes Management in Patients with Heart Failure. Diabetes and Metabolism Journal, 2021, 45, 158-172.	1.8	9
1352	Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use. Current Drug Safety, 2021, 16, 73-81.	0.3	7
1353	Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovascular Diabetology, 2021, 20, 57.	2.7	76
1354	Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease. Cardiovascular Drugs and Therapy, 2021, 35, 1161-1170.	1.3	4
1355	Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis. Cardiology Research and Practice, 2021, 2021, 1-12.	0.5	13
1356	Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diabetes and Vascular Disease Research, 2021, 18, 147916412110110.	0.9	41
1357	Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation. PLoS ONE, 2021, 16, e0248577.	1.1	6
1359	Novel Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease: What Cardiologists and Diabetologists Should Know. European Cardiology Review, 2021, 16, e12.	0.7	0
1360	Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes. Current Opinion in Nephrology and Hypertension, 2021, 30, 361-368.	1.0	3
1361	Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitusâ€”is metabolic reprogramming the mechanism for these favorable outcomes?. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.4	0
1362	Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events. American Journal of Epidemiology, 2021, 190, 1572-1581.	1.6	8

#	Article	IF	Citations
1363	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovascular Diabetology, 2021, 20, 75.	2.7	9
1364	Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus. Current Drug Safety, 2021, 16, 32-51.	0.3	1
1365	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia, 2021, 64, 1256-1267.	2.9	103
1366	Effects of Sodium Glucose Co-TransporterÂ2 Inhibitors in TypeÂ1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial. Diabetes Therapy, 2021, 12, 1415-1427.	1.2	6
1367	Use of <scp>sodiumâ€“glucose</scp> coâ€transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2021, 23, 1012-1022.	2.9	33
1368	Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments. Endocrine Reviews, 2021, 42, 658-690.	8.9	50
1369	Diabetes and Stroke. Journal of Korean Diabetes, 2021, 22, 26-37.	0.1	1
1371	Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016. Kidney Medicine, 2021, 3, 173-182.e1.	1.0	7
1373	The Management of Coronary Artery Disease in Ethiopia: Emphasis on Revascularization. Ethiopian Journal of Health Sciences, 2021, 31, 439-454.	0.2	2
1374	Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports. BMC Infectious Diseases, 2021, 21, 284.	1.3	9
1375	Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials. Frontiers in Endocrinology, 2021, 12, 619586.	1.5	28
1376	Alternative strategies in cardiac preclinical research and new clinical trial formats. Cardiovascular Research, 2022, 118, 746-762.	1.8	13
1377	Efficacy and Safety of Ertugliflozin in Patients with TypeÂ2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV. Diabetes Therapy, 2021, 12, 1279-1297.	1.2	7
1378	eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined. Kidney360, 2021, 2, 1042-1047.	0.9	40
1379	Effect of dapagliflozin in patients with heart failure. Drug and Therapeutics Bulletin, 2021, 59, 86-87.	0.3	0
1380	Revealing hypoglycemic and hypolipidemic mechanism of Xiaokeyinshui extract combination on streptozotocin-induced diabetic mice in high sucrose/high fat diet by metabolomics and lipidomics. Biomedicine and Pharmacotherapy, 2021, 135, 111219.	2.5	19
1381	Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. Diabetes Care, 2021, 44, 1211-1218.	4.3	32
1382	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1159-1167.	4.3	25

#	Article	IF	Citations
1383	Glucose-Lowering Medications and Cardiovascular Outcomes. Current Cardiology Reports, 2021, 23, 24.	1.3	2
1384	Prevention of heart failure events with sodiumâ€“glucose coâ€transporter 2 inhibitors across a spectrum of cardioâ€renalâ€metabolic risk. European Journal of Heart Failure, 2021, 23, 1002-1008.	2.9	25
1385	Abnormal Glucose Tolerance in Prediabetes Patients with Acute Myocardial Infarction: Implications for Therapy. Journal of Endocrinological Science, 2021, 3, 16-21.	0.1	1
1386	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes. Cardiac Failure Review, 2021, 7, e04.	1.2	7
1387	Quality Matters? The Involvement of Mitochondrial Quality Control in Cardiovascular Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 636295.	1.8	11
1388	Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. Diabetes and Metabolism Journal, 2021, 45, 146-157.	1.8	56
1389	Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients. Cardiovascular Drugs and Therapy, 2021, , 1.	1.3	3
1390	Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs. International Journal of Molecular Sciences, 2021, 22, 2796.	1.8	10
1391	Diabetes in People with HIV. Current Diabetes Reports, 2021, 21, 13.	1.7	19
1392	GlifozinesÂ: actions cardiovasculaires et rÃ©nales. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2021, 2021, 9-11.	0.0	1
1393	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. European Cardiology Review, 2021, 16, e11.	0.7	2
1394	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation, 2021, 143, 949-958.	1.6	15
1395	Cardiovascular Disease in Chronic Kidney Disease. Circulation, 2021, 143, 1157-1172.	1.6	680
1396	SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 2210-2219.	1.4	26
1397	Sex- and Gender-Based Pharmacological Response to Drugs. Pharmacological Reviews, 2021, 73, 730-762.	7.1	80
1398	Cardiovascular Safety and Sclerostin Inhibition. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1845-1853.	1.8	26
1399	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 2021, 233, 141-148.	1.2	30
1400	Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology, 2021, 20, 74.	2.7	44

#	Article	IF	Citations
1401	A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials. Journal of the American Association of Nurse Practitioners, 2021, Publish Ahead of Print, 1139-1147.	0.5	0
1402	Pharmacotherapy in Stable Coronary Artery Disease: Historical Perspectives and New Insights from the ISCHEMIA Trial. European Cardiology Review, 2021, 16, e04.	0.7	1
1403	Expert Consensus on Telemedicine Management of Diabetes (2020 Edition). International Journal of Endocrinology, 2021, 2021, 1-12.	0.6	12
1405	Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV. Diabetes Therapy, 2021, 12, 1175-1192.	1.2	4
1406	Using machine learning to identify diabetes patients with canagliflozin prescriptions at highâ€risk of lower extremity amputation using realâ€world data. Pharmacoepidemiology and Drug Safety, 2021, 30, 644-651.	0.9	8
1408	Effects of 6â€‰weeks of treatment with dapagliflozin, a sodiumâ€glucose coâ€transporterâ€2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placeboâ€controlled, exploratory study. Diabetes, Obesity and Metabolism, 2021, 23, 1505-1517.	2.2	42
1409	Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece. Clinical Drug Investigation, 2021, 41, 371-380.	1.1	6
1410	Importance of performance status and physical activity in cancer patients. Memo - Magazine of European Medical Oncology, 2021, 14, 154-156.	0.3	1
1411	<scp>S</scp>odiumâ€glucose coâ€transporterâ€2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 1672-1676.	2.2	30
1412	The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. European Heart Journal, 2021, 42, 1458-1459.	1.0	4
1413	Sodiumâ€“Glucose Co-TransporterÂ2 Inhibitors (SGLT2i) Exposure and Outcomes in TypeÂ2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy, 2021, 12, 991-1028.	1.2	20
1414	Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome. Current Atherosclerosis Reports, 2021, 23, 16.	2.0	6
1415	Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice. American Journal of Preventive Cardiology, 2021, 5, 100144.	1.3	7
1416	Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. Diabetes Care, 2021, 44, 1236-1241.	4.3	37
1417	A bioinformatics and transcriptomics based investigation reveals an inhibitory role of Huanglian-Renshen-Decoction on hepatic glucose production of T2DM mice via PI3K/Akt/FoxO1 signaling pathway. Phytomedicine, 2021, 83, 153487.	2.3	26
1418	Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. American Heart Journal, 2021, 233, 86-91.	1.2	38
1419	Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.4	14
1420	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	2.9	630

#	Article	IF	Citations
1421	Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. Diabetes Therapy, 2021, 12, 1099-1116.	1.2	8
1423	Use of diabetes medications in traditional Medicare and Medicare Advantage. American Journal of Managed Care, 2021, 27, e80-e88.	0.8	4
1425	Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24Âmonths follow-up study. Diabetes Research and Clinical Practice, 2021, 173, 108681.	1.1	8
1426	Blood glucose, antidiabetic drugs, and risk of stroke. Precision and Future Medicine, 2021, 5, 13-20.	0.5	0
1427	Metaâ€analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodiumâ€glucose coâ€transporterâ€2 inhibitors: Implications for the <scp>COVIDâ€19</scp> pandemic. Diabetes, Obesity and Metabolism, 2021, 23, 1696-1700.	2.2	4
1428	Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitationâ€induced Myocardial Dysfunction. Journal of the American Heart Association, 2021, 10, e019274.	1.6	22
1429	Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. Cardiovascular Research, 2022, 118, 686-715.	1.8	24
1430	Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study. Cardiovascular Diabetology, 2021, 20, 67.	2.7	27
1431	Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison. British Journal of Clinical Pharmacology, 2021, 87, 3938-3948.	1.1	0
1432	Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people. Hospital Practice (1995), 2021, 49, 164-175.	0.5	2
1433	Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes. Cureus, 2021, 13, e14268.	0.2	1
1434	Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy. Cardiovascular Drugs and Therapy, 2022, 36, 619-632.	1.3	12
1435	Novelties in Therapy of Chronic Heart Failure. Heart Failure Clinics, 2021, 17, 255-262.	1.0	3
1436	How to appropriately update practicing clinicians on innovations in heart failure therapy waiting for the new version of the guidelines?. International Journal of Cardiology, 2021, 329, 148-149.	0.8	0
1437	Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Endocrinology and Metabolism, 2021, 36, 388-400.	1.3	15
1438	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2021, 174, 108737.	1.1	61
1439	Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Pharmacotherapy, 2021, 41, 526-536.	1.2	5
1440	SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases. Endocrinology, 2021, 162, .	1.4	35

#	Article	IF	Citations
1441	Therapeutic Manipulation of Myocardial Metabolism. Journal of the American College of Cardiology, 2021, 77, 2022-2039.	1.2	40
1442	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2Â°Pâ€TIMI 50. Journal of the American Heart Association, 2021, 10, e018673.	1.6	7
1443	Stage A Heart Failure. Heart Failure Clinics, 2021, 17, 167-177.	1.0	4
1444	SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits. International Journal of Molecular Sciences, 2021, 22, 4441.	1.8	27
1445	Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 678530.	1.1	6
1446	Sodium-Glucose CotransporterÂ2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease. Advances in Therapy, 2021, 38, 2201-2212.	1.3	23
1447	A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe. Frontiers in Pharmacology, 2021, 12, 626766.	1.6	0
1448	A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metabolism, 2021, 33, 732-739.	7.2	75
1449	Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?. Kidney360, 2021, 2, 1174-1178.	0.9	14
1450	Henagliflozin as addâ€on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, doubleâ€blind, placeboâ€controlled, phase 3 trial. Diabetes, Obesity and Metabolism, 2021, 23, 1754-1764.	2.2	12
1451	Clinical Adverse Events Associated with Sodiumâ€“Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2133-2145.	1.8	35
1452	The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodiumâ€“glucose cotransporter 2 inhibitor. Cardiovascular Diabetology, 2021, 20, 93.	2.7	8
1453	Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?. Molecular Metabolism, 2021, 46, 101158.	3.0	17
1454	Cardiorenal Protection in Diabetic Kidney Disease. Endocrinology and Metabolism, 2021, 36, 256-269.	1.3	10
1455	Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Diabetes Care, 2021, 44, 1353-1360.	4.3	22
1456	The changing landscape of atherosclerosis. Nature, 2021, 592, 524-533.	13.7	921
1457	Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients. Cardiovascular Diabetology, 2021, 20, 78.	2.7	11
1458	Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study. Revista Clínica Espanõla, 2021, 221, 517-528.	0.3	1

#	Article	IF	Citations
1460	Current trends in diabetes mellitus database research in Japan. Diabetes, Obesity and Metabolism, 2021, 23, 3-18.	2.2	20
1461	The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection. Russian Journal of Cardiology, 2021, 26, 4323.	0.4	1
1462	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. New England Journal of Medicine, 2021, 384, 1248-1260.	13.9	60
1463	Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i). Current Opinion in Cardiology, 2021, 36, 420-428.	0.8	8
1464	Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines. Pharmacological Research, 2021, 166, 105530.	3.1	7
1465	From glucose lowering agents to disease/diabetes modifying drugs: a â€œSIMPLEâ€•approach for the treatment of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 92.	2.7	28
1466	Rol de nuevos fÃ¡rmacos antidiabÃ©ticos en prevenciÃ³n cardiovascular e insuficiencia cardiaca. ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 314-322.	0.4	0
1467	Sex-disparities in risk factors and atherosclerosis cardiovascular disease in diabetic patients. Postgraduate Medicine, 2021, 133, 860-864.	0.9	2
1468	Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats. Frontiers in Pharmacology, 2021, 12, 578716.	1.6	2
1469	Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control. International Journal of Molecular Sciences, 2021, 22, 4374.	1.8	18
1470	Diabetic patient in a general practitioner's office - part 1 Type 2 diabetes mellitus and its treatment. MedicÃ¤na Pro Praxi, 2021, 18, 104-111.	0.0	0
1471	Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis. Diabetes, 2021, 70, 1767-1779.	0.3	17
1472	Diabetes and Its Complications: Therapies Available, Anticipated and Aspired. Current Diabetes Reviews, 2021, 17, 397-420.	0.6	6
1473	Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Diabetes Care, 2021, 44, 1334-1343.	4.3	32
1474	Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors. International Journal of Molecular Sciences, 2021, 22, 4416.	1.8	18
1475	Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. IJC Heart and Vasculature, 2021, 33, 100725.	0.6	18
1476	Diabetic heart disease: A clinical update. World Journal of Diabetes, 2021, 12, 383-406.	1.3	28
1477	Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study. BMC Cardiovascular Disorders, 2021, 21, 217.	0.7	13

#	Article	IF	Citations
1478	Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 Inhibitor Use and Recent Sleeve Gastrectomy. Cureus, 2021, 13, e14297.	0.2	5
1479	Lipid effects of sodium-glucose cotransporter 2 inhibitors. Current Opinion in Lipidology, 2021, 32, 183-190.	1.2	6
1480	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	2.3	56
1481	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	0.7	362
1482	Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses. Heart, 2021, 107, 1962-1973.	1.2	13
1483	Empagliflozin Inhibits Proximal Tubule NHE3 Activity, Preserves GFR, and Restores Euvolemia in Nondiabetic Rats with Induced Heart Failure. Journal of the American Society of Nephrology: JASN, 2021, 32, 1616-1629.	3.0	46
1484	Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105799.	0.7	4
1485	Lower heart failure and chronic kidney disease risks associated with sodiumâ€glucose cotransporterâ€2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases. Diabetes, Obesity and Metabolism, 2021, 23, 19-27.	2.2	12
1486	Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis. Expert Opinion on Drug Safety, 2021, 20, 1-14.	1.0	6
1487	Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes. European Cardiology Review, 2021, 16, e14.	0.7	4
1488	Sodiumâ€“Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPKâ€“mTOR Signaling Pathwayâ€“Mediated Autophagy. Frontiers in Pharmacology, 2021, 12, 664181.	1.6	46
1489	Kidney Outcomes With SGLT-2 Inhibitors. ADCES in Practice, 2021, 9, 12-15.	0.2	0
1490	Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes. Diabetes Therapy, 2021, 12, 1613-1630.	1.2	8
1491	One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus. Diabetes Therapy, 2021, 12, 1677-1688.	1.2	0
1492	Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Canadian Journal of Diabetes, 2022, 46, 10-15.e2.	0.4	31
1493	Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors. Diabetes, Obesity and Metabolism, 2021, 23, 1614-1623.	2.2	13
1494	Heart Failure And Diabetes: Perspective Of A Dangerous Association. Current Hypertension Reviews, 2021, 17, 85-93.	0.5	2
1495	Healthcare resource utilization after initiation of sodiumâ€glucose coâ€transporterâ€2 inhibitors versus dipeptidyl peptidaseâ€4 inhibitors or other glucoseâ€lowering drugs in <scp>Japanese</scp> patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 28-39.	2.2	2

#	Article	IF	Citations
1496	Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure. Circulation, 2021, 143, 1673-1686.	1.6	129
1497	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. JACC: Heart Failure, 2021, 9, 254-264.	1.9	75
1498	Sodiumâ€“glucose coâ€transporter 2 inhibitors: strength of evidence for a cardioâ€renalâ€metabolic therapy. European Journal of Heart Failure, 2021, 23, 1009-1011.	2.9	0
1499	SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review. Journal of Clinical Medicine, 2021, 10, 2036.	1.0	6
1500	Stroke prevention in patients with type 2 diabetes mellitus or prediabetes: recommendations of the Spanish Society of Neurologyâ€™s Stroke Study Group. NeurologÃa (English Edition), 2021, 36, 305-323.	0.2	2
1501	Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Research and Care, 2021, 9, e001313.	1.2	15
1502	Deciphering the Efficacy and Mechanisms of Chinese Herbal Medicine for Diabetic Kidney Disease by Integrating Web-Based Biochemical Databases and Real-World Clinical Data: Retrospective Cohort Study. JMIR Medical Informatics, 2021, 9, e27614.	1.3	10
1503	SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. Current Cardiology Reports, 2021, 23, 59.	1.3	7
1504	The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1365-1374.	1.1	7
1505	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2021, 23, 872-881.	2.9	160
1506	Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovascular Diabetology, 2021, 20, 100.	2.7	92
1507	Chronic kidney disease in patients with diabetes mellitus. Endocrine Connections, 2021, 10, R151-R159.	0.8	12
1508	Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodiumâ€“glucose co-transporter 2 inhibitors?. Future Cardiology, 2021, 17, 497-506.	0.5	2
1509	Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide. Future Cardiology, 2021, 17, 459-473.	0.5	4
1510	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. Circulation, 2021, 143, 1735-1749.	1.6	60
1511	Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A<scp>VERTIS CV</scp>substudy. Diabetes, Obesity and Metabolism, 2021, 23, 1640-1651.	2.2	8
1512	Empagliflozin induced euglycemic diabetic ketoacidosis in a patient undergoing coronary artery bypass graft despite discontinuation of the drug 48 hours prior to the surgery. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 909-911.	1.8	6
1513	Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease. Hypertension, 2021, 77, 1442-1455.	1.3	22

#	Article	IF	Citations
1514	Proglucagon-Derived Peptides as Therapeutics. Frontiers in Endocrinology, 2021, 12, 689678.	1.5	34
1515	Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2021, 77, 1453-1464.	0.8	8
1516	SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study. Minerva Endocrinology, 2021, , .	0.6	8
1517	The effect of sodiumâ€glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studies. Diabetic Medicine, 2021, 38, e14600.	1.2	3
1518	Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease. Nuclear Medicine Communications, 2021, 42, 972-978.	0.5	4
1519	A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists. Diabetes Research and Clinical Practice, 2021, 175, 108800.	1.1	15
1520	Stress Induced Hyperglycemia in the Context of Acute Coronary Syndrome: Definitions, Interventions, and Underlying Mechanisms. Frontiers in Cardiovascular Medicine, 2021, 8, 676892.	1.1	12
1521	Cardiovascular outcomeÂtrials in Type 2 diabetes: food for thought. Future Cardiology, 2021, 17, 407-410.	0.5	1
1522	RÃ©sultats des Ã©tudes cliniques de sÃ©curitÃ© cardiovasculaire avec les inhibiteurs des SGLT-2Âet les agonistes des rÃ©cepteurs du GLP-1Â: quels enseignementsÂ?. Medecine Des Maladies Metaboliques, 2021, 15, 252-259.	0.1	0
1523	Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 539-546.	1.4	22
1524	Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study. International Journal of Cardiology, 2021, 330, 91-97.	0.8	10
1525	InterpretaciÃ³n de los ensayos clÃnicos sobre efectos cardiovasculares de los fÃ¡rmacos hipoglucemiantes en personas con diabetes tipo 2. Endocrinologia, Diabetes Y NutriciÃ“n, 2021, 68, 741-750.	0.1	0
1526	Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. Heart, 2022, 108, 16-21.	1.2	7
1527	Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. Diabetes Research and Clinical Practice, 2021, 175, 108796.	1.1	11
1528	Heart failure subtypes: Pathophysiology and definitions. Diabetes Research and Clinical Practice, 2021, 175, 108815.	1.1	9
1529	Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 697-705.	1.5	8
1530	Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D). Journal of Diabetes and Its Complications, 2021, 35, 107949.	1.2	4
1531	Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial. Diabetes Therapy, 2021, 12, 2101-2113.	1.2	6

#	Article	IF	Citations
1532	Pharmacotherapy for weight loss in adults with type 2 diabetes: a systematic review of randomised controlled trials. British Journal of Diabetes, 2021, 21, 20-29.	0.1	1
1533	High-Sensitivity Cardiac Troponin Predicts Major Cardiovascular Events in Diabetic Patients With Critical Limb Ischemia and Foot Lesions. Frontiers in Cardiovascular Medicine, 2021, 8, 595701.	1.1	3
1534	Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nature Reviews Endocrinology, 2021, 17, 364-377.	4.3	70
1535	Recent advances in new-onset diabetes mellitus after kidney transplantation. World Journal of Diabetes, 2021, 12, 541-555.	1.3	4
1536	Sex and Heart Failure Treatment Prescription and Adherence. Frontiers in Cardiovascular Medicine, 2021, 8, 630141.	1.1	5
1537	Mechanisms and Models in Heart Failure. Circulation Research, 2021, 128, 1435-1450.	2.0	24
1538	The impact of diabetes on heart failure development: The cardio-renal-metabolic connection. Diabetes Research and Clinical Practice, 2021, 175, 108831.	1.1	5
1539	Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction. CJC Open, 2021, 3, 646-657.	0.7	2
1541	Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 474-481.	1.0	6
1542	Delivering joined-up care for people with type 2 diabetes: rationale, challenges and examples. British Journal of Diabetes, 2021, 21, 89-95.	0.1	4
1543	Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101484.	2.2	42
1544	Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan. International Heart Journal, 2021, 62, 592-600.	0.5	7
1545	Das kardiorenale Syndrom ist die hÃufigste erste kardiovaskulÄre Manifestation beim Typ-2-Diabetes und mit erhÃ¶hter MortalitÄt assoziiert: eine groÃŸe multinationale Beobachtungsstudie. Diabetologie Und Stoffwechsel, 2021, 16, .	0.0	0
1547	Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus. Diabetes and Vascular Disease Research, 2021, 18, 147916412110215.	0.9	1
1548	Design and rationale of the EMPAâ€VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. ESC Heart Failure, 2021, 8, 2580-2590.	1.4	18
1549	A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy older adults. British Journal of Diabetes, 2021, 21, 30-35.	0.1	7
1550	Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease. FEBS Open Bio, 2021, 11, 1395-1405.	1.0	19
1551	Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a. International Journal of Molecular Sciences, 2021, 22, 5437.	1.8	24

#	Article	IF	Citations
1552	Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients. Antioxidants and Redox Signaling, 2021, 35, 1426-1448.	2.5	56
1553	De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study. Journal of Clinical Medicine, 2021, 10, 2013.	1.0	2
1554	Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients. Scientific Reports, 2021, 11, 10166.	1.6	14
1555	A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology. Cardiovascular Drugs and Therapy, 2022, 36, 713-726.	1.3	6
1556	Does Combination Therapy With SGLT2 Inhibitors and Reninâ€“Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?. Frontiers in Cardiovascular Medicine, 2021, 8, 679124.	1.1	5
1557	Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease. Journal of the Endocrine Society, 2021, 5, bvab083.	0.1	4
1558	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. American Journal of Kidney Diseases, 2022, 79, 244-256.e1.	2.1	23
1559	Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovascular Diabetology, 2021, 20, 109.	2.7	54
1560	Type 2 diabetes and bone fragility- An under-recognized association. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 927-935.	1.8	12
1561	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. Stroke, 2021, 52, 1545-1556.	1.0	60
1562	Hypertension: Current trends and future perspectives. British Journal of Clinical Pharmacology, 2021, 87, 3721-3736.	1.1	18
1563	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrology Dialysis Transplantation, 2023, 38, 10-25.	0.4	30
1564	Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report. World Journal of Clinical Cases, 2021, 9, 3163-3169.	0.3	1
1565	SGLT2 inhibitors: Do we need other evidences?. European Journal of Internal Medicine, 2021, 87, 18-19.	1.0	0
1566	NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction. Lancet Diabetes and Endocrinology,the, 2021, 9, 261-263.	5.5	0
1567	Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model. Journal of Inflammation Research, 2021, Volume 14, 2277-2287.	1.6	17
1568	Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. International Journal of Molecular Sciences, 2021, 22, 5863.	1.8	48
1569	Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?. European Journal of Internal Medicine, 2021, 87, 98-99.	1.0	3

#	Article	IF	Citations
1570	Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study. Diabetes Research and Clinical Practice, 2021, 175, 108843.	1.1	1
1571	Bakterielle Prostatitis nach Therapie mit Empagliflozin. , 2021, 16, .		0
1572	Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105708.	0.7	8
1573	Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease. Current Diabetes Reports, 2021, 21, 21.	1.7	10
1574	Eligibility of outpatients with chronic heart failure for sodiumâ€“glucose coâ€transporterâ€2 inhibitors. ESC Heart Failure, 2021, 8, 2951-2958.	1.4	8
1575	Do sodiumâ€glucose coâ€transporterâ€2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?. Diabetes, Obesity and Metabolism, 2021, 23, 2009-2019.	2.2	3
1576	Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study. BMC Nephrology, 2021, 22, 177.	0.8	24
1577	Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. Frontiers in Pharmacology, 2021, 12, 670155.	1.6	27
1578	Treatment of Heart Failure With Mid-Range Ejection Fraction: A Summary of Current Evidence. Frontiers in Cardiovascular Medicine, 2021, 8, 653336.	1.1	3
1579	Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care?. Journal of the Royal Society of Medicine, 2021, 114, 351-358.	1.1	0
1580	Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK). PLoS ONE, 2021, 16, e0251135.	1.1	9
1581	Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications. Journal of Clinical Medicine, 2021, 10, 2233.	1.0	15
1582	Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement. British Journal of Diabetes, 2021, 21, 132-148.	0.1	0
1583	A year in diabetic nephropathy. British Journal of Diabetes, 2021, 21, 100-109.	0.1	0
1584	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). Eurasian Heart Journal, 2021, , 6-61.	0.2	9
1585	Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 103.	2.7	3
1586	Canagliflozin: metabolic, cardiovascular and renal protection. Future Cardiology, 2021, 17, 443-458.	0.5	5
1587	Metformin in the era of new antidiabetics. Future Cardiology, 2021, 17, 475-485.	0.5	2

#	Article	IF	Citations
1588	A bibliometric analysis of global research output on network meta-analysis. BMC Medical Informatics and Decision Making, 2021, 21, 144.	1.5	29
1589	Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodiumâ€Glucose Cotransporterâ€2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes. Journal of the American Heart Association, 2021, 10, e020237.	1.6	19
1590	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1522-1545.	0.3	47
1591	Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement. American Journal of Preventive Cardiology, 2021, 6, 100183.	1.3	4
1592	Type 2 diabetes mellitus in older adults: clinical considerations and management. Nature Reviews Endocrinology, 2021, 17, 534-548.	4.3	186
1593	Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study. Diabetes Therapy, 2021, 12, 1979-1992.	1.2	4
1594	Clinical outcomes of Sodium-glucose cotransporter-2Âinhibitors in patients with Type 2 Diabetes Mellitus:ÂAnÂobservational study from Pakistan. Pakistan Journal of Medical Sciences, 2021, 37, 1342-1346.	0.3	2
1595	High glucoseâ€“induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model. Bioscience Reports, 2021, 41, .	1.1	5
1596	Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis. European Journal of Endocrinology, 2021, 184, 783-790.	1.9	3
1597	A Review of the Role of Type 2 Diabetes and SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction. Cardiology in Review, 2021, Publish Ahead of Print, .	0.6	1
1598	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial. European Journal of Heart Failure, 2021, 23, 1217-1225.	2.9	195
1599	Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice. European Journal of Pharmaceutical Sciences, 2021, 161, 105788.	1.9	21
1600	Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis. Cardiovascular Diabetology, 2021, 20, 130.	2.7	6
1601	Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis. European Journal of Preventive Cardiology, 2022, 28, 1840-1849.	0.8	6
1602	Postoperative Euglycemic Ketoacidosis in Type 2 Diabetes Associated with Sodium-Glucose Cotransporter 2 Inhibitor: Insights Into Pathogenesis and Management Strategy. Cureus, 2021, 13, e15533.	0.2	2
1603	Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease. Frontiers in Endocrinology, 2021, 12, 661185.	1.5	20
1604	STUDY THE LEVEL OF ARGINASE ACTIVITY AND ITS CORRELATION WITH LIVER AND KIDNEY FUNCTIONS FOR PATIENTS WITH TYPE-2 DIABETES IN NINEVEH GOVERNORATE. Egyptian Journal of Chemistry, 2021, .	0.1	0
1605	Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1590-1600.	2.2	11

#	Article	IF	Citations
1606	Diabetes Mellitus and Its Implications in Aortic Stenosis Patients. International Journal of Molecular Sciences, 2021, 22, 6212.	1.8	7
1607	Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials. Cardiovascular Diagnosis and Therapy, 2021, 11, 699-706.	0.7	4
1608	Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators. Journal of Clinical Medicine, 2021, 10, 2713.	1.0	5
1609	Sodiumâ€glucose cotransporterâ€2 inhibitors and nonâ€steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond reninâ€angiotensin system blockade. Nephrology, 2021, 26, 858-871.	0.7	11
1610	Kidney outcomes using a sustained â‰¥40% decline in <scp>eGFR</scp>: A metaâ€analysis of <scp>SGLT2</scp> inhibitor trials. Clinical Cardiology, 2021, 44, 1139-1143.	0.7	20
1611	New Aspects of Diabetes Research and Therapeutic Development. Pharmacological Reviews, 2021, 73, 1001-1015.	7.1	10
1612	Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care, 2021, 44, 1774-1782.	4.3	24
1614	Sodiumâ€“glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. CKJ: Clinical Kidney Journal, 2021, 14, 2463-2471.	1.4	12
1615	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1671-1690.	1.1	5
1616	Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 2021, 77, 787-795.	0.8	5
1617	Sodium-glucose cotransporter 2Âinhibitors: aÂpractical guide for the Dutch cardiologist based on real-world experience. Netherlands Heart Journal, 2021, 29, 490-499.	0.3	3
1618	SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials. Kidney Medicine, 2021, 3, 732-744.e1.	1.0	10
1619	The Johns Hopkins Ciccarone Center's expanded â€˜ABC's approach to highlight 2020 updates in cardiovascular disease prevention. American Journal of Preventive Cardiology, 2021, 6, 100181.	1.3	0
1620	Sodiumâ€“glucose cotransporter 2 inhibitorâ€induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 2631-2636.	1.4	6
1621	SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine, 2021, 36, 100933.	3.2	67
1622	Thrombolysis In Myocardial InfarctionÂ(TIMI) Study Group. Journal of the American College of Cardiology, 2021, 77, 2822-2845.	1.2	23
1623	Obesity and Post-Transplant Diabetes Mellitus in Kidney Transplantation. Journal of Clinical Medicine, 2021, 10, 2497.	1.0	10
1624	Sodium glucoseâ€linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications. International Journal of Urology, 2021, 28, 984-990.	0.5	6

#	Article	IF	Citations
1625	Evidence-based use of newer agents in type 2 diabetes. Journal of Prescribing Practice, 2021, 3, 224-234.	0.1	1
1626	An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. Expert Opinion on Pharmacotherapy, 2021, 22, 2087-2094.	0.9	5
1627	Towards precision medicine in heart failure. Nature Reviews Cardiology, 2021, 18, 745-762.	6.1	34
1628	Interdisciplinary assessment and diagnostic algorithm: The role of the diabetologist. Diabetes Research and Clinical Practice, 2021, 176, 108850.	1.1	2
1629	Blood pressure control in patients with chronic kidney disease. Korean Journal of Internal Medicine, 2021, 36, 780-794.	0.7	6
1630	Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. Free Radical Biology and Medicine, 2021, 169, 317-342.	1.3	73
1631	Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: Do they have a role in primary prevention?. Metabolism Open, 2021, 10, 100082.	1.4	1
1632	Optimal medical therapy after coronary artery bypass grafting: a primer for surgeons. Current Opinion in Cardiology, 2021, 36, 609-615.	0.8	6
1633	Impact of the initial decline in estimated glomerular filtration rate on the risk of newâ€onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodiumâ€glucose coâ€transporterâ€2 inhibitors. Diabetes, Obesity and Metabolism, 2021, 23, 2077-2089.	2.2	11
1634	Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An opportunity for pharmacists. American Journal of Health-System Pharmacy, 2022, 79, e65-e70.	0.5	5
1635	Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study. Journal of the American Heart Association, 2021, 10, e019356.	1.6	20
1636	Treating heart failure in patients with diabetes: The view of the cardiologist. Diabetes Research and Clinical Practice, 2021, 176, 108852.	1.1	2
1637	Heart failure management; a perspective from diabetes care. Diabetes Research and Clinical Practice, 2021, 176, 108849.	1.1	1
1638	The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials. Frontiers in Clinical Diabetes and Healthcare, 2021, 2, .	0.3	6
1639	Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy â€“ current and future perspectives. Clinical Science, 2021, 135, 1369-1387.	1.8	8
1640	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs, 2021, 81, 1243-1255.	4.9	2
1642	Management of Kidney Failure in Patients with Diabetes Mellitus: What Are the Best Options?. Journal of Clinical Medicine, 2021, 10, 2943.	1.0	4
1643	Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. American Journal of Cardiovascular Drugs, 2022, 22, 35-46.	1.0	4

#	Article	IF	Citations
1644	Cardiovascular Outcome Trials with Glucose-Lowering Drugs. Current Cardiology Reports, 2021, 23, 75.	1.3	6
1645	Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species. International Journal of Molecular Sciences, 2021, 22, 6044.	1.8	37
1646	Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. Journal of Personalized Medicine, 2021, 11, 499.	1.1	8
1647	Use of Sodium-Glucose Cotransporter-2 Inhibitors in Renal Transplant Patients With Diabetes: A Brief Review of the Current Literature. Canadian Journal of Diabetes, 2022, 46, 207-212.	0.4	7
1648	Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 503-518.	0.7	4
1650	The effects of antidiabetic agents on heart failure. Netherlands Heart Journal, 2022, 30, 65-75.	0.3	2
1651	Sodiumâ€“Glucose Cotransporter-2 Inhibitors for Heart Failure: The New Kid on the Block. Journal for Nurse Practitioners, 2021, 17, 652-656.	0.4	2
1652	Using adjuvant pharmacotherapy in the treatment of type 1 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2143-2148.	0.9	4
1653	Recent advances in pharmacological treatment of heart failure. European Journal of Clinical Investigation, 2021, 51, e13624.	1.7	19
1654	Contemporary Medical Management of Peripheral Artery Disease. Circulation Research, 2021, 128, 1868-1884.	2.0	53
1655	Empagliflozin in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 2021, 8, 683281.	1.1	6
1656	Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Diabetologia, 2021, 64, 1834-1849.	2.9	22
1658	Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. International Journal of Obesity, 2021, 45, 1687-1695.	1.6	4
1659	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	6
1660	Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. Current Opinion in Cardiology, 2021, 36, 672-681.	0.8	9
1661	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes, Obesity and Metabolism, 2021, 23, 2099-2108.	2.2	5
1662	Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3060-3067.	1.8	7
1663	Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge. Frontiers in Medicine, 2021, 8, 654557.	1.2	15

#	Article	IF	Citations
1664	The TIMI Study Groupâ€™s Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-. Journal of Atherosclerosis and Thrombosis, 2021, 28, 563-572.	0.9	1
1665	Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials. Diabetology International, 2022, 13, 325-329.	0.7	2
1666	Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts. Frontiers in Aging, 2021, 2, .	1.2	20
1668	Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM. Frontiers in Cardiovascular Medicine, 2021, 8, 690529.	1.1	9
1669	Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2021, 332, 119-126.	0.8	12
1670	Costâ€“Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with TypeÂ2 Diabetes and High Risk of Cardiovascular Disease in Thailand. Diabetes Therapy, 2021, 12, 1947-1963.	1.2	5
1671	Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors. Diabetologia, 2021, 64, 1949-1962.	2.9	29
1672	An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is). Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 2955-2972.	1.1	8
1673	The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. International Journal of Molecular Sciences, 2021, 22, 5973.	1.8	20
1674	Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 2022, 108, 312-320.	1.2	2
1675	Hemodynamic arterial changes in heart failure: a proposed new paradigm of "heart and vessels failure". Minerva Cardiology and Angiology, 2022, 70, .	0.4	8
1676	Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKÎ±/TGFâ€Î²2/Smad signalling in type 2 diabetic rats. Journal of Cellular and Molecular Medicine, 2021, 25, 7642-7659.	1.6	81
1677	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study. Terapevticheskii Arkhiv, 2021, 93, 713-723.	0.2	3
1678	Managing dyslipidemia in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2221-2234.	0.9	14
1679	Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. Drugs, 2021, 81, 1381-1395.	4.9	10
1680	Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials. Frontiers in Pharmacology, 2021, 12, 724405.	1.6	10
1681	Chronic Kidney Allograft Disease: New Concepts and Opportunities. Frontiers in Medicine, 2021, 8, 660334.	1.2	5
1682	Cardiovascular outcomes with sodiumâ€“glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovascular Diabetology, 2021, 20, 159.	2.7	15

#	Article	IF	Citations
1683	Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis. Advances in Therapy, 2021, 38, 4195-4214.	1.3	3
1684	Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial Î±1AMPK. Scientific Reports, 2021, 11, 13700.	1.6	10
1685	Review of the top 5 cardiology studies of 2019-20. Canadian Pharmacists Journal, 2021, 154, 388-393.	0.4	0
1686	Bexagliflozin for type 2 diabetes: an overview of the data. Expert Opinion on Pharmacotherapy, 2021, 22, 2095-2103.	0.9	9
1687	Dapagliflozin for the treatment of type 2 diabetes mellitus â€“ an update. Expert Opinion on Pharmacotherapy, 2021, 22, 2303-2310.	0.9	8
1688	2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. Diabetes and Metabolism Journal, 2021, 45, 461-481.	1.8	146
1689	The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure. Journal of Cardiac Failure, 2021, 27, 1447-1455.	0.7	14
1690	Cardioprotection by SGLT2 Inhibitorsâ€”Does It All Come Down to Na+?. International Journal of Molecular Sciences, 2021, 22, 7976.	1.8	39
1691	Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Metabolism: Clinical and Experimental, 2021, 120, 154799.	1.5	32
1692	Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms. Cardiovascular Drugs and Therapy, 2021, 35, 1253-1267.	1.3	8
1693	Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares. Russian Journal of Cardiology, 2021, 26, 4534.	0.4	1
1694	SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot. Journal of the American Heart Association, 2021, 10, e021949.	1.6	10
1695	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation, 2021, 144, 74-84.	1.6	34
1696	Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults. Expert Opinion on Pharmacotherapy, 2021, 22, 1-22.	0.9	2
1697	Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2020. American Journal of Medicine, 2021, 134, 854-859.	0.6	1
1698	New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	5
1699	Pharmacist intervention lowers HgbA1c in diabetic patients regardless of HIV status. Journal of Pharmacy Practice and Research, 2021, 51, 307-313.	0.5	1
1700	Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics. CKJ: Clinical Kidney Journal, 2022, 15, 5-13.	1.4	10

#	Article	IF	Citations
1701	Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. Drug Design, Development and Therapy, 2021, Volume 15, 3057-3069.	2.0	11
1702	Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. Heart Rhythm, 2021, 18, 1098-1105.	0.3	103
1703	Osteopontin in Cardiovascular Diseases. Biomolecules, 2021, 11, 1047.	1.8	36
1704	Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 691907.	1.1	26
1705	Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2021, 45, 505-514.	1.8	11
1706	Cardio-renal benefits of sodiumâ€“glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 311-321.	1.4	25
1707	Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs. American Journal of Cardiovascular Drugs, 2021, , 1.	1.0	7
1708	Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin. Cardiovascular Diabetology, 2021, 20, 160.	2.7	2
1709	Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 549-556.	1.4	14
1710	Impact of Sodiumâ€“Glucose Co-Transporter 2 Inhibitors on Cardiac Protection. International Journal of Molecular Sciences, 2021, 22, 7170.	1.8	9
1711	Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants, 2021, 10, 1166.	2.2	37
1712	Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease. Pharmaceuticals, 2021, 14, 751.	1.7	13
1713	Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 419-426.	5.5	158
1714	Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60). Diabetology International, 2022, 13, 132-141.	0.7	0
1715	<scp>Sodiumâ€glucose cotransporterâ€2</scp> inhibition reduces cellular senescence in the diabetic kidney by promoting ketone bodyâ€induced <scp>NRF2</scp> activation. Diabetes, Obesity and Metabolism, 2021, 23, 2561-2571.	2.2	36
1716	Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure. BMC Cardiovascular Disorders, 2021, 21, 347.	0.7	4
1717	Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial. EClinicalMedicine, 2021, 37, 100895.	3.2	45
1718	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1805-1815.	4.3	49

#	Article	IF	Citations
1719	Increased risk of adverse cardiovascular events by strict glycemic control after percutaneous coronary intervention (HbA1c < 6.5% at 2 years) in type 2 diabetes mellitus combined with acute coronary syndrome: a 5-years follow-up study. Current Medical Research and Opinion, 2021, 37, 1517-1528.	0.9	3
1720	Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia. Life Sciences, 2021, 276, 119440.	2.0	29
1721	Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. Drugs, 2021, 81, 1373-1379.	4.9	13
1722	Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?. Drugs, 2021, 81, 1365-1371.	4.9	19
1723	Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Scientific Reports, 2021, 11, 15364.	1.6	40
1724	Left Ventricular SGLT1 Protein Expression Correlates with the Extent of Myocardial Nitro-Oxidative Stress in Rats with Pressure and Volume Overload-Induced Heart Failure. Antioxidants, 2021, 10, 1190.	2.2	5
1725	Cardiac, renal, and metabolic effects of sodiumâ€“glucose coâ€transporter 2 inhibitors: a position paper from the European Society of Cardiology adâ€hoc task force on sodiumâ€“glucose coâ€transporter 2 inhibitors. European Journal of Heart Failure, 2021, 23, 1260-1275.	2.9	36
1726	Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. Medicine (United) Tj ETQq1 1 0.784314 rgBT /O	0.4	1
1727	Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2021, 12, 691878.	1.6	8
1728	Pharmacological secondary prevention of MI. The Prescriber, 2021, 32, 13-20.	0.1	0
1729	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). Archivos De Cardiologia De Mexico, 2021, 92, .	0.1	4
1730	Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Research and Care, 2021, 9, e002300.	1.2	12
1731	Efficacy and safety of dapagliflozin in the treatment of chronic heart failure. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262	0.4	3
1733	Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept. Journal of Cardiovascular Pharmacology, 2021, 78, e12-e19.	0.8	5
1735	Which drug is best for a patient with type 2 diabetes and heart failure?. JAAPA: Official Journal of the American Academy of Physician Assistants, 2021, 34, 49-52.	0.1	0
1736	Safety of Semaglutide. Frontiers in Endocrinology, 2021, 12, 645563.	1.5	66
1737	The challenges of an aging tetralogy of Fallot population. Expert Review of Cardiovascular Therapy, 2021, 19, 581-593.	0.6	6
1738	Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea. Diabetes and Metabolism Journal, 2021, 45, 502-504.	1.8	1

#	Article	IF	Citations
1739	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Network Open, 2021, 4, e2114501.	2.8	49
1740	Sodiumâ€glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review. ESC Heart Failure, 2021, 8, 4093-4118.	1.4	11
1741	Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 463-482.	1.0	4
1742	Relationship Between HbA1c Level and Effectiveness of SGLT2 Inhibitors in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus. International Heart Journal, 2021, 62, 843-849.	0.5	2
1743	Longâ€Term Effects of <scp>Sglt2</scp> Deletion on Bone and Mineral Metabolism in Mice. JBMR Plus, 2021, 5, e10526.	1.3	5
1744	The challenge of choosing in cardiovascular risk management. Netherlands Heart Journal, 2022, 30, 47-57.	0.3	5
1745	Empagliflozin confers renoâ€protection in acute myocardial infarction and type 2 diabetes mellitus. ESC Heart Failure, 2021, 8, 4161-4173.	1.4	9
1746	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 801.	3.0	26
1747	Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2021, 150, 65-68.	0.7	5
1749	SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in TypeÂ2 Diabetes: A Narrative Review. Diabetes Therapy, 2021, 12, 2249-2261.	1.2	18
1750	Effects of Sodiumâ€Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice. Journal of the American Heart Association, 2021, 10, e019995.	1.6	39
1751	Shear Stress and Metabolic Disordersâ€”Two Sides of the Same Plaque. Antioxidants and Redox Signaling, 2022, 37, 820-841.	2.5	4
1752	Current and emerging drug targets in heart failure treatment. Heart Failure Reviews, 2022, 27, 1119-1136.	1.7	22
1753	Effects of canagliflozin on human myocardial redox signalling: clinical implications. European Heart Journal, 2021, 42, 4947-4960.	1.0	57
1754	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet, The, 2021, 398, 262-276.	6.3	222
1755	A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro. Frontiers in Pharmacology, 2021, 12, 708177.	1.6	25
1756	SGLT2 inhibitors. Nurse Practitioner, 2021, 46, 30-37.	0.2	4
1757	Obesity and Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 345-356.	1.0	9

#	Article	IF	Citations
1758	The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?. Journal of Membrane Biology, 2021, 254, 513-529.	1.0	7
1760	Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis. International Journal of Cardiovascular Sciences, 2021, , .	0.0	0
1761	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2021, 32, 2352-2361.	3.0	88
1762	CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovascular Diabetology, 2021, 20, 154.	2.7	111
1763	Impact of <scp>SGLT2</scp> inhibitors in comparison with <scp>DPP4</scp> inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes, Obesity and Metabolism, 2021, 23, 2402-2408.	2.2	10
1764	<scp>Sodiumâ€glucose cotransporterâ€2</scp> inhibitors for type 2 diabetes mellitus in adults: An overview of 46 systematic reviews. Diabetes, Obesity and Metabolism, 2021, 23, 2289-2302.	2.2	7
1765	Comparative effectiveness and safety of sodiumâ€glucose cotransporterâ€2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. Diabetes, Obesity and Metabolism, 2021, 23, 2320-2328.	2.2	12
1766	Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus. Cureus, 2021, 13, e16868.	0.2	6
1767	Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?. Frontiers in Medicine, 2021, 8, 712671.	1.2	11
1769	Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Heart Failure. ADCES in Practice, 0, , 2633559X2110344.	0.2	0
1770	Management of Obesity in CardiovascularÂPractice. Journal of the American College of Cardiology, 2021, 78, 513-531.	1.2	36
1771	Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients. Heart Failure Reviews, 2023, 28, 733-744.	1.7	19
1772	Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. JAMA Internal Medicine, 2021, 181, 1043.	2.6	32
1773	Reasons for hospitalizations in patients with type 2 diabetes in the <scp>CANVAS</scp> programme: A secondary analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2707-2715.	2.2	6
1774	Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease. Acta Clinica Belgica, 2021, , 1-10.	0.5	2
1775	The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with TypeÂ2 Diabetes Mellitus. Diabetes Therapy, 2021, 12, 2499-2515.	1.2	3
1776	Sodiumâ€“glucose cotransporter 2 inhibitors for the management of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2181-2198.	0.9	2
1777	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovascular Research, 2022, 118, 2231-2252.	1.8	23

#	Article	IF	Citations
1778	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	1.0	2,517
1779	Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence. Cardiovascular Diabetology, 2021, 20, 169.	2.7	17
1780	Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors. , 2021, 224, 107832.		26
1781	Introduction to Nephrocardiology. Cardiology Clinics, 2021, 39, 295-306.	0.9	4
1782	How Low Can You Go? Safety and Efficacy of Sodium-Glucose Cotransporter Inhibitors in Decreased Renal Function. Journal of Pharmacy Practice, 2021, , 089719002110397.	0.5	0
1783	Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis. Cells, 2021, 10, 2150.	1.8	32
1784	Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease. Nefrologia, 2021, , .	0.2	4
1785	SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes. Cardiovascular Drugs and Therapy, 2022, 36, 1091-1108.	1.3	2
1786	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European Heart Journal, 2021, 42, 4891-4901.	1.0	80
1787	Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling. International Journal of Molecular Sciences, 2021, 22, 8786.	1.8	48
1788	The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors. Cardiovascular Diabetology, 2021, 20, 167.	2.7	2
1789	Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on firstâ€line oral therapy for type 2 diabetes: A claimsâ€based observational cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 2741-2751.	2.2	4
1790	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. Expert Opinion on Pharmacotherapy, 2021, 22, 1-13.	0.9	2
1791	Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD. Kidney International Reports, 2021, 6, 2803-2810.	0.4	7
1792	HbA1c and beyond. Nephrology Dialysis Transplantation, 2023, 38, 34-40.	0.4	1
1793	Prospective association of serum adipocyte fatty acidâ€binding protein with heart failure hospitalization in diabetes. ESC Heart Failure, 2021, 8, 3964-3974.	1.4	2
1794	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace, 2021, 23, 1873-1891.	0.7	10
1795	Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic Î² cells in diabetic db/db mice. Scientific Reports, 2021, 11, 16120.	1.6	10

#	Article	IF	Citations
1796	Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. Atherosclerosis, 2021, 330, 8-13.	0.4	10
1797	Comorbidities and complications in Japanese patients with type 2 diabetes mellitus: Retrospective analyses of J-DREAMS, an advanced electronic medical records database. Diabetes Research and Clinical Practice, 2021, 178, 108845.	1.1	11
1798	New Antidiabetes Medications and Their Cardiovascular and Renal Benefits. Cardiology Clinics, 2021, 39, 335-351.	0.9	10
1799	Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 926.	3.0	65
1800	Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature. Cardiology Research, 2021, 12, 210-218.	0.5	7
1801	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	2.0	32
1802	Retrospective nationwide study on the trends in firstâ€line antidiabetic medication for patients with typeâ€‰2 diabetes in Japan. Journal of Diabetes Investigation, 2022, 13, 280-291.	1.1	44
1803	Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review. Heart, 2022, 108, 593-605.	1.2	3
1804	Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure. Journal of Clinical Medicine, 2021, 10, 3540.	1.0	6
1805	The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone. Journal of Personalized Medicine, 2021, 11, 828.	1.1	3
1806	ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes. European Heart Journal Supplements, 2021, 23, C184-C195.	0.0	5
1807	Efficacy and safety of sotagliflozin in patients with type <scp>2</scp> diabetes and severe renal impairment. Diabetes, Obesity and Metabolism, 2021, 23, 2632-2642.	2.2	30
1808	Trends in Adaptive Design Methods in Dialysis Clinical Trials: A Systematic Review. Kidney Medicine, 2021, 3, 925-941.	1.0	5
1809	Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placeboâ€controlled study. Diabetes, Obesity and Metabolism, 2021, 23, 2814-2818.	2.2	38
1810	Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control. Cureus, 2021, 13, e17452.	0.2	3
1811	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. JACC: Heart Failure, 2021, 9, 568-577.	1.9	8
1812	Cardiovascular disease in diabetes, beyond glucose. Cell Metabolism, 2021, 33, 1519-1545.	7.2	87
1813	Acute effect of addâ€on therapy with tofogliflozin, a sodium glucose coâ€transporter 2 inhibitor, on 24â€hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidaseâ€4 inhibitors. International Journal of Clinical Practice, 2021, 75, e14732.	0.8	2

#	Article	IF	Citations
1814	Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management. Cureus, 2021, 13, e17240.	0.2	6
1815	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. Journal of the American Heart Association, 2021, 10, e020418.	1.6	12
1816	New Drugs for Heart Failure: What is the Evidence in Older Patients?. Journal of Cardiac Failure, 2022, 28, 316-329.	0.7	1
1817	Chronic lowâ€grade inflammation in heart failure with preserved ejection fraction. Aging Cell, 2021, 20, e13453.	3.0	33
1818	Lower risk of hospitalization for heart failure, kidney disease and death with sodiumâ€glucose coâ€transporterâ€2 inhibitors compared with dipeptidyl peptidaseâ€4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care. Diabetes, Obesity and Metabolism, 2021, 23, 2207-2214.	2.2	22
1819	Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. Transplantation, 2022, 106, 734-748.	0.5	6
1820	A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. Drugs, 2021, 81, 1491-1511.	4.9	18
1821	Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors. Internal Medicine, 2021, 60, 2367-2374.	0.3	4
1822	Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2022, 20, 90-102.	0.4	3
1823	Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. Diabetes Spectrum, 2021, 34, 248-256.	0.4	1
1825	Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102035.	1.1	9
1826	Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure. Frontiers in Clinical Diabetes and Healthcare, 2021, 2, .	0.3	5
1827	Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review. Cardiovascular & Hematological Disorders Drug Targets, 2021, 21, 1-6.	0.2	4
1828	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. Diabetologia, 2021, 64, 2402-2414.	2.9	6
1829	Lessons Learned From Major Clinical Outcomes Trials Involving Sodiumâ€“Glucose Cotransporter 2 Inhibitors. Diabetes Spectrum, 2021, 34, 235-242.	0.4	0
1830	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients, 2021, 13, 2830.	1.7	27
1831	Sodiumâ€“Glucose Cotransporter 2 Inhibitors and the Kidney. Diabetes Spectrum, 2021, 34, 225-234.	0.4	1
1832	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558

#	Article	IF	Citations
1833	Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes. Circulation Reports, 2021, 3, 440-448.	0.4	18
1834	The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence. Therapeutics and Clinical Risk Management, 2021, Volume 17, 823-830.	0.9	9
1835	Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure. Cardiovascular Drugs and Therapy, 2022, 36, 497-504.	1.3	8
1836	Cardiovascular Disease in Patients with Diabetes: a Comparison of Professional Society Guidelines. Current Diabetes Reviews, 2021, 17, .	0.6	0
1837	Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study. Diabetes Care, 2021, 44, 2293-2301.	4.3	23
1838	Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. Kidney International Reports, 2021, 6, 2095-2104.	0.4	23
1839	Age- and sex-specific risk of urogenital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A population-based self-controlled case-series study. Maturitas, 2021, 150, 30-36.	1.0	7
1840	Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus. Endocrine Practice, 2022, 28, 16-24.	1.1	6
1841	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without HeartÂFailure. JACC: Heart Failure, 2021, 9, 807-820.	1.9	49
1842	Overestimation of glomerular filtration rate calculated from creatinine as compared with cystatin C in patients with type 2 diabetes receiving sodiumâ€glucose cotransportor 2 inhibitors. Diabetic Medicine, 2021, , e14659.	1.2	2
1843	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. European Heart Journal, 2021, 43, 56-67.	1.0	23
1844	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	0.8	220
1845	Costâ€utility analysis of addâ€on dapagliflozin in heart failure with reduced ejection fraction in the Philippines. ESC Heart Failure, 2021, 8, 5132-5141.	1.4	12
1846	Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain. Revista Clínica Espanõla, 2022, 222, 195-204.	0.3	6
1847	Are novel glucoseâ€lowering agents' cardiorenal benefits generalizable to individuals of <scp>Black</scp> race? A metaâ€trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. Diabetes, Obesity and Metabolism, 2022, 24, 154-159.	2.2	5
1848	Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980â€“2020. , 0, , .		4
1849	SGLT2 Inhibitors: Physiology and Pharmacology. Kidney360, 2021, 2, 2027-2037.	0.9	50
1850	Studies and research design in medicine. SeÄenovskij Vestnik, 2021, 12, 4-17.	0.3	3

#	Article	IF	Citations
1851	Effects of Metabolic Factors, Race-Ethnicity, and Sex on the Development of Nephropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study. Diabetes Care, 2022, 45, 1056-1064.	4.3	8
1852	Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study. BMJ Open, 2021, 11, e046912.	0.8	1
1853	An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 29-42.	0.9	4
1854	Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines, 2021, 9, 1356.	1.4	45
1855	Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents. Cardiovascular Diabetology, 2021, 20, 175.	2.7	6
1856	Glycemic Variability, Oxidative Stress, and Impact on Complications Related to Type 2 Diabetes Mellitus. Current Diabetes Reviews, 2021, 17, e071620183816.	0.6	15
1857	Aortic plaque burden predicts vascular events in patients with cardiovascular disease: The EAST-NOGA study. Journal of Cardiology, 2022, 79, 144-152.	0.8	12
1858	The sodiumâ€“glucose coâ€transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox. European Journal of Heart Failure, 2021, 23, 1673-1676.	2.9	8
1859	Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy. World Journal of Cardiology, 2021, 13, 464-471.	0.5	3
1860	Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study. Journal of Diabetes and Its Complications, 2021, 35, 107972.	1.2	14
1861	SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 687-693.	0.2	3
1862	Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial. Cardiovascular Diabetology, 2021, 20, 186.	2.7	8
1863	The evaluation of noninferiority for renal composite outcomes between sodiumâ€“glucose cotransporter inhibitors in Japan. Primary Care Diabetes, 2021, 15, 1058-1062.	0.9	2
1864	Efficacy and safety of Sodium-Glucose-Transporter-2 inhibitors in kidney transplant patients. Current Opinion in Nephrology and Hypertension, 2021, Publish Ahead of Print, 577-583.	1.0	2
1865	Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study. BMC Cardiovascular Disorders, 2021, 21, 456.	0.7	19
1866	Renoprotection with sodiumâ€glucose cotransporterâ€2 inhibitors in children: Known and unknown. Nephrology, 2021, , .	0.7	4
1867	Is There a Diabetesâ€“Kidneyâ€“Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors. Frontiers in Cardiovascular Medicine, 2021, 8, 716083.	1.1	1
1868	Post-Transplant Cardiovascular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1878-1889.	2.2	16

#	Article	IF	Citations
1869	Management of type 2 diabetes without insulin: An update for the PCP. Disease-a-Month, 2021, , 101290.	0.4	0
1870	A Comparative Study of Safety Outcomes of Sodium Glucose Cotransporter-2 Inhibitors and Loop Diuretics Among Diabetic Patients Using Real-world Data. Current Problems in Cardiology, 2022, 47, 100995.	1.1	4
1871	Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). Diabetes Research and Clinical Practice, 2021, 180, 109069.	1.1	4
1872	A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus. American Journal of Medicine, 2021, 134, 1076-1084.	0.6	3
1873	SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction. Revista Portuguesa De Cardiologia, 2021, 40, 687-693.	0.2	6
1874	Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes. Biomedicines, 2021, 9, 1154.	1.4	2
1875	Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes. Current Diabetes Reviews, 2021, 17, .	0.6	1
1876	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	4.3	13
1877	Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function. Diabetes and Metabolism, 2021, 47, 101274.	1.4	11
1878	Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats. Chemico-Biological Interactions, 2021, 347, 109617.	1.7	12
1879	Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations. International Journal of Molecular Sciences, 2021, 22, 9800.	1.8	11
1880	Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments. Hypertension, 2021, 78, 564-577.	1.3	35
1881	Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus. , 0, , .		4
1882	Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors. Frontiers in Pharmacology, 2021, 12, 689885.	1.6	0
1883	Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload. Frontiers in Physiology, 2021, 12, 738594.	1.3	11
1884	Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 12-20.	2.2	1
1885	Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A populationâ€based observational retrospective cohort study. Diabetic Medicine, 2022, 39, e14697.	1.2	4
1886	Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 2021, , .	1.4	9

#	Article	IF	Citations
1887	Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study. BMJ Open, 2021, 11, e051549.	0.8	10
1888	Drug utilisation study of antidiabetic medication during 2012â€2019 in Romania. International Journal of Clinical Practice, 2021, 75, e14770.	0.8	4
1889	Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodiumâ€“glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study. Diabetes Research and Clinical Practice, 2021, 180, 109037.	1.1	6
1890	The comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors. Journal of Diabetes and Its Complications, 2021, 35, 108052.	1.2	7
1891	Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR. Kidney International Reports, 2021, 6, 2415-2424.	0.4	8
1892	Evolving Concepts of Type 2 Diabetes Management. Medical Clinics of North America, 2021, 105, 955-966.	1.1	3
1893	Changes in the prognostic values of modern cardiovascular biomarkers in relation to duration of diabetes mellitus. Journal of Diabetes and Its Complications, 2021, 35, 107990.	1.2	4
1894	Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacological Research, 2021, 171, 105782.	3.1	72
1895	Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy. Journal of Clinical Medicine, 2021, 10, 4409.	1.0	5
1896	Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. Annual Review of Pharmacology and Toxicology, 2022, 62, 109-120.	4.2	6
1897	Analysis of robustness of the landmark Cardiovascular outcome trials of antidiabetic drugs â€“ A systematic review. Current Diabetes Reviews, 2021, 17, .	0.6	0
1898	2021 Consensus Pathway of the TaiwanÂSociety of Cardiology on NovelÂTherapyÂfor Type 2 Diabetes. JACC Asia, 2021, 1, 129-146.	0.5	1
1899	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2021, 27, 1404-1444.	0.7	60
1900	Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 586-594.	5.5	145
1901	Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload. Scientific Reports, 2021, 11, 18384.	1.6	18
1902	External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease. Cardiovascular Diabetology, 2021, 20, 181.	2.7	0
1903	Effects of SGLT2 Inhibitors beyond Glycemic Controlâ€”Focus on Myocardial SGLT1. International Journal of Molecular Sciences, 2021, 22, 9852.	1.8	9
1904	Sodium glucose coâ€transporterâ€2 inhibitorâ€induced diabetic ketoacidosis following tooth extraction: improving awareness among dental practitioners. Australian Dental Journal, 2021, 66, 444-447.	0.6	1

#	Article	IF	Citations
1905	Sodiumâ€€Glucose Cotransporter 2 Inhibitors, Allâ€€Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Metaâ€€Analysis and Metaâ€€Regression. Journal of the American Heart Association, 2021, 10, e019918.	1.6	8
1906	Chronic Kidney Disease: Strategies to Retard Progression. International Journal of Molecular Sciences, 2021, 22, 10084.	1.8	30
1907	An Efficacy and Safety Study of Remogliflozin in Obese Indian Type 2 Diabetes Mellitus Patients Who Were Inadequately Controlled on Insulin Glargine Plus other Oral Hypoglycemic Agents. Current Diabetes Reviews, 2021, 17, e122120189341.	0.6	1
1908	Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria. Journal of Diabetes and Its Complications, 2021, 35, 108046.	1.2	1
1909	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circulation Journal, 2021, 85, 2252-2291.	0.7	80
1910	Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. International Journal of Cardiology, 2021, 338, 248-257.	0.8	1
1911	Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention. Frontiers in Cardiovascular Medicine, 2021, 8, 746382.	1.1	23
1912	Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A retrospective multi-institutional study. Diabetes Research and Clinical Practice, 2021, 180, 109076.	1.1	14
1913	Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review. Journal of Clinical Medicine, 2021, 10, 4497.	1.0	10
1914	Role of diabetes in stroke: Recent advances in pathophysiology and clinical management. Diabetes/Metabolism Research and Reviews, 2022, 38, e3495.	1.7	10
1915	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2021, 174, 1528-1541.	2.0	52
1916	Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies. Metabolism: Clinical and Experimental, 2021, 124, 154890.	1.5	54
1917	The Potential Role of EHR data in optimizing eligibility criteria definition for cardiovascular outcome trials. International Journal of Medical Informatics, 2021, 156, 104587.	1.6	0
1918	Sodium-Glucose Cotransporter-2 Inhibitors: Heart Failure and Renal Protection Indications. Journal for Nurse Practitioners, 2021, , .	0.4	0
1919	The effect of sodium-glucose link transporter 2 inhibitors on heart failure end points in people with type 2 diabetes mellitus: a systematic review and meta-analysis. British Journal of Diabetes, 0, , .	0.1	1
1920	New progress in drugs treatment of diabetic kidney disease. Biomedicine and Pharmacotherapy, 2021, 141, 111918.	2.5	36
1921	Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clinical Research in Cardiology, 2022, 111, 428-439.	1.5	22
1922	The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia, 2021, 64, 2676-2686.	2.9	44

#	Article	IF	Citations
1923	Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection. Cardiovascular Drugs and Therapy, 2021, , 1.	1.3	11
1924	SGLT2 Inhibitors and Their Mode of Action in Heart Failureâ€"Has the Mystery Been Unravelled?. Current Heart Failure Reports, 2021, 18, 315-328.	1.3	43
1925	The pleiotropic cardiovascular effects of sodium-glucose cotransporter-2 inhibitors. Current Opinion in Cardiology, 2021, Publish Ahead of Print, 764-768.	0.8	6
1926	Quantifying the Risk Continuum for Cardiovascular Death in Adults with Type 2 Diabetes. Canadian Journal of Diabetes, 2021, 45, 650-658.e2.	0.4	4
1927	SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies. Pharmacological Research, 2021, 172, 105836.	3.1	26
1928	Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases. Medicine (United States), 2021, 100, e27362.	0.4	7
1929	Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists. Diabetes Research and Clinical Practice, 2021, 180, 109036.	1.1	13
1930	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. American Heart Journal, 2021, 240, 73-80.	1.2	1
1931	A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol. Journal of Diabetes and Its Complications, 2021, 35, 107996.	1.2	8
1932	Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation. Atherosclerosis, 2021, 335, 16-22.	0.4	10
1933	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. EuroIntervention, 2021, 17, e618-e630.	1.4	3
1934	Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism: Clinical and Experimental, 2021, 123, 154838.	1.5	84
1935	Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors. Cardiology Research, 2021, 12, 324-326.	0.5	2
1936	Disease-modifier Drugs in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 561-573.	1.0	2
1937	Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. Biomedicine and Pharmacotherapy, 2021, 143, 112169.	2.5	22
1938	Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102275.	1.8	17
1939	Sodium/glucose cotransporter 2 and renoprotection: From the perspective of energy regulation and water conservation. Journal of Pharmacological Sciences, 2021, 147, 245-250.	1.1	4
1940	Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice. Journal of Pharmacological Sciences, 2021, 147, 340-347.	1.1	2

#	Article	IF	Citations
1941	Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy. , 2021, 228, 107920.		20
1942	Significance of Glycemic Variability in Diabetes Mellitus. Internal Medicine, 2022, 61, 281-290.	0.3	10
1943	Detection of subclinical heart failure. , 2022, , 20-50.		1
1944	Preventive Cardiology. , 2022, , 341-375.		0
1945	SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucoseâ€lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review. Diabetic Medicine, 2021, 38, e14502.	1.2	14
1946	Should metformin remain the first-line therapy for treatment of type 2 diabetes?. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882098022.	1.4	58
1947	The Forgotten Antiproteinuric Properties of Diuretics. American Journal of Nephrology, 2021, 52, 435-449.	1.4	22
1948	Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial. Cardiovascular Diabetology, 2021, 20, 4.	2.7	27
1949	SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. Diabetes Mellitus, 2021, 23, 475-491.	0.5	11
1950	Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovascular Diabetology, 2021, 20, 6.	2.7	42
1952	AtualizaÃ§Ã£o de TÃ³picos Emergentes da Diretriz Brasileira de InsuficiÃªncia CardÃaca â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 116, 1174-1212.	0.3	13
1953	Â¿Son los inhibidores del receptor SGLT2 fÃ¡rmacos antidiabÃ©ticos o cardiovasculares?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 33-40.	0.4	2
1954	Hipoglucemiantes y riesgo cardiovascular. FMC Formacion Medica Continuada En Atencion Primaria, 2021, 28, 4-13.	0.0	0
1955	SGLT2 Inhibitors: the Gift that Keeps on Giving. Korean Circulation Journal, 2021, 51, 263.	0.7	0
1957	Modelâ€Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 108-118.	1.3	11
1958	A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure. Cardiology Research, 2021, 12, 60-66.	0.5	17
1960	Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2020, 11, 604250.	1.5	9
1961	Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. Internal Medicine, 2021, 60, 3391-3399.	0.3	11

#	Article	IF	Citations
1962	The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. Therapeutic Advances in Cardiovascular Disease, 2021, 15, 175394472110026.	1.0	10
1963	Sodiumâ€“glucose Cotransporter 2 Inhibitorsâ€™ Rise to the Backbone of Heart Failure Management: A Clinical Review. Heart International, 2021, 15, 42.	0.4	0
1964	Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment. Korean Circulation Journal, 2021, 51, 399.	0.7	9
1965	Pharmacological treatment of hyperglycemia in type 2 diabetes. Journal of Clinical Investigation, 2021, 131, .	3.9	102
1966	Genetic Variation in Sodiumâ€glucose Cotransporter 2 and Heart Failure. Clinical Pharmacology and Therapeutics, 2021, 110, 149-158.	2.3	11
1967	Poor adherence and persistence to sodium glucose coâ€transporter 2 inhibitors in realâ€world settings: Evidence from a systematic review and metaâ€analysis. Diabetes/Metabolism Research and Reviews, 2021, 37, e3350.	1.7	15
1968	Is the steppingâ€down approach a better option than multiple daily injections in obese patients with poorly controlled Type 2 diabetes on advanced insulin therapy?. Endocrinology, Diabetes and Metabolism, 2021, 4, e00204.	1.0	7
1969	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and metaâ€analysis. ESC Heart Failure, 2020, 7, 3298-3309.	1.4	76
1971	Antidiabetika. , 2019, , 471-490.		1
1972	Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Failure Reviews, 2021, 26, 1037-1062.	1.7	3
1973	Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. Diabetes Therapy, 2020, 11, 33-48.	1.2	17
1974	SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes. Diabetes Therapy, 2020, 11, 2757-2774.	1.2	20
1975	Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis. Clinical Drug Investigation, 2020, 40, 665-669.	1.1	5
1976	Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease. Journal of Nephrology, 2020, 33, 917-929.	0.9	38
1977	A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?. International Review of Neurobiology, 2020, 155, 113-140.	0.9	27
1978	Myocardial Ketones Metabolism in Heart Failure. Journal of Cardiac Failure, 2020, 26, 998-1005.	0.7	36
1979	Glucagon-like peptide-1 receptor agonists or sodiumâ€“glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints. Diabetes and Metabolism, 2020, 46, 272-279.	1.4	9
1981	Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacological Research, 2020, 159, 104916.	3.1	56

#	Article	IF	Citations
1982	Abordaje integral del paciente con diabetes mellitus tipo 2 y enfermedad cardiovascular o de muy alto riesgo cardiovascular. REC: CardioClinics, 2019, 54, 183-192.	0.1	9
1983	Uso de terapia antihiperglucemiante con beneficio cardiovascular en pacientes con diabetes tipo 2 que requieren hospitalizaciÃ³n: un estudio transversal. Revista Clinica Espanola, 2020, 221, 517-517.	0.2	7
1984	ESVM Guideline on peripheral arterial disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 1-79.	0.6	110
1985	5 Conservative treatment for PAD â€“ Risk factor management. Vasa - European Journal of Vascular Medicine, 2019, 48, 1-12.	0.6	15
1986	Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes. Scientific Reports, 2020, 10, 22396.	1.6	29
1987	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. American Journal of Kidney Diseases, 2020, 76, 842-850.	2.1	4
1990	Pharmacotherapy of hypertension in patients with pre-dialysis chronic kidney disease. Expert Opinion on Pharmacotherapy, 2020, 21, 1201-1217.	0.9	2
1991	Safety of injectable semaglutide for type 2 diabetes. Expert Opinion on Drug Safety, 2020, 19, 785-798.	1.0	10
1992	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal, 2021, 42, 700-710.	1.0	117
1993	Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. European Journal of Preventive Cardiology, 2021, 28, 69-75.	0.8	19
1994	Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes. Nephrology Dialysis Transplantation, 2020, 35, i24-i32.	0.4	15
1995	Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?. Nephrology Dialysis Transplantation, 2020, 35, i48-i55.	0.4	18
1996	Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?. Nephrology Dialysis Transplantation, 2020, 35, i33-i42.	0.4	43
1997	Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, i43-i47.	0.4	9
1998	Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Journal of Hypertension, 2021, 39, 749-758.	0.3	38
1999	Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial. Blood Pressure Monitoring, 2020, 25, 346-350.	0.4	12
2000	Sodiumâ€“Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?. American Journal of Therapeutics, 2021, 28, e96-e110.	0.5	2
2001	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms. Current Opinion in Nephrology and Hypertension, 2020, 29, 112-118.	1.0	17

#	Article	IF	Citations
2002	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research and Care, 2020, 8, e001238.	1.2	43
2003	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 506-522.	1.1	39
2004	Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment. Diabetes and Vascular Disease Research, 2020, 17, 147916412097122.	0.9	5
2005	Diabetes Mellitus and Long-Term Risk for Heart Failure After Coronary Revascularization. Circulation Journal, 2020, 84, 471-478.	0.7	7
2006	A Case of Fournierâ€™s Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus. American Journal of Case Reports, 2020, 21, e920115.	0.3	9
2007	Recent advances in the treatment of chronic heart failure. F1000Research, 2019, 8, 2134.	0.8	7
2008	Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. Translational and Clinical Pharmacology, 2020, 28, 17.	0.3	11
2009	Positioning Metabolism as a Central Player in the Diabetic Heart. Journal of Lipid and Atherosclerosis, 2020, 9, 92.	1.1	7
2010	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. PLoS ONE, 2020, 15, e0240567.	1.1	4
2011	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes Mellitus, 2019, 22, 1-121.	0.5	20
2012	Diabetes mellitus type 2 in adults. Diabetes Mellitus, 2020, 23, 4-102.	0.5	16
2013	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes Mellitus, 2019, 22, 1-121.	0.5	195
2014	Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center. Journal of Clinical Medicine Research, 2019, 11, 267-274.	0.6	20
2015	Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus. Journal of Clinical Medicine Research, 2020, 12, 165-171.	0.6	10
2016	Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis. Endocrinology, Diabetes and Metabolism Case Reports, 2019, 2019, .	0.2	19
2017	Sodiumâ€“Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes. Cardiac Failure Review, 2019, 5, 169-172.	1.2	1
2018	Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition. Cardiac Failure Review, 2020, 6, e28.	1.2	7
2019	Sodiumâ€“Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice. Cardiac Failure Review, 2020, 6, e31.	1.2	17

#	Article	IF	Citations
2020	Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review, 2020, 15, e13.	0.7	20
2021	Novel treatment options for chronic kidney disease complications. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2020, 66, s01-s02.	0.3	1
2022	SGLT-2 inhibitors in diabetes: a focus on renoprotection. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2020, 66, s17-s24.	0.3	14
2023	Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 467-477.	0.4	3
2024	Cardiorenal Syndrome in Type 2 Diabetes Mellitus â€“ Rational Use of Sodiumâ€“glucose Cotransporter-2 Inhibitors. European Endocrinology, 2020, 16, 113.	0.8	8
2025	Vasculo-metabolic Axis in Type 2 Diabetes Mellitusâ€”Abductive Reasoning from Sodium-glucose Cotransporter 2-inhibitor Evidence. US Endocrinology, 2019, 15, 27.	0.3	1
2026	Once-weekly Dulaglutide and Major Cardiovascular Eventsâ€”Results of the REWIND Trial. US Endocrinology, 2019, 15, 65.	0.3	2
2028	Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan. Aging, 2020, 12, 24940-24956.	1.4	20
2029	Patients with Combination of Cardiovascular Diseases and Type 2 Diabetes in RECVASA and REGION Registries: Multimorbidity, Outcomes and Potential Effect of Dapagliflozin in the Russian Clinical Practice. Rational Pharmacotherapy in Cardiology, 2020, 16, 59-68.	0.3	2
2030	Chronic Kidney Disease: Current State of the Problem. Rational Pharmacotherapy in Cardiology, 2020, 16, 938-947.	0.3	7
2031	A 7.0â€“7.7% value for glycated haemoglobin is better than a <7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus. Annals of Translational Medicine, 2019, 7, S122-S122.	0.7	3
2032	Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes managementâ€¦and potentially beyond. Annals of Translational Medicine, 2019, 7, S132-S132.	0.7	6
2033	Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. Current Pharmaceutical Design, 2020, 26, 5911-5932.	0.9	8
2034	Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection. Current Diabetes Reviews, 2020, 16, 869-873.	0.6	2
2035	Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials. Current Diabetes Reviews, 2020, 16, 917-921.	0.6	2
2036	Pharmacological Management of Diabetes for Reducing Glucose Levels and Cardiovascular Disease Risk: What Evidence in South Asians?. Current Diabetes Reviews, 2020, 17, e122820189511.	0.6	3
2037	Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 70-78.	2.2	54
2038	Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1433-1444.	2.2	40

#	Article	IF	Citations
2039	Sodiumâ€“Glucose Cotransporter 2 Inhibitorâ€“Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review. Clinical Diabetes, 2020, 38, 112-116.	1.2	6
2040	SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial. Diabetes, 2021, 70, 800-808.	0.3	32
2041	Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabetes Care, 2021, 44, 440-447.	4.3	70
2042	12. Older Adults:Standards of Medical Care in Diabetesâ€”2021. Diabetes Care, 2021, 44, S168-S179.	4.3	149
2043	Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor Î±-Stimulated Human Coronary Arterial Endothelial Cells. Cellular Physiology and Biochemistry, 2019, 53, 865-886.	1.1	120
2044	Trends in diabetes medication use in Australia, Canada, England, and Scotland: a repeated cross-sectional analysis in primary care. British Journal of General Practice, 2021, 71, e209-e218.	0.7	24
2045	Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction. Cardiovascular Prevention and Pharmacotherapy, 2020, 2, 113.	0.0	12
2046	Common Co-Morbidities in Heart Failure â€“ Diabetes, Functional Mitral Regurgitation and Sleep Apnoea. International Journal of Heart Failure, 2019, 1, 25.	0.9	22
2047	Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials. International Journal of Heart Failure, 2020, 2, 12.	0.9	15
2048	Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World Journal of Gastroenterology, 2020, 26, 2740-2757.	1.4	14
2049	Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. World Journal of Gastroenterology, 2020, 26, 3225-3235.	1.4	17
2050	Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea. Endocrinology and Metabolism, 2020, 35, 329-338.	1.3	7
2051	Current status of heart failure: global and Korea. Korean Journal of Internal Medicine, 2020, 35, 487-497.	0.7	27
2052	Heart Failure with Preserved Ejection Fraction: the Major Unmet Need in Cardiology. Korean Circulation Journal, 2020, 50, 1051.	0.7	15
2053	Associations among Obesity Degree, Glycemic Status, and Risk of Heart Failure in 9,720,220 Korean Adults. Diabetes and Metabolism Journal, 2020, 44, 592.	1.8	19
2054	Mitochondrial Mechanisms in Diabetic Cardiomyopathy. Diabetes and Metabolism Journal, 2020, 44, 33.	1.8	62
2055	Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations. Diabetes and Metabolism Journal, 2020, 44, 11.	1.8	30
2056	SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins. Indian Journal of Endocrinology and Metabolism, 2019, 23, 175.	0.2	2

#	Article	IF	Citations
2057	Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control. Indian Journal of Endocrinology and Metabolism, 2019, 23, 140.	0.2	7
2058	Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. Journal of Family Medicine and Primary Care, 2019, 8, 1855.	0.3	21
2059	Implications of CVD-REAL 2 study for Indian diabetic population. Journal of Diabetology, 2019, 10, 57.	0.1	3
2060	Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date. World Journal of Diabetes, 2019, 10, 490-510.	1.3	56
2061	Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. World Journal of Diabetes, 2019, 10, 291-303.	1.3	14
2062	Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus. World Journal of Diabetes, 2020, 11, 150-154.	1.3	1
2063	Sodium-glucose cotransporter 2 inhibitorsâ€™ mechanisms of action in heart failure. World Journal of Diabetes, 2020, 11, 269-279.	1.3	19
2064	Range of adiposity and cardiorenal syndrome. World Journal of Diabetes, 2020, 11, 322-350.	1.3	13
2065	Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. International Journal of Endocrinology and Metabolism, 2019, In Press, e84353.	0.3	27
2066	Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke. Journal of Stroke, 2019, 21, 139-150.	1.4	8
2067	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 787-891.	0.3	102
2068	2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. Acta Cardiologica Sinica, 2019, 35, 244-283.	0.1	50
2069	Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. Journal of Obesity and Metabolic Syndrome, 2019, 28, 254-261.	1.5	13
2070	Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease. Journal of Obesity and Metabolic Syndrome, 2020, 29, 215-221.	1.5	12
2071	DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs in Context, 2020, 9, 1-7.	1.0	20
2072	Management of type 2 diabetes: consensus of diabetes organizations. Drugs in Context, 2020, 9, 1-25.	1.0	19
2073	Euglycemic Diabetic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor Use Post-Bariatric Surgery: A Brief Review of the Literature. Cureus, 2020, 12, e10878.	0.2	9
2074	Hochpreisige Arzneimittel â€“ Herausforderungen und Perspektiven aus Sicht der VertragsÃrzteschaft. , 2021, , 191-208.		1

#	Article	IF	Citations
2075	Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. European Journal of Preventive Cardiology, 2022, 28, 1961-1973.	0.8	37
2076	Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. International Journal of Molecular Sciences, 2021, 22, 1680.	1.8	17
2077	Obesity-Related Glomerulopathy: Clinical Management. Seminars in Nephrology, 2021, 41, 358-370.	0.6	6
2078	Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. Seminars in Nephrology, 2021, 41, 331-348.	0.6	3
2079	Sodiumâ€“Glucose Cotransporter 2 Inhibitor Use Associated With Fournierâ€™s Gangrene: A Review of Case Reports and Spontaneous Post-Marketing Cases. Clinical Diabetes, 2022, 40, 78-86.	1.2	9
2080	Epigenetic Alterations in Podocytes in Diabetic Nephropathy. Frontiers in Pharmacology, 2021, 12, 759299.	1.6	16
2081	Effectiveness and safety of ertugliflozin for typeâ€‰2 diabetes: A metaâ€analysis of data from randomized controlled trials. Journal of Diabetes Investigation, 2022, 13, 478-488.	1.1	1
2082	Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism: Clinical and Experimental, 2022, 126, 154918.	1.5	42
2083	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. European Cardiology Review, 2021, 16, e40.	0.7	9
2084	Intersection Between Diabetes and Heart Failure: Is SGLT2i the â€œOne Stone for Two Birdsâ€•Approach?. Current Cardiology Reports, 2021, 23, 171.	1.3	2
2085	Stroke prevention in diabetes with glucagon-like peptide-1 receptor agonists: A game-changer?. Journal of Diabetes and Its Complications, 2021, 35, 108075.	1.2	0
2086	The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms. Cells, 2021, 10, 2699.	1.8	7
2087	Body mass index is inversely associated with capillary ketones at the time of colonoscopy: Implications for SGLT2i use. Clinical Endocrinology, 2021, , .	1.2	1
2088	Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (<scp>DapaTAVI</scp>) randomized trial. European Journal of Heart Failure, 2022, 24, 581-588.	2.9	13
2089	Long-term effects of the mean hemoglobin A1c levels after percutaneous coronary intervention in patients with diabetes. Korean Journal of Internal Medicine, 2021, 36, 1365-1376.	0.7	7
2090	The role of hyperglycaemia in the development of diabetic cardiomyopathy. Archives of Cardiovascular Diseases, 2021, 114, 748-760.	0.7	24
2091	Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors. Acta Diabetologica, 2022, 59, 233-241.	1.2	4
2092	Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review. Cureus, 2021, 13, e18485.	0.2	1

#	Article	IF	Citations
2093	Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 200.	2.7	10
2095	SGLT2 inhibitors in heart failure with reduced ejection fraction. Egyptian Heart Journal, 2021, 73, 93.	0.4	8
2096	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. JAMA Internal Medicine, 2021, 181, 1575.	2.6	28
2097	Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies. Cells, 2021, 10, 2832.	1.8	66
2098	Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Frontiers in Endocrinology, 2021, 12, 738848.	1.5	36
2099	Kidney single-cell transcriptome profile reveals distinct response of proximal tubule cells to SGLT2i and ARB treatment in diabetic mice. Molecular Therapy, 2022, 30, 1741-1753.	3.7	17
2100	Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 664533.	1.5	6
2101	Current Evidence on Prevention of Atrial Fibrillation: Modifiable Risk Factors and the Effects of Risk Factor Intervention. Cardiology in Review, 2023, 31, 70-79.	0.6	2
2102	Impact of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) On Cardiac Bioenergetic Properties and Cardiorespiratory Fitness. Cardiology in Review, 2021, Publish Ahead of Print, .	0.6	1
2103	Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Diseaseâ€"From Bench to Bedside. Frontiers in Physiology, 2021, 12, 755060.	1.3	13
2104	Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. Journal of Endocrinological Investigation, 2022, 45, 489-495.	1.8	17
2105	Role of neutrophils in type 2 diabetes and associated atherosclerosis. International Journal of Biochemistry and Cell Biology, 2021, 141, 106098.	1.2	7
2108	Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction. American Journal of Cardiovascular Drugs, 2021, 21, 701-710.	1.0	9
2109	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. International Journal of Cardiovascular Imaging, 2021, , 1.	0.7	6
2110	Sodiumâ€glucose coâ€transporterâ€2 inhibitors in the nonâ€diabetic heart failure patient. British Journal of Clinical Pharmacology, 2021, , .	1.1	0
2111	The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?. , 2022, 232, 108008.		19
2112	Euglycemic Diabetic Ketoacidosis Following Major Vascular Surgery is a New Item on the Differential for Post-operative Acidosis. Journal of Vascular Surgery Cases and Innovative Techniques, 2021, 7, 778-780.	0.3	4
2113	Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease. Cardiovascular Diabetology, 2021, 20, 213.	2.7	17

#	Article	IF	Citations
2114	Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovascular Diabetology, 2021, 20, 210.	2.7	31
2115	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013650.	1.5	28
2117	Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease. Clinical Diabetes, 2022, 40, 158-167.	1.2	1
2119	Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials. Diabetes Research and Clinical Practice, 2022, 183, 109080.	1.1	12
2120	One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. British Journal of Clinical Pharmacology, 2022, 88, 1598-1612.	1.1	4
2121	Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes. Diabetes, 2021, 70, 2810-2822.	0.3	36
2122	Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice. Frontiers in Pharmacology, 2021, 12, 729334.	1.6	13
2123	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine, 2021, 41, 101163.	3.2	33
2124	Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Hypertension, 2021, 78, 1197-1205.	1.3	85
2126	Navigating the Major Adverse Cardiovascular Event (MACE)-atherosclerotic Cardiovascular Disease versus Heart Failure. US Endocrinology, 2019, 15, 24.	0.3	0
2128	Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-NaÃ¯ve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711â€“7). Diabetes and Metabolism Journal, 2019, 43, 906.	1.8	0
2129	An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?. Diabetes and Metabolism Journal, 2019, 43, 578.	1.8	0
2130	Heart Failure with Preserved Ejection Fraction. , 2019, , 397-408.		1
2132	Does Metformin Assist New Anti-Diabetic Drugs to Succeed?. Journal of Clinical Medicine Research, 2019, 11, 151-155.	0.6	2
2133	Essential Points of Treatment and Examination to Prevent Diabetic Kidney Disease Aggravation. Juntendo Medical Journal, 2019, 65, 529-536.	0.1	0
2134	Safety Issues with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical Considerations. Journal of Korean Diabetes, 2019, 20, 127.	0.1	0
2135	Fisiopatologia e Tratamento da InsuficiÃªncia CardÃaca com FraÃ§Ã£o de EjeÃ§Ã£o Preservada: Estado da Arte e Perspectivas para o Futuro. Arquivos Brasileiros De Cardiologia, 2019, 114, 120-129.	0.3	2
2136	3. Recent Progress in the Treatment of Type 2 Diabetes. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 460-467.	0.0	0

#	Article	IF	Citations
2137	Copyright and licensing of E-journals:. Japanese Journal of Electrocardiology, 2019, 39, 3-4.	0.0	0
2138	II. Prevention of Cardiac-events by Treatments of Lifestyle Diseases. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 673-680.	0.0	0
2139	Diabetes Mellitus and Chronic Heart Failure. Vnitrni Lekarstvi, 2019, 65, 307-313.	0.1	0
2140	Series: Cardiovascular outcome trials for diabetes drugs Saxagliptin and SAVOR-TIMI 53. British Journal of Diabetes, 2019, 19, 34-36.	0.1	1
2141	Diabetes medications with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, SGLT2 inhibitors and long-acting GLP-1 receptor agonists complement each other to save lives by different mechanisms?. British Journal of Diabetes, 2019, 19, 1-5.	0.1	4
2143	Pharmacotherapy of Diabetes Focused on Stroke. Journal of the Korean Neurological Association, 2019, 37, 235-250.	0.0	3
2144	Diabetes management: Beyond hemoglobin A1c. Cleveland Clinic Journal of Medicine, 2019, 86, 595-600.	0.6	3
2145	7. Diabetes and Heart Failure: How to Treat Doubles Dangers. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1902-1911.	0.0	0
2146	Hypoglycaemic Agents in Patients with Heart Failure. International Cardiovascular Forum Journal, 0, 18, .	1.1	1
2147	A modern view on the mechanisms of diabetic cardiomyopathy development and the its modification options. Russian Journal of Cardiology, 2019, , 142-147.	0.4	3
2148	The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. Russian Journal of Cardiology, 2019, , 98-111.	0.4	6
2149	SGLT2-Hemmer als Ursache fÃ¼r die Entstehung einer Ketoazidose. Diabetologie Und Stoffwechsel, 2019, 14, 439-442.	0.0	0
2151	Tip 2 diyabetli hastalarda dapagliflozin tedavisinin trombosit fonksiyonlarÄ± ve inflamasyon Ã¼zerine etkisi. UludaÄŸ Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.2	0
2152	COMPARISON OF THE EFFECT OF DAPAGLIFLOZIN ON CONTRAST TO STANDARD THERAPY OF THE PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CONCOMITANT OBESITY, THEIR EFFECT ON LABORATORY AND ANTHROPOMETRIC PARAMETERS. WiadomoÅ›ci Lekarskie, 2020, 73, 457-461.	0.1	0
2153	Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective. Cardiovascular Prevention and Pharmacotherapy, 2020, 2, 11.	0.0	0
2155	SelecciÃ³n de lo mejor del aÃ±o 2019 en insuficiencia cardiaca. REC: CardioClinics, 2020, 55, 44-50.	0.1	0
2156	Effective SGLT2 Inhibitor for Patient with Type 2 Diabetes Mellitus (T2DM) and Depression. , 2020, 2, 26-32.		4
2157	MANAGEMENT OF HEART FAILURE PATIENTS (UPDATE 2019) â€“ PHARMACOLOGICAL THERAPY. In A Good Rythm, 2020, 1, 30-32.	0.0	0

#	Article	IF	Citations
2160	Management of the heart failure patient in the primary care setting. Singapore Medical Journal, 2020, 61, 225-229.	0.3	5
2161	Patient and Provider Characteristics Associated With Sodiumâ€“Glucose Cotransporter 2 Inhibitor Prescription in Patients With Diabetes and Proteinuric Chronic Kidney Disease. Clinical Diabetes, 2020, 38, 240-247.	1.2	9
2163	Profil de tolÃ©rance des inhibiteurs de SGLT2Â: le point en 2020. Medecine Des Maladies Metaboliques, 2020, 14, 331-341.	0.1	0
2164	Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data. Russian Journal of Cardiology, 2020, 25, 3870.	0.4	6
2165	Glifozines and cardiorenal outcomes. Minerva Cardioangiologica, 2020, 68, 188-196.	1.2	0
2166	Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. World Journal of Gastroenterology, 2020, 26, 3225-3235.	1.4	0
2167	The year in cardiology: heart failureâ€The year in cardiology 2019. Cardiologia Croatica, 2020, 15, 167-188.	0.0	1
2168	Ã€ propos de lâ€™expÃ©rience belge avec les inhibiteurs des SGLT2. Medecine Des Maladies Metaboliques, 2020, 14, 320-330.	0.1	3
2169	Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic review and meta-analysis. Cardiovascular Endocrinology and Metabolism, 2021, 10, 89-98.	0.5	4
2170	First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases. Cardiology Journal, 2020, 27, 639-641.	0.5	0
2172	Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.2	1
2174	New Insight into the Regulation of Glucose Metabolism in the Pathophysiology of Ischemic Heart Diseases. The Journal of Japanese College of Angiology, 2020, 60, 127-134.	0.1	0
2176	Possible Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Reducing Effects of Blood Glucose and also Blood Pressure. , 2020, 3, 186-190.		0
2177	Association of Sodium-Glucose Cotransporterâ€“2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Network Open, 2021, 4, e2130762.	2.8	32
2178	Endocrine system dysfunction and chronic heart failure: a clinical perspective. Endocrine, 2021, , 1.	1.1	9
2179	Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure. Journal of the American Heart Association, 2021, 10, e022637.	1.6	13
2181	Novel Therapeutic Strategies for Cardiorenal Protection in Patients with Type 2 Diabetes and Chronic Kidney Disease. Current Vascular Pharmacology, 2022, 20, 117-120.	0.8	1
2182	Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-NaÃ¯ve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial. Diabetes Therapy, 2021, 12, 3201-3215.	1.2	7

#	Article	IF	Citations
2183	Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 605-612.	1.0	5
2184	Cardiovascular medicine: a year in review. Minerva Cardiology and Angiology, 2021, , .	0.4	4
2185	New way, new recommendation: Individualized treatment of novel antidiabetic drugs for people living with type 2 diabetes based on the cardiorenal risks. Journal of Evidence-Based Medicine, 2021, 14, 262-264.	0.7	1
2186	Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis. Frontiers in Medicine, 2021, 8, 728089.	1.2	30
2187	Expert Opinion About the Pharmacoeconomic Edge of Low-Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings. Cureus, 2021, 13, e19194.	0.2	0
2188	Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. Heart Failure Reviews, 2023, 28, 683-695.	1.7	3
2189	DAPA-HF trial signals the birth of â€˜diabetic cardiologyâ€™ and more. Global Cardiology Science & Practice, 2020, 2020, e202022.	0.3	1
2190	Pharmacotherapy for patients with diabetes mellitus. Journal of the Korean Medical Association, 2020, 63, 766-775.	0.1	0
2191	SGLT 2 Inhibitors; glycemic control, weight loss andÂsafety profile in patients with type 2 Diabetes,Âat Medicell Institute (MIDEM). Pakistan Journal of Medical Sciences, 2020, 37, 87-92.	0.3	5
2192	The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support. Global Cardiology Science & Practice, 2020, 2020, e202031.	0.3	1
2193	Liraglutid in diabetic patients in LEADER study - is there any benefit in patients with heart failure?. Klinicka Farmakologie A Farmacie, 2020, 34, 168-170.	0.1	0
2194	Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition. Diabetes Care, 2021, 44, 541-548.	4.3	16
2195	A Current Review on Analytical Tools for Determination of New Oral Antidiabetic Drugs, Empagliflozin, Linagliptin and Biguanides in Bulk Materials, Pharmaceuticals & Biological Samples. Journal of Pharmaceutical Research International, 0, , 67-83.	1.0	2
2197	Prevention of Heart Failure. Contemporary Cardiology, 2021, , 489-512.	0.0	1
2198	A stepwise approach for pharmacists: Cardiovascular risk reduction with novel antihyperglycemic agents in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Canadian Pharmacists Journal, 2021, 154, 30-35.	0.4	0
2199	The role of SGLT-2 inhibitors in managing type 2 diabetes. Cleveland Clinic Journal of Medicine, 2021, 88, 47-58.	0.6	13
2200	(Dapagliflozin and heart failure). Cor Et Vasa, 2020, 62, 618-623.	0.1	2
2201	Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease. Endocrine Practice, 2020, 26, 1486-1496.	1.1	4

#	Article	IF	Citations
2202	Sodium-glucose cotransporter-2 inhibitors in heart failure patients: an appraisal of recent cardiovascular outcome trials. Minerva Cardioangiologica, 2020, 68, 629-651.	1.2	2
2203	SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now. Cleveland Clinic Journal of Medicine, 2021, 88, 59-63.	0.6	4
2204	The role of sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: from clinical research to real practice. AlÊ¹manah KliniÄeskoj Mediciny, 2020, 48, 500-509.	0.2	0
2205	Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. Current Pharmaceutical Design, 2020, 26, 5953-5968.	0.9	4
2206	The Association Between Baseline Insulin Treatment and Cardiovascular Events: A Meta-Analysis. Journal of the Endocrine Society, 2021, 5, bvaa193.	0.1	4
2207	Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020. British Journal of Diabetes, 2020, 20, 85-88.	0.1	4
2208	Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice. World Journal of Diabetes, 2020, 11, 596-610.	1.3	16
2209	Heart Failure in Diabetes Mellitus: An Updated Review. Current Pharmaceutical Design, 2020, 26, 5933-5952.	0.9	3
2210	Acute Kidney Injury after Administering Dapagliflozin to a Diabetic Patient with Acute Cerebral Infarction. Korean Journal of Medicine, 2020, 95, 404-408.	0.1	0
2211	Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME. British Journal of Diabetes, 2020, 20, 138-141.	0.1	1
2212	SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acidâ€“base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes. Clinical Science, 2020, 134, 3107-3118.	1.8	19
2213	Nutritional and metabolic management of the diabetic patient with chronic kidney disease and chronic renal failure. , 2022, , 805-827.		0
2214	Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106159.	0.7	17
2215	Prevention and management of cardiovascular disease in kidney disease and kidney failure. , 2022, , 207-223.		0
2216	Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement. Diabetes and Metabolism Journal, 2020, 44, 489.	1.8	3
2217	GLP1-Receptor Agonists in Diabetes: Drugs, General Effects, and Cardiovascular Impact. , 2020, , 695-704.		0
2218	Novel pharmacotherapies for heart failure. , 2020, , 359-380.		0
2219	Standard Pharmacological Treatment of Diabetes Based on the Guidelines. Stroke Revisited, 2021, , 179-187.	0.2	0

#	Article	IF	Citations
2220	SGLT2 Inhibitors. Stroke Revisited, 2021, , 155-166.	0.2	0
2221	Innovations in pharmacological treatment of heart failure. Vnitrni Lekarstvi, 2019, 65, 611-619.	0.1	0
2223	Targeting the Epicardial Adipose Tissue. Contemporary Cardiology, 2020, , 173-187.	0.0	1
2224	Antidiabetika. , 2020, , 339-358.		0
2225	Cardiovascular Impact of Newer Diabetes Medications. , 2020, , 735-745.		0
2227	Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View. , 2020, 2, 9-13.		5
2228	The role of novel antihyperglycaemic agents in the treatment of Type 2 diabetes: From glycaemic control to cardiovascular protection. Arhiv Za Farmaciju, 2020, 70, 198-223.	0.2	0
2229	An updated perspective and pooled analysis of Cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. Anatolian Journal of Cardiology, 2020, 25, 61-76.	0.5	1
2230	Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure. Circulation Reports, 2020, 2, 51-59.	0.4	1
2231	Empagliflozin is more Effective in Reducing Microalbuminuria and alt Levels Compared with Dapagliflozin: Real Life Experience. Acta Endocrinologica, 2020, 16, 59-67.	0.1	9
2232	Gender Differences in Cardiac Function Following Three-Month Administration of Tofogliflozin in Patients With Diabetes Mellitus. Journal of Clinical Medicine Research, 2020, 12, 530-538.	0.6	4
2233	Treatment of Diabetes and Heart Failure. , 2020, , 719-733.		0
2234	Insight Into the Perioperative Management of Type 2 Diabetes. Cureus, 2020, 12, e6878.	0.2	4
2235	The Effects and the Mechanisms of Sodium Glucose Cotransporter-2 Inhibition in Heart Failure. Interventions in Obesity & Diabetes, 2020, 3, .	0.0	0
2236	III. Treatment of Heart Failure; 3. Novel Topics of Pharmacological Therapy for Chronic Heart Failure. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 215-223.	0.0	0
2237	Macro- and Microvascular Complications of Diabetes. Stroke Revisited, 2021, , 25-31.	0.2	0
2240	The position of SGLT2 inhibitors in current medicine. Vnitrni Lekarstvi, 2020, 66, 82-88.	0.1	0
2241	The year in cardiology: cardiovascular prevention. The year in cardiology 2019.. SA Heart Journal, 2020, 17, .	0.0	0

#	Article	IF	Citations
2242	Diabetes and Cardiovascular Disease in Women: Current Challenges and New Hope. Texas Heart Institute Journal, 2020, 47, 123-124.	0.1	1
2243	GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients. Current Hypertension Reviews, 2021, 17, 149-158.	0.5	2
2244	Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review. Current Hypertension Reviews, 2021, 17, 159-169.	0.5	3
2245	Cardiovascular benefits beyond urinary glucose excretion: <scp>A hypothesis generated from two metaâ€analyses</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 550-554.	2.2	3
2246	The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review. Frontiers in Pharmacology, 2021, 12, 751214.	1.6	21
2247	A Narrative Review of ChronicÂKidneyÂDisease in Clinical Practice: Current Challenges and Future Perspectives. Advances in Therapy, 2022, 39, 33-43.	1.3	57
2248	SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence. Journal of Diabetes Research, 2021, 2021, 1-17.	1.0	1
2250	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovascular Diabetology, 2021, 20, 218.	2.7	38
2251	Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial. American Journal of Kidney Diseases, 2022, 79, 796-806.	2.1	14
2252	Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. Diabetes Research and Clinical Practice, 2021, 182, 109123.	1.1	15
2253	The management of membranous nephropathyâ€”an update. Nephrology Dialysis Transplantation, 2022, 37, 1033-1042.	0.4	7
2254	Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, , 1.	1.7	3
2255	Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 712-720.	1.4	6
2256	Effectiveness and safety of empagliflozin in routine care patients: Results from the <scp>EMPagliflozin compaRative effectIveness</scp> and <scp>SafEty</scp> (<scp>EMPRISE</scp>) study. Diabetes, Obesity and Metabolism, 2022, 24, 442-454.	2.2	29
2257	Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes. Current Diabetes Reports, 2021, 21, 45.	1.7	3
2258	SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes. American Journal of Kidney Diseases, 2022, 79, 858-867.e1.	2.1	29
2259	Challenges and opportunities in realâ€world evidence on the renal effects of sodiumâ€glucose cotransporterâ€2 inhibitors. Diabetes, Obesity and Metabolism, 2022, 24, 177-186.	2.2	11
2260	GMP Compliant Synthesis of [¹⁸F]Canagliflozin, a Novel PET Tracer for the Sodiumâ€“Glucose Cotransporter 2. Journal of Medicinal Chemistry, 2021, 64, 16641-16649.	2.9	2

#	Article	IF	Citations
2261	SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation. Cleveland Clinic Journal of Medicine, 2021, 88, 601-606.	0.6	2
2262	Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 2021, 12, 752370.	1.3	12
2263	The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure. Cureus, 2021, 13, e19379.	0.2	1
2264	Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with TypeÂ2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis. Diabetes Therapy, 2022, 13, 25-42.	1.2	4
2265	Synthesis and Structureâ€“Activity Relationship of <i>C</i>-Phenyl D-Glucitol (TP0454614) Derivatives as Selective Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitors. Chemical and Pharmaceutical Bulletin, 2020, 68, 635-652.	0.6	1
2267	Treatment Options for Patients with Type 2 Diabetes Mellitus during the Fasting Month of Ramadan. Annals of the Academy of Medicine, Singapore, 2020, 49, 468-476.	0.2	3
2268	The Effect of Long-Term Sodium-Glucose Cotransporter 2 Inhibitor Treatment on Renal Function in Patients with Type 2 Diabetes. Journal of Korean Diabetes, 2020, 21, 105-115.	0.1	0
2270	Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2020, 66, 1283-1288.	0.3	1
2271	Epicardial Adipose Tissue as a New Target of Therapeutic Interventions. Rational Pharmacotherapy in Cardiology, 2020, 16, 585-589.	0.3	0
2272	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. PLoS ONE, 2020, 15, e0240166.	1.1	2
2273	Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement. Kidney Research and Clinical Practice, 2020, 39, 269-283.	0.9	6
2274	Diabetic Kidney Disease. Nephrology Self-assessment Program: NephSAP, 2020, 19, 110-139.	3.0	1
2275	Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease. Cureus, 2020, 12, e10783.	0.2	2
2276	Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction. Russian Journal of Cardiology, 2020, 25, 4049.	0.4	1
2278	Primary Prevention of Coronary Artery Disease. , 2021, , 81-123.		0
2279	Stable Ischemic Heart Disease. , 2021, , 125-154.		0
2280	Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes. , 2021, , 295-313.		0
2281	Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combinationâ€”are we exploiting their full potential in a real life setting?. World Journal of Diabetes, 2020, 11, 540-552.	1.3	2

#	Article	IF	Citations
2282	Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan. PeerJ, 2020, 8, e9998.	0.9	5
2283	Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Case Report and Review of Literature. Cureus, 2020, 12, e11554.	0.2	1
2285	SGLT-2i and Cardiovascular Prognosis. Current Pharmaceutical Design, 2020, 26, 3905-3907.	0.9	4
2286	Jak postupovat v boji s inzulinovou rezistencÃ-u pacientÅ¯ s DM 2. typu. Vnitrni Lekarstvi, 2020, 66, 4-6.	0.1	1
2288	Newer Oral Antihyperglycemics: From to. Canadian Journal of Hospital Pharmacy, 2019, 72, 385-387.	0.1	0
2289	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). BMJ Open, 2019, 9, e029098.	0.8	3
2290	Finding the sweet spot in managing diabetes with coronary artery disease and chronic kidney disease: Pharmacotherapy pearls with a focus on sodium-glucose cotransporter-2 inhibitors. Canadian Family Physician, 2020, 66, 341-346.	0.1	0
2291	Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ, The, 2020, 370, m2812.	3.0	7
2292	Harms and benefits of sodium-glucose co-transporter 2 inhibitors. Australian Prescriber, 2020, 43, 168-171.	0.5	0
2293	Ertugliflozin in the treatment of type 2 diabetes mellitus. Drugs in Context, 2020, 9, .	1.0	0
2294	ARNI and SGLT2i: a promising association to be used with caution. Journal of Geriatric Cardiology, 2020, 17, 728-732.	0.2	1
2295	Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes in elderly patients with comorbid coronary heart disease and diabetes mellitus. Journal of Geriatric Cardiology, 2021, 18, 440-448.	0.2	0
2296	Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. Conditioning Medicine, 2020, 3, 82-97.	1.3	3
2297	The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction. Archives of Medical Sciences Atherosclerotic Diseases, 2021, 6, e176-e181.	0.5	0
2298	Features of course and treatment of chronic heart failure in patients with diabetes mellitus type 2. Medicina SÊ¹ogodnÃ¬ Ã¬ Zavtra, 2020, 86, 17-32.	0.0	0
2299	Vasodilator Dysfunction in Human Obesity. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	1
2300	Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. Cardiology Discovery, 2021, 1, 70-104.	0.6	13
2301	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med, 2021, 2, 1203-1230.	2.2	17

#	Article	IF	Citations
2302	The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. Journal of Personalized Medicine, 2021, 11, 1249.	1.1	7
2303	Crosstalk between Sodiumâ€“Glucose Cotransporter Inhibitors and Sodiumâ€“Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases. International Journal of Molecular Sciences, 2021, 22, 12677.	1.8	6
2304	Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology. European Journal of Epidemiology, 2021, 36, 1103-1109.	2.5	1
2305	Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. Journal of General Internal Medicine, 2022, 37, 439-448.	1.3	8
2306	Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations. Postgraduate Medicine, 2022, 134, 376-387.	0.9	13
2307	Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction. Clinical Drug Investigation, 2021, 41, 1027-1036.	1.1	3
2308	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation, 2022, 145, 565-574.	1.6	59
2310	Optimization of Medication Regimens in Patients with Type 2 Diabetes and Clinical Atherosclerotic Cardiovascular Disease. Pharmacy (Basel, Switzerland), 2021, 9, 186.	0.6	2
2311	Neuroprotective Effect of SGLT2 Inhibitors. Molecules, 2021, 26, 7213.	1.7	79
2312	Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1191-1203.	1.8	6
2313	Expert consensus on the practical aspects of the cooperation of cardiologist and diabetologist in the management of the patients with chronic heart failure and reduced ejection fraction. Vnitrni Lekarstvi, 2021, 67, 404-410.	0.1	1
2314	SGLT-2 inhibitors as cardio-renal protective agents. Metabolism: Clinical and Experimental, 2022, 127, 154937.	1.5	20
2315	Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 2022, 79, e145-e152.	0.8	27
2316	Heart Failure Incidence Following ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2022, 164, 14-20.	0.7	7
2317	Sodiumâ€“glucose cotransporterâ€‰2 inhibitors and anemia among diabetes patients in real clinical practice. Journal of Diabetes Investigation, 2022, 13, 638-646.	1.1	7
2318	Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Advances in Therapy, 2022, 39, 148-164.	1.3	41
2319	Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, .	0.9	27
2320	Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction. Scientific Reports, 2021, 11, 22342.	1.6	12

#	Article	IF	Citations
2321	Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians. Metabolites, 2021, 11, 794.	1.3	0
2322	The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria. International Urology and Nephrology, 2022, 54, 1907-1914.	0.6	3
2323	Cardiovascular benefit of SGLT2 inhibitors. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 142-155.	2.7	6
2324	Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. Clinical Drug Investigation, 2022, 42, 1-16.	1.1	4
2325	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Eurasian Heart Journal, 2021, , 6-59.	0.2	4
2326	Epidemiology and resource use in Spanish type 2 diabetes patients without previous cardiorenal disease: CaReMe Spain study summary. Endocrinologia, Diabetes Y NutriciÃ“n, 2022, 69, 509-519.	0.1	1
2327	Clinical relevance of recent outcome trials with antidiabetic drugs. Practical Diabetes, 2021, 38, 3-6.	0.1	0
2328	Glucagon-like peptide-1 receptor agonists and sodiumâ^'glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. European Journal of Internal Medicine, 2022, 96, 26-33.	1.0	7
2329	Role of newer antidiabetic drugs on cardiovascular prevention and heart failure. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2021, 33, 314-314.	0.1	0
2330	Utilization of glucagonâ€like peptideâ€1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database. Diabetes, Obesity and Metabolism, 2022, 24, 486-498.	2.2	3
2331	Current perspectives of the use of Sodium Glucose Transport-2 Inhibitors for patients with heart failure and chronic kidney disease. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	1
2332	Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Expert Review of Endocrinology and Metabolism, 2022, 17, 35-46.	1.2	8
2333	Association between body mass index and survival in Taiwanese heart failure patients with and without diabetes mellitus. Medicine (United States), 2021, 100, e28114.	0.4	1
2334	Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Diseaseâ€"Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. Antioxidants, 2021, 10, 1935.	2.2	15
2336	Diabetes and treatment of chronic heart failure in a large realâ€world heart failure population. ESC Heart Failure, 2022, 9, 353-362.	1.4	13
2337	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. Heart Failure Reviews, 2023, 28, 667-681.	1.7	14
2338	Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials. Frontiers in Endocrinology, 2021, 12, 743807.	1.5	7
2340	Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes. European Journal of Clinical Pharmacology, 2021, , 1.	0.8	0

#	Article	IF	Citations
2341	Diuretic Agents. , 2021, , .		0
2342	Comparative Effectiveness of SGLT2i Versus GLP1-RA on Cardiovascular Outcomes in Routine Clinical Practice. SSRN Electronic Journal, 0, , .	0.4	0
2343	Hypertension Management in Patients with Chronic Kidney Disease in the Post-SPRINT Era. Electrolyte and Blood Pressure, 2021, 19, 19.	0.6	4
2344	Current Understanding of Pressure Natriuresis. Electrolyte and Blood Pressure, 2021, 19, 38.	0.6	9
2345	The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction. Archives of Medical Sciences Atherosclerotic Diseases, 2021, 6, 176-181.	0.5	3
2346	Impact of sodium-glucose co-transporter inhibitors on cardiac autonomic function and mortality: no time to die. Europace, 2022, 24, 1052-1057.	0.7	9
2347	Cardiovascular Protection of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Type 2 Diabetes Mellitus. International Journal of Pharmaceutical Research and Allied Sciences, 2021, 10, 139-143.	0.1	0
2348	Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes. European Endocrinology, 2021, 17, 92.	0.8	1
2349	Compliance with Cardiovascular Prevention Guidelines in Individuals with Type 2 Diabetes in a Middle-Income Region: Cross-Sectional Analysis. SSRN Electronic Journal, 0, , .	0.4	0
2350	Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease. JAMA Network Open, 2022, 5, e2142078.	2.8	31
2352	Initial combination of metformin, sitagliptin, and empagliflozin in drugâ€naÃ¯ve patients with type 2 diabetes: Safety and metabolic effects. Diabetes, Obesity and Metabolism, 2022, 24, 757-762.	2.2	2
2353	Update on the pathophysiology and medical treatment of peripheral artery disease. Nature Reviews Cardiology, 2022, 19, 456-474.	6.1	64
2354	Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovascular Diabetology, 2022, 21, 4.	2.7	4
2356	Atypical Presentations. , 2022, , 219-241.		0
2357	The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients. Current Cardiology Reports, 2022, , .	1.3	1
2358	Kidney hemodynamic profile and systemic vascular function in adults with type 2 diabetes: Analysis of three clinical trials. Journal of Diabetes and Its Complications, 2022, 36, 108127.	1.2	2
2359	Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment. Pharmacological Research, 2022, 176, 106062.	3.1	44
2360	Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: Mechanism progresses and challenges. Pharmacological Research, 2022, 176, 106049.	3.1	7

#	Article	IF	Citations
2361	HÃmoglobin A 1c: Die heutige Rolle fÃ¼r die therapeutische Entscheidung. , 0, , .		0
2362	Typ-2-Diabetes: Wie Endpunktstudien die Therapie verÃndern. , 0, , .		0
2363	Current topics of possible pharmacotherapy for chronic kidney disease (CKD) and diabetes. Pharmacy & Pharmacology International Journal, 2020, 8, 87-89.	0.1	2
2364	Diabetische Nephropathie: Die neue Rolle der Niere. , 0, , .		0
2365	Herzinsuffizienz als KomorbiditÃt: Kardioprotektion ist mÃ¶glich. , 0, , .		0
2366	Medicine, 2020, 109, 1809-1814.	0.0	0
2367	The Impact of SGLT2i Therapy on the Onset and Prognosis of Heart Failure in Patients with Type 2 Diabetes. Timisoara Medical Journal, 2020, 2020, 1.	0.1	0
2368	Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis. Cardiology Journal, 2020, , .	0.5	1
2369	Harms and benefits fo sodium-glucose co-transporter 2 inhibitors. Australian Prescriber, 2020, 43, 168-171.	0.5	9
2370	Ertugliflozin in the treatment of type 2 diabetes mellitus. Drugs in Context, 2020, 9, 1-10.	1.0	27
2371	Glycaemic Control in Diabetes. Handbook of Experimental Pharmacology, 2021, , 47-71.	0.9	1
2372	Antidiabetika. , 2021, , 241-260.		0
2373	Possible Mechanisms of Action of SGLT2 Inhibitors in Heart Failure. , 2021, 1, 33-43.		1
2374	Diabetes and cardiovascular outcome trials: a review with a focus on the use of glucagon-like peptide-1 receptor agonists in clinical practice. South African General Practitioner, 2021, 2, 100-105.	0.0	0
2375	Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes. Advances in Chronic Kidney Disease, 2021, 28, 298-308.	0.6	6
2376	Non-Insulin Glucose-Lowering Agents. , 2022, , 1987-2003.		0
2377	Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. Advances in Chronic Kidney Disease, 2021, 28, 347-360.	0.6	5
2378	Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus. Advances in Chronic Kidney Disease, 2021, 28, 309-317.	0.6	4

#	Article	IF	Citations
2379	Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation. Advances in Chronic Kidney Disease, 2021, 28, 361-370.	0.6	1
2380	Strategies for the Management of Type 2 Diabetes. , 2022, , 2046-2052.		0
2381	Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned. Advances in Chronic Kidney Disease, 2021, 28, 318-327.	0.6	9
2382	Effect of SLGT2 Inhibitors on Patients with Atrial Fibrillation. Journal of Atrial Fibrillation, 2021, 14, 20200502.	0.5	1
2383	A Lifestyle Intervention to Delay Early Chronic Kidney Disease in African Americans With Diabetic Kidney Disease: Pre-Post Pilot Study. JMIR Formative Research, 2022, 6, e34029.	0.7	3
2384	(Expert consensus on the practical aspects of collaboration between cardiologists and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	0.1	0
2385	Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		2
2386	Endpoints in Heart Failure Drug Development. Cardiac Failure Review, 2022, 8, e01.	1.2	10
2387	The effect of diabetes on mid-term survival of open heart surgery patients aged over 70 years. Journal of Health Sciences and Medicine, 2022, 5, 184-188.	0.0	0
2388	Can glucoseâ€lowering medications improve outcomes in nonâ€diabetic heart failure patients? A Bayesian network metaâ€analysis. ESC Heart Failure, 2022, 9, 1338-1350.	1.4	13
2389	The effect of modern hypoglycemic therapy on the course of chronic kidney disease in patients with type 2 diabetes mellitus. MÃ¬Å¾narodnij EndokrinologÃ¬Änij Å½urnal, 2021, 17, 624-632.	0.1	0
2390	Costâ€“Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand. Advances in Therapy, 2022, 39, 1279-1292.	1.3	10
2391	Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Frontiers in Pharmacology, 2021, 12, 751496.	1.6	4
2392	Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure. International Journal of Heart Failure, 2022, 4, 75.	0.9	10
2393	Antioxidant Roles of SGLT2 Inhibitors in the Kidney. Biomolecules, 2022, 12, 143.	1.8	16
2394	SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 557-567.	1.4	20
2395	Cardiometabolic Syndrome and Vascular Calcification. Cardiometabolic Syndrome Journal, 2022, 2, 1.	1.0	1
2396	Cardiorenal disease in the United States: future health care burden and potential impact of novel therapies. Journal of Managed Care & Specialty Pharmacy, 2022, , 1-10.	0.5	3

#	Article	IF	Citations
2397	Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 787810.	1.1	6
2398	Polypharmacy influences the renal composite outcome in patients treated with sodiumâ€glucose cotransporter 2 inhibitors. Clinical and Translational Science, 2022, , .	1.5	2
2399	Are High- or Low-dose SGLT2 Inhibitors Associated With Cardiovascular and Respiratory Adverse Events? A Meta-analysis. Journal of Cardiovascular Pharmacology, 2022, 79, 655-662.	0.8	9
2400	SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. Journal of Lipid and Atherosclerosis, 2022, 11, 1.	1.1	25
2401	Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis. Kidney360, 2022, 3, 455-464.	0.9	22
2402	Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails. Diabetes Mellitus, 2022, 24, 553-564.	0.5	0
2403	Sodiumâ€Glucose Coâ€Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetesâ€Induced Atherosclerotic Plaque Instability. Journal of the American Heart Association, 2022, 11, e022761.	1.6	22
2404	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulmonary Circulation, 2022, 12, e12028.	0.8	8
2405	Putting it All Together: Practical Approach to the Patient with Diabetic Kidney Disease. , 2022, , 637-659.		1
2406	Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System. Journal of General Internal Medicine, 2022, 37, 3562-3569.	1.3	7
2407	Current status of diabetes treatment in Miyazaki Prefecture, Japan: Results of a questionnaire survey conducted in 2016 and 2020. Journal of Diabetes Investigation, 2022, 13, 1011-1020.	1.1	1
2408	Evolving channeling in prescribing <scp>SGLT</scp>â€2 inhibitors as firstâ€line treatment for type 2 diabetes. Pharmacoepidemiology and Drug Safety, 2022, 31, 566-576.	0.9	2
2409	Sodiumâ€“glucose coâ€transporter 2 inhibitors as an early, firstâ€line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	2.9	67
2410	Therapeutic Advances in Diabetic Nephropathy. Journal of Clinical Medicine, 2022, 11, 378.	1.0	49
2411	Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank. American Journal of Kidney Diseases, 2022, 80, 196-206.e1.	2.1	12
2412	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care, 2022, 45, 938-946.	4.3	20
2413	Manifestation of Heart Failure and Chronic Kidney Disease are Associated with Increased Mortality Risk in Early Stages of TypeÂ2 Diabetes Mellitus: Analysis of a Japanese Real-World Hospital Claims Database. Diabetes Therapy, 2022, 13, 275-286.	1.2	6
2414	Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip. Cureus, 2022, 14, e21768.	0.2	1

#	Article	IF	Citations
2415	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2022, 175, W4.	2.0	0
2416	Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin. Cureus, 2022, 14, e21720.	0.2	2
2417	The role of SGLT2 inhibitors in heart failure. , 0, 1, 2.		0
2418	Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Pharmacological Research, 2022, 177, 106094.	3.1	12
2419	Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice. International Journal of Cardiology, 2022, 352, 172-179.	0.8	13
2420	Nonâ€alcoholic fatty liver disease and typeâ€‰2 diabetes: An update. Journal of Diabetes Investigation, 2022, 13, 930-940.	1.1	25
2421	Characterizing a Clinical Trial â€“ Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction. Clinical Epidemiology, 2022, Volume 14, 39-49.	1.5	1
2422	Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study. Diabetology and Metabolic Syndrome, 2022, 14, 5.	1.2	0
2423	Development and Validation of a Long-Term Incident Heart Failure Risk Model. Circulation Research, 2022, 130, 200-209.	2.0	9
2425	Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes. Heart Failure Reviews, 2022, , 1.	1.7	4
2427	A Scoping Review Evaluating the Effect of SGLT-2 Inhibitors on Insulin Dose Requirements in Insulin-Dependent Patients With Type 2 Diabetes. Annals of Pharmacotherapy, 2022, 56, 1030-1040.	0.9	2
2428	Hypertension and heart failure with preserved ejection fraction. A past, present, and future relationship. Hipertension Y Riesgo Vascular, 2022, 39, 34-41.	0.3	1
2429	SGLT2 Inhibitors and Their Antiarrhythmic Properties. International Journal of Molecular Sciences, 2022, 23, 1678.	1.8	24
2430	Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis. PLoS ONE, 2022, 17, e0261986.	1.1	15
2431	Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells. Cell Death Discovery, 2022, 8, 12.	2.0	18
2432	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation, 2022, 145, CIR0000000000001040.	1.6	193
2433	Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial. Diabetes, 2022, 71, 812-820.	0.3	5
2434	SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice. International Journal of Cardiology, 2022, 351, 66-70.	0.8	9

#	Article	IF	Citations
2435	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Diabetes Care, 2022, 45, e27-e29.	4.3	10
2436	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine, 2022, 43, 101240.	3.2	6
2437	EstÃ¡ndares SEA 2022 para el control global del riesgo cardiovascular. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2022, 34, 130-179.	0.4	11
2438	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	2.9	41
2439	Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. Kidney360, 2022, 3, 477-487.	0.9	16
2440	Dapagliflozin Ameliorates the Formation and Progression of Experimental Abdominal Aortic Aneurysms by Reducing Aortic Inflammation in Mice. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-11.	1.9	9
2441	Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management. Stem Cell Research and Therapy, 2022, 13, 25.	2.4	31
2442	Use of oral anti-diabetic drugs and risk of hospital and intensive care unit admissions for infections. American Journal of the Medical Sciences, 2022, 364, 53-58.	0.4	3
2443	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
2444	Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Current Diabetes Reports, 2022, 22, 39-52.	1.7	55
2445	The Role of Inflammation as a Preponderant Risk Factor in Cardiovascular Diseases. Current Vascular Pharmacology, 2022, 20, 244-259.	0.8	5
2446	Cardiovascular outcomes associated with prescription of sodiumâ€glucose coâ€transporterâ€2 inhibitors versus dipeptidyl peptidaseâ€4 inhibitors in patients with diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 928-937.	2.2	2
2447	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	1.2	23
2448	Outcome trial data on sodium glucose cotransporter-2 inhibitors: Putting clinical benefits and risks in perspective. International Journal of Cardiology, 2022, 349, 96-98.	0.8	1
2449	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. Kidney International Reports, 2022, 7, 699-707.	0.4	6
2450	Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept. Clinical Drug Investigation, 2022, 42, 113-125.	1.1	2
2451	Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. Lancet Diabetes and Endocrinology,the, 2022, 10, 142-148.	5.5	7
2452	Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-ÎºB activation in human endothelial cells and differentiated macrophages. European Journal of Pharmacology, 2022, 918, 174715.	1.7	51

#	Article	IF	Citations
2453	Nano-oxygenated hydrogels for locally and permeably hypoxia relieving to heal chronic wounds. Biomaterials, 2022, 282, 121401.	5.7	45
2454	Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) â€“ A phase III study. American Heart Journal, 2022, 246, 152-160.	1.2	9
2455	Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy. Phytomedicine Plus, 2022, 2, 100225.	0.9	0
2456	Chronic kidney disease and vascular risk - what's new?. Hipertension Y Riesgo Vascular, 2022, 39, 3-7.	0.3	1
2457	Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy. Handbook of Experimental Pharmacology, 2022, , 93-108.	0.9	3
2458	Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect. Heart Failure Reviews, 2022, , .	1.7	0
2459	Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes. Nature Communications, 2022, 13, 784.	5.8	19
2460	Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2022, 46, 567-577.	1.8	3
2461	Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease. Bioengineered, 2022, 13, 3911-3929.	1.4	8
2462	Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 281-295.	1.1	35
2463	Egyptian expert opinion for the use of sodiumâ€glucose cotransporterâ€2 inhibitors in patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 800-811.	1.4	4
2464	Physiologic Insulin Resensitization as a Treatment Modality for Insulin Resistance Pathophysiology. International Journal of Molecular Sciences, 2022, 23, 1884.	1.8	5
2465	Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. Canadian Journal of Physiology and Pharmacology, 2022, 100, 93-106.	0.7	11
2466	Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nature Reviews Nephrology, 2022, 18, 294-306.	4.1	64
2467	SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes. Current Cardiology Reports, 2022, 24, 183-189.	1.3	3
2468	Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021). ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2022, , .	0.1	0
2469	Sodiumâ€“glucose cotransporterâ€‰2 inhibitors do not increase the risk of fractures in realâ€world clinical practice in Korea: A national observational cohort study. Journal of Diabetes Investigation, 2022, 13, 986-996.	1.1	11
2470	Mitochondria as Therapeutic Targets in Heart Failure. Current Heart Failure Reports, 2022, 19, 27-37.	1.3	23

#	Article	IF	Citations
2471	Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care, 2022, 45, 965-974.	4.3	13
2472	Cardiovascular Effectiveness of Sodiumâ€Glucose Cotransporter 2 Inhibitors and Glucagonâ€Like Peptideâ€1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. Journal of the American Heart Association, 2022, 11, e022376.	1.6	14
2473	Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodiumâ€“Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus. Pharmaceuticals, 2022, 15, 203.	1.7	0
2474	KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. American Journal of Kidney Diseases, 2022, 79, 457-479.	2.1	18
2475	Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease. Journal of Personalized Medicine, 2022, 12, 223.	1.1	5
2476	Comparative Safety of Sodiumâ€“Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis. Diabetes Care, 2022, 45, 919-927.	4.3	11
2477	Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Diabetes Research and Clinical Practice, 2022, 185, 109231.	1.1	4
2478	Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Heart Failure: A Prospective Study. Journal of Clinical Medicine, 2022, 11, 6.	1.0	4
2479	Anti-inflammatory Strategies in Atherosclerosis. Hamostaseologie, 2021, 41, 433-442.	0.9	11
2480	Nephron overload as a therapeutic target to maximize kidney lifespan. Nature Reviews Nephrology, 2022, 18, 171-183.	4.1	28
2481	Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ, The, 2020, 370, m2812.	3.0	38
2482	Effects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. Pharmacology, 2022, 107, 123-130.	0.9	9
2483	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation, 2022, 145, 575-585.	1.6	88
2484	Ketone bodies: from enemy to friend and guardian angel. BMC Medicine, 2021, 19, 313.	2.3	109
2485	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2022. Diabetes Care, 2022, 45, S144-S174.	4.3	282
2486	11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2022. Diabetes Care, 2022, 45, S175-S184.	4.3	168
2487	Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis. International Journal of Molecular Sciences, 2022, 23, 437.	1.8	18
2488	Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units. Medicina (Lithuania), 2021, 57, 1376.	0.8	1

#	Article	IF	Citations
2489	Increased Prevalence of Cardiovascular Risk Factors in Newly Diagnosed Type 2 Diabetes Patients â€“ a Retrospective Study. Acta Endocrinologica, 2021, 17, 331-336.	0.1	0
2490	Efficacy of Dapagliflozin on Type 2 Diabetic Patients with Chronic Heart Failure and Its Effect on Thickness of Epicardial Adipose Tissue. Ya Zhou Xin Nao Xue Guan Bing Li Bao Gao, 2022, 10, 1-7.	0.3	0
2491	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. Korean Circulation Journal, 2022, 52, 173.	0.7	9
2492	Prescription of DPP4 inhibitors: indication and effect on glycosylated hemoglobin in a primary care institution of Colombia. Revista De La Universidad Industrial De Santander Salud, 2022, 54, .	0.0	0
2493	Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. Current Hypertension Reports, 2022, 24, 1-20.	1.5	5
2494	Capillaries as a Therapeutic Target for Heart Failure. Journal of Atherosclerosis and Thrombosis, 2022, 29, 971-988.	0.9	4
2495	Review on prevention of cardiovascular disease. , 0, , 09-14.		0
2496	Diabetische Nephropathie. , 2022, , 32-41.		0
2497	Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation. SSRN Electronic Journal, 0, , .	0.4	0
2498	Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis. Journal of Family Medicine and Primary Care, 2022, 11, 927.	0.3	23
2499	Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. Archives of Endocrinology and Metabolism, 2022, 66, 68-76.	0.3	6
2500	Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor. Internal Medicine, 2022, 61, 3239-3243.	0.3	5
2501	Two Cases of Thyrotoxicosis and Euglycemic Diabetic Ketoacidosis Under Sodium-glucose Transport Protein 2 Inhibitor Treatment. Internal Medicine, 2022, , .	0.3	4
2503	Integrating traditional Chinese medicine and western medicine for cardiovascular disease. Scientia Sinica Vitae, 2022, 52, 832-839.	0.1	1
2504	Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2022, 13, 826604.	1.5	26
2505	New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?. Journal of Cardiology, 2023, 81, 26-32.	0.8	3
2506	A real-world study on SGLT2 inhibitors and diabetic kidney disease progression. CKJ: Clinical Kidney Journal, 2022, 15, 1403-1414.	1.4	7
2507	Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?. Cardiology Journal, 2022, 29, 166-169.	0.5	0

#	Article	IF	Citations
2508	Genetic variation in sodium glucose coâ€transporter 1 and cardiac structure and function at middle age. ESC Heart Failure, 2022, 9, 1496-1501.	1.4	1
2509	Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?. Heart Failure Reviews, 2022, 27, 1973-1990.	1.7	5
2510	Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus. Endocrinology and Metabolism, 2022, 37, 26-37.	1.3	20
2511	Growing role of SGLT2i in heart failure: evidence from clinical trials. Expert Review of Clinical Pharmacology, 2022, 15, 147-159.	1.3	8
2512	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Frontiers in Pharmacology, 2022, 13, 800490.	1.6	21
2513	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes, 2022, 16, 223-244.	0.9	15
2514	Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The <scp>EXCEED</scp> randomized controlled multicenter study. Geriatrics and Gerontology International, 2022, 22, 298-304.	0.7	13
2515	Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes. Canadian Journal of Diabetes, 2022, 46, 487-494.	0.4	4
2516	Diabetes mellitus and heart failure: an update on pathophysiology and therapy. Minerva Cardiology and Angiology, 2022, , .	0.4	5
2517	SGLT-2 Inhibitors: Proliferating Indications and Perioperative Pitfalls. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 1815-1819.	0.6	4
2518	Management of heart failure in older people. Journal of Pharmacy Practice and Research, 2022, 52, 72-79.	0.5	2
2519	Review of non-insulin antidiabetic pharmacotherapy in patients with heart failure diabetes mellitus in the Czech Republic in 2018. Cor Et Vasa, 2022, 64, 20-24.	0.1	1
2520	Alternate-day add-on therapy with dapagliflozin in patients with type 2 diabetes mellitus: potential benefits and concerns. Expert Review of Clinical Pharmacology, 2022, 15, 197-203.	1.3	1
2521	SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. PLoS ONE, 2022, 17, e0263285.	1.1	17
2523	Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence. Current Cardiology Reports, 2022, 24, 567-576.	1.3	2
2524	Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study. Drugs in Context, 2022, 11, 1-9.	1.0	2
2525	Dapagliflozin Reduces Apoptosis of Diabetic Retina and Human Retinal Microvascular Endothelial Cells Through ERK1/2/cPLA2/AA/ROS Pathway Independent of Hypoglycemic. Frontiers in Pharmacology, 2022, 13, 827896.	1.6	23
2526	Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis. Minerva Cardiology and Angiology, 2023, 71, .	0.4	6

#	Article	IF	Citations
2527	Development and Current Role of SGLT Inhibition in Cardiorenal Metabolic Syndrome. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, 593-604.	0.8	1
2528	Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study. PLoS ONE, 2022, 17, e0262831.	1.1	4
2529	Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study. BMC Health Services Research, 2022, 22, 217.	0.9	3
2530	Empagliflozin does not reverse lipotoxicity-induced impairment in human myeloid angiogenic cell bioenergetics. Cardiovascular Diabetology, 2022, 21, 27.	2.7	1
2531	Seven suggestions for successful SGLT2i use in glomerular disease - a standalone CKD therapy?. Current Opinion in Nephrology and Hypertension, 2022, 31, 272-277.	1.0	4
2532	Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis. International Journal of Molecular Sciences, 2022, 23, 2336.	1.8	4
2533	Time-series analysis of recent antihyperglycemic medication prescribing trends for a diverse sample of Medicare enrollees with type 2 diabetes mellitus in an integrated health system. American Journal of Health-System Pharmacy, 2022, 79, 950-959.	0.5	2
2534	Mechanisms of antidiabetic drugs and cholesterol efflux: A clinical perspective. Drug Discovery Today, 2022, , .	3.2	2
2535	Clinical progress note: Indications for and management of sodiumâ€glucose cotransporterâ€2 (SGLTâ€2) inhibitors in hospitalized patients. Journal of Hospital Medicine, 2022, 17, 360-363.	0.7	1
2536	Soluble Epoxide Hydrolase Inhibition Protected against Diabetic Cardiomyopathy through Inducing Autophagy and Reducing Apoptosis Relying on Nrf2 Upregulation and Transcription Activation. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-20.	1.9	9
2537	An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. International Journal of Molecular Sciences, 2022, 23, 3651.	1.8	67
2538	Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Diseases. Clinical Diabetes, 2022, 40, 401-412.	1.2	3
2539	Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. Diabetes, Obesity and Metabolism, 2022, 24, 1277-1287.	2.2	15
2540	Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation, 2022, 37, 1317-1329.	0.4	58
2541	The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy. Diabetology and Metabolic Syndrome, 2022, 14, 47.	1.2	4
2542	Diabetes Mellitus and the Heart. Experimental and Clinical Endocrinology and Diabetes, 2022, , .	0.6	1
2543	Deleterious synergistic effects of acute heart failure and diabetes mellitus in patients with acute coronary syndrome: Data from the FAST-MI Registries. Archives of Cardiovascular Diseases, 2022, , .	0.7	0
2544	SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failureâ€"A Concise Review. Journal of Clinical Medicine, 2022, 11, 1470.	1.0	16

#	Article	IF	Citations
2545	Preventing allâ€cause hospitalizations in type 2 diabetes with sodiumâ€glucose cotransporterâ€2 inhibitors and <scp>glucagonâ€like peptide</scp>â€1 receptor agonists: A narrative review and proposed clinical approach. Diabetes, Obesity and Metabolism, 2022, 24, 969-982.	2.2	5
2546	Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors. Expert Review of Cardiovascular Therapy, 2022, 20, 223-232.	0.6	4
2547	Drugâ€“Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. Drug Safety, 2022, 45, 287-295.	1.4	7
2548	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation, 2022, 145, 693-712.	1.6	57
2549	Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovascular Diabetology, 2022, 21, 47.	2.7	49
2550	Opportunistic screening for asymptomatic left ventricular dysfunction in type 2 diabetes mellitus. Postgraduate Medical Journal, 2023, 99, 476-483.	0.9	3
2551	Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study. Frontiers in Cardiovascular Medicine, 2022, 9, 794707.	1.1	9
2552	Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials. European Journal of Internal Medicine, 2022, 97, 78-85.	1.0	2
2553	Geroscienceâ€guided repurposing of FDAâ€approved drugs to target aging: A proposed process and prioritization. Aging Cell, 2022, 21, e13596.	3.0	32
2554	Implementation of Cardiometabolic Centers and Training Programs. Current Diabetes Reports, 2022, , 1.	1.7	0
2555	Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report. A&A Practice, 2022, 16, e01570.	0.2	8
2557	Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition. Current Hypertension Reports, 2022, 24, 67-74.	1.5	11
2558	Renoprotective effect of additional sodiumâ€“glucose cotransporterâ€‰2 inhibitor therapy in typeâ€‰2 diabetes patients with rapid decline and preserved renal function. Journal of Diabetes Investigation, 2022, 13, 1330-1338.	1.1	2
2559	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Therapy, 2022, 13, 847-872.	1.2	5
2560	Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study. Expert Opinion on Drug Safety, 2022, 21, 1315-1328.	1.0	7
2561	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research, 2022, 2022, 1-10.	1.0	1
2562	Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations. Therapeutics and Clinical Risk Management, 2022, Volume 18, 315-322.	0.9	13
2563	Role of new drug therapies and innovative procedures in older patients with heart failure: from trials to clinical practice. Minerva Medica, 2022, , .	0.3	2

#	Article	IF	Citations
2564	Rethinking Resistant Hypertension. Journal of Clinical Medicine, 2022, 11, 1455.	1.0	9
2565	Sodiumâ€glucose cotransporterâ€2 inhibitors in heart failure: an updated metaâ€analysis. ESC Heart Failure, 2022, 9, 1942-1953.	1.4	9
2566	Effects of Dapagliflozin in Asian Patients With HeartÂFailure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , .	0.5	2
2567	Pathophysiological aspects of insulin resistance in Atrial Fibrillation: novel therapeutic approaches. International Journal of Arrhythmia, 2022, 23, .	0.3	2
2568	Sodiumâ€glucose coâ€transporterâ€2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. Diabetes, Obesity and Metabolism, 2022, 24, 1187-1196.	2.2	12
2569	Heart Failure and Drug Therapies: A Metabolic Review. International Journal of Molecular Sciences, 2022, 23, 2960.	1.8	7
2570	Risk of outcomes in a Spanish population with chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 1415-1424.	1.4	2
2571	Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1072-1083.	2.2	20
2572	Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications. Diabetes Therapy, 2022, 13, 873-888.	1.2	4
2574	Retrospective evaluation of microalbuminuria and GFR levels of diabetic patients taking DPP-4 Inhibitor, GLP-1 Analog, or SGLT-2 Inhibitor. Turkish Journal of Internal Medicine, 0, , .	0.3	0
2575	Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis. Frontiers in Endocrinology, 2022, 13, 850836.	1.5	5
2576	Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects. Frontiers in Cardiovascular Medicine, 2022, 9, 854230.	1.1	8
2577	The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People WithÂType 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet. Kidney International Reports, 2022, 7, 1084-1092.	0.4	12
2580	Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Therapy, 2022, 13, 889-911.	1.2	2
2581	Cardiorenal outcomes with ertugliflozin assessed according to baseline glucoseâ€lowering agent: An analysis from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, , .	2.2	5
2582	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care, 2022, 45, 1007-1012.	4.3	4
2583	Increasing Sodium-Glucose Cotransporter 2 Inhibitor Use in CKD: Perspectives and Presentation of a Clinical Pathway. Kidney Medicine, 2022, 4, 100446.	1.0	3
2584	The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. Journal of Clinical Medicine, 2022, 11, 1904.	1.0	4

#	Article	IF	Citations
2585	Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, , 1-10.	0.7	3
2586	Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus. Diabetology International, 0, , 1.	0.7	1
2587	Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis. Diagnostics, 2022, 12, 814.	1.3	1
2588	Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2iâ€‰+â€‰DPP4i in the Indian Diabetes Setting. Diabetes Therapy, 2022, 13, 1097-1114.	1.2	9
2589	Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. International Journal of Molecular Sciences, 2022, 23, 3587.	1.8	48
2590	Epicardial adipose tissue in contemporary cardiology. Nature Reviews Cardiology, 2022, 19, 593-606.	6.1	160
2591	Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression. Molecular and Cellular Biochemistry, 2022, 477, 1865-1872.	1.4	7
2592	Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2022, 13, 802992.	1.5	16
2593	Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update. Expert Opinion on Pharmacotherapy, 2022, 23, 673-680.	0.9	3
2594	Potential roles of sodiumâ€glucose coâ€transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure. Journal of Cellular Physiology, 2022, 237, 2404-2419.	2.0	8
2596	Analyzing human knockouts to validate GPR151 as a therapeutic target for reduction of body mass index. PLoS Genetics, 2022, 18, e1010093.	1.5	1
2597	The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis. Diabetes Research and Clinical Practice, 2022, 186, 109824.	1.1	5
2598	2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of Cardiac Failure, 2022, 28, 810-830.	0.7	42
2599	Glomerular hyperfiltration. Nature Reviews Nephrology, 2022, 18, 435-451.	4.1	60
2600	Ceramides and phospholipids in plasma extracellular vesicles are associated with high risk of major cardiovascular events after carotid endarterectomy. Scientific Reports, 2022, 12, 5521.	1.6	8
2601	Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon. Sleep and Breathing, 2023, 27, 77-89.	0.9	9
2602	Amelioration of endothelial dysfunction by sodium glucose coâ€transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection. British Journal of Pharmacology, 2022, 179, 4047-4062.	2.7	16
2603	SGLT-2 Inhibitor Use in Heart Failure. Critical Care Nursing Quarterly, 2022, 45, 189-198.	0.4	2

#	Article	IF	Citations
2604	A Clinician's Guide to the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure. Journal of Cardiac Failure, 2022, 28, 831-834.	0.7	24
2605	Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors. Canadian Journal of Hospital Pharmacy, 2022, 75, 104-107.	0.1	1
2606	Doseâ€dependent glucosuria of DWP16001, a novel selective sodiumâ€“glucose cotransporterâ€2 inhibitor, in healthy subjects. British Journal of Clinical Pharmacology, 2022, 88, 4100-4110.	1.1	14
2607	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 1757-1780.	1.2	314
2608	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063.	1.6	756
2609	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001062.	1.6	133
2610	Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes. Primary Care Diabetes, 2022, , .	0.9	1
2611	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovascular Diabetology, 2022, 21, 50.	2.7	8
2612	Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: A retrospective cohort study. Diabetes Research and Clinical Practice, 2022, 186, 109816.	1.1	4
2613	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	1.2	774
2614	Reduction in cardiovascular disease events in patients with typeâ€‰2 diabetes mellitus treated with a sodiumâ€“glucose cotransporterâ€‰2 inhibitor versus a dipeptidyl peptidaseâ€4 inhibitor: A realâ€world retrospective administrative database analysis in Japan. Journal of Diabetes Investigation, 2022, 13, 1175-1189.	1.1	5
2615	Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines. , 2022, 238, 108185.		16
2616	Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes. Diabetes Research and Clinical Practice, 2022, 187, 109855.	1.1	4
2617	Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus. European Journal of Endocrinology, 2022, 186, 597-605.	1.9	2
2618	Low glucose metabolizing capacity and not insulin resistance is primary etiology of type 2 Diabetes Mellitus: A hypothesis. Medical Hypotheses, 2022, 162, 110804.	0.8	0
2619	Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. Journal of Molecular and Cellular Cardiology, 2022, 167, 17-31.	0.9	52
2620	Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes â€“ Data from a randomized, placebo-controlled study. Bone Reports, 2022, 16, 101175.	0.2	11
2621	Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study). JMIR Research Protocols, 2022, 11, e34206.	0.5	0

#	Article	IF	Citations
2622	Case presentation and panel discussion: Cardiometabolic risk mitigation. Journal of Parenteral and Enteral Nutrition, 2021, 45, 93-99.	1.3	0
2623	Diabetes in Kidney Transplantation. Advances in Chronic Kidney Disease, 2021, 28, 596-605.	0.6	4
2624	Why do SGLT2 Inhibitors Act as Cardio-renal Protective even in Non-diabetics?. Japanese Journal of Clinical Pharmacology and Therapeutics, 2021, 52, 157-164.	0.1	0
2625	Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A metaâ€analysis. Journal of Cellular and Molecular Medicine, 2022, 26, 540-547.	1.6	15
2626	Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study. CKJ: Clinical Kidney Journal, 2022, 15, 738-746.	1.4	7
2627	Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting. Frontiers in Pharmacology, 2021, 12, 781379.	1.6	8
2628	New Therapeutic Horizons in ChronicÂKidneyÂDisease: The Role of SGLT2 Inhibitors in Clinical Practice. Drugs, 2022, 82, 97-108.	4.9	4
2629	Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Structural and Electrical Remodeling: From Myocardial Cytology to Cardiodiabetology. Current Vascular Pharmacology, 2022, 20, 178-188.	0.8	2
2631	Variability of arterial pressure and cardiac rhythm in patients with coronary heart disease and diabetes mellitus: Effect of sodium-glucose co-transporter 2 inhibitor. I P Pavlov Russian Medical Biological Herald, 2021, 29, 489-496.	0.2	2
2632	Empagliflozin Protects against Pulmonary Ischemia/Reperfusion Injury via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent Mechanism. Journal of Pharmacology and Experimental Therapeutics, 2022, 380, 230-241.	1.3	13
2633	2021 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk. Journal of Korean Diabetes, 2021, 22, 259-267.	0.1	1
2634	Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population. Cardiovascular Therapeutics, 2021, 2021, 1-8.	1.1	9
2635	Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study. BMJ Open Diabetes Research and Care, 2021, 9, e002352.	1.2	8
2636	Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Advances in Therapy, 2022, 39, 845-861.	1.3	13
2637	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1016-1030.	0.7	5
2638	Three new categories of hypoglycaemic agents and various cardiovascular diseases: A metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 636-642.	0.7	3
2639	Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2021, 68, 741-750.	0.1	0
2640	13. Older Adults: Standards of Medical Care in Diabetesâ€”2022. Diabetes Care, 2022, 45, S195-S207.	4.3	114

#	Article	IF	Citations
2641	Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey. Frontiers in Cardiovascular Medicine, 2021, 8, 810791.	1.1	12
2642	Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression. Current Opinion in Nephrology and Hypertension, 2022, 31, 205-211.	1.0	1
2643	Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome. Scientific Reports, 2021, 11, 24263.	1.6	9
2644	Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study. BMJ Open Diabetes Research and Care, 2021, 9, e002496.	1.2	8
2645	Glycated hemoglobin as a surrogate for evaluating the effectiveness of drugs in diabetes mellitus trials: a systematic review and trial-level meta-analysis. International Journal of Technology Assessment in Health Care, 2022, 38, e12.	0.2	2
2646	SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovascular Diabetology, 2021, 20, 236.	2.7	63
2647	Empagliflozin Reduces Renal Hyperfiltration in Response to Uninephrectomy, but Is Not Nephroprotective in UNx/DOCA/Salt Mouse Models. Frontiers in Pharmacology, 2021, 12, 761855.	1.6	12
2648	Different Effects of Empagliflozin on Markers of Mineral-Bone Metabolism in Diabetic and Non-Diabetic Patients with Stage 3 Chronic Kidney Disease. Medicina (Lithuania), 2021, 57, 1352.	0.8	5
2649	Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Scoreâ€“matched Population-based Cohort Study. Canadian Journal of Diabetes, 2022, 46, 392-403.e13.	0.4	6
2650	Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system. Current Opinion in Nephrology and Hypertension, 2022, 31, 135-141.	1.0	4
2651	Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy. World Journal of Cardiology, 2021, 13, 676-694.	0.5	2
2652	The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Journal of Diabetes Research, 2021, 2021, 1-7.	1.0	1
2653	2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea. Journal of Korean Diabetes, 2021, 22, 244-249.	0.1	8
2654	Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations. Russian Journal of Cardiology, 2022, 26, 4807.	0.4	0
2655	Series: Cardiovascular outcome trials for diabetes drugs Canagliflozin and the CANVAS Program, dapagliflozin and DECLARE-TIMI 58, ertugliflozin and VERTIS CV. British Journal of Diabetes, 0, , .	0.1	0
2656	Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Frontiers in Medicine, 2021, 8, 777861.	1.2	55
2657	SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney. FASEB Journal, 2022, 36, e22078.	0.2	37
2658	ABCD debate at the annual ABCD virtual meeting 18 December 2020. British Journal of Diabetes, 2021, 21, 286-288.	0.1	0

#	Article	IF	Citations
2659	Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials. Advances in Therapy, 2022, 39, 193-220.	1.3	12
2660	2021 Korean Diabetes Association Clinical Practice Guidelines for Diabetes: Diabetic Kidney Disease. Journal of Korean Diabetes, 2021, 22, 268-273.	0.1	1
2662	Pharmacotherapy of diabetes mellitus in patients with heart failure - a nation-wide analysis of contemporary treatment. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2021, , .	0.2	1
2663	Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. Journal of Clinical Medicine, 2022, 11, 137.	1.0	15
2664	SGLT2 Inhibition for Diabetic and Non-diabetic Kidney Disease. Korean Journal of Medicine, 2021, 96, 455-462.	0.1	0
2665	SGLT-2 Inhibitorâ€"Versatile Newcomer in Heart Failure Management. Indian Journal of Clinical Cardiology, 2021, 2, 193-194.	0.3	0
2666	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	1.0	8
2667	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition. Diabetes Mellitus, 2022, 24, 1-148.	0.5	123
2668	Opportunities of Antidiabetic Drugs in Cardiovascular Medicine. Hypertension, 2020, 76, 420-431.	1.3	6
2669	The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 622-632.	1.4	13
2670	Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882210900.	1.4	16
2671	Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210869.	1.1	12
2672	Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis. European Heart Journal Digital Health, 2022, 3, 181-194.	0.7	1
2673	Sodiumâ€"Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure. Annals of Internal Medicine, 2022, 175, 851-861.	2.0	23
2674	Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations. Journal of Diabetes, 2022, 14, 315-333.	0.8	4
2675	Modifiers of the Risk of Diabetes for Long-Term Outcomes After Coronary Revascularization. JACC Asia, 2022, , .	0.5	0
2676	The Role of Mitochondrial Biogenesis Dysfunction in Diabetic Cardiomyopathy. Biomolecules and Therapeutics, 2022, 30, 399-408.	1.1	5
2677	Diabetes Medications and Cardiovascular Disease Prevention. Korean Journal of Family Practice, 2022, 12, 61-71.	0.1	0

#	Article	IF	Citations
2678	Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology. European Journal of Internal Medicine, 2022, 100, 13-20.	1.0	4
2679	Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion. Diagnostics, 2022, 12, 989.	1.3	9
2680	New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada. Canadian Journal of Diabetes, 2022, 46, 691-698.	0.4	5
2681	GuÃa ESC 2021 sobre el diagnÃ³stico y tratamiento de la insuficiencia cardiaca aguda y crÃ³nica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	0.6	40
2682	GuÃa ESC 2021 sobre la prevenciÃ³n de la enfermedad cardiovascular en la prÃ¡ctica clÃ¬nica. Revista Espanola De Cardiologia, 2022, 75, 429.e1-429.e104.	0.6	27
2683	New Approaches to Diabetic Nephropathy from Bed to Bench. Biomedicines, 2022, 10, 876.	1.4	4
2685	Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis. Diabetes Research and Clinical Practice, 2022, 187, 109871.	1.1	7
2706	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, 2022, 65, 1085-1097.	2.9	28
2707	Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduction and Targeted Therapy, 2022, 7, 131.	7.1	190
2708	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S127-S136.	0.6	1
2709	Biochemical Efficacy of Sodiumâ€“Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population. Journal of Cardiovascular Pharmacology, 2022, 80, 140-147.	0.8	1
2710	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). BMJ Open, 2019, 9, e029098.	0.8	5
2711	Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial. BMJ Open, 2022, 12, e059073.	0.8	9
2712	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 2022, 145, 1460-1470.	1.6	97
2715	Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. Journal of Geriatric Cardiology, 2021, 18, 783-795.	0.2	7
2716	Medication management for heart failure with reduced ejection fraction. Canadian Family Physician, 2021, 67, 915-922.	0.1	1
2719	Modern approaches to the treatment of atrial fibrillation in patients with diabetes mellitus.. Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini, 2022, 2022, 69-85.	0.0	0
2720	The physiological and pathophysiological roles of carbohydrate response element binding protein in the kidney. Endocrine Journal, 2022, , .	0.7	0

#	Article	IF	Citations
2721	SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist. , 2022, 2, .		4
2722	Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 643-654.	2.2	10
2723	Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study. Frontiers in Cardiovascular Medicine, 2022, 9, 882181.	1.1	5
2724	Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care, 2022, 45, 1445-1452.	4.3	18
2725	Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2022, 46, 843-854.	1.8	4
2726	Macrovascular Complications. Primary Care - Clinics in Office Practice, 2022, 49, 255-273.	0.7	2
2727	SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 2022, 9, 826684.	1.1	3
2728	Strategic Recommendations to Bridge the Gaps in Awareness, Diagnosis and Prevention of Heart Failure in the Middle East Region and Africa. Journal of the Saudi Heart Association, 2022, 34, 53-65.	0.2	1
2729	The position of SGLT2 inhibitors in current medical practice - update 2022. Vnitrni Lekarstvi, 2022, 68, 96-103.	0.1	1
2730	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2022, 24, 1734-1740.	2.2	0
2731	Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis. Cardiovascular Diabetology, 2022, 21, 58.	2.7	6
2732	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. Journal of Molecular Cell Biology, 2022, 14, .	1.5	16
2733	Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease. Current Cardiology Reviews, 2022, 18, .	0.6	1
2734	Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases. BMC Nephrology, 2022, 23, 168.	0.8	4
2735	Association between glucagonâ€like peptideâ€1 receptor agonists and biliaryâ€related diseases in patients with type 2 diabetes: a nationwide cohort study. Pharmacotherapy, 2022, , .	1.2	2
2736	Patientsâ€™ Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation. Patient Preference and Adherence, 2022, Volume 16, 1201-1211.	0.8	1
2737	Individualized Glycemic Goals for Older Adults Are a Moving Target. Diabetes Care, 2022, 45, 1029-1031.	4.3	6
2738	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 2022, 145, 1581-1591.	1.6	13

#	Article	IF	Citations
2739	Recent advances in the pharmacotherapeutic management of diabetic kidney disease. Expert Opinion on Pharmacotherapy, 2022, 23, 791-803.	0.9	5
2741	Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Pancreatic Î²-Cell Mass and Function. International Journal of Molecular Sciences, 2022, 23, 5104.	1.8	3
2742	The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients. Peritoneal Dialysis International, 2023, 43, 139-144.	1.1	7
2743	Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nature Reviews Endocrinology, 2022, 18, 413-432.	4.3	62
2744	Comparative cardiovascular effectiveness of glucagonâ€like peptideâ€1 receptor agonists versus sodiumâ€glucose cotransporterâ€2 inhibitors in patients with type 2 diabetes: A populationâ€based cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 1623-1637.	2.2	9
2745	The current status of lowâ€density lipoprotein cholesterol for primary prevention of coronary artery disease in lateâ€stage elderly persons with type 2 diabetes mellitus: A retrospective, singleâ€center study. Journal of Diabetes Investigation, 2022, , .	1.1	2
2746	Sodiumâ€Glucose Cotransporterâ€2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. Basic and Clinical Pharmacology and Toxicology, 2022, , .	1.2	1
2747	Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cellular and Molecular Life Sciences, 2022, 79, 273.	2.4	40
2748	Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. Journal of Cardiac Failure, 2022, 28, 1050-1062.	0.7	19
2749	The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Medicine, 2022, 11, 2653.	1.0	2
2750	New therapies for the treatment of heart failure with preserved ejection fraction. American Journal of Health-System Pharmacy, 2022, 79, 1424-1430.	0.5	4
2751	Type 2 diabetes medication and HbA1c levels in North Karelia Finland, 2013â€“2019. Diabetic Medicine, 2022, 39, e14866.	1.2	3
2752	Concomitant treatment with insulin and sodiumâ€glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity scoreâ€matched analysis. Journal of Diabetes Investigation, 2022, , .	1.1	1
2753	Microvascular disease increases the risk of lower limb amputation â€“ A Western Danish cohort study. European Journal of Clinical Investigation, 2022, 52, e13812.	1.7	4
2754	Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney International Reports, 2022, 7, 1463-1476.	0.4	59
2755	Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?. Endocrine Practice, 2022, 28, 795-801.	1.1	5
2756	Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2022, 38, 1434-1441.	0.8	2
2757	Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Research and Clinical Practice, 2022, 188, 109927.	1.1	18

#	Article	IF	Citations
2758	Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovascular Diabetology, 2022, 21, 74.	2.7	82
2759	Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-Î²1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure. Frontiers in Pharmacology, 2022, 13, .	1.6	8
2760	Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study. International Urology and Nephrology, 2022, , .	0.6	3
2761	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 2058-2068.	1.2	41
2762	The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice. Acta Cardiologica, 2023, 78, 552-564.	0.3	2
2763	Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American Heart Journal, 2022, 253, 86-98.	1.2	48
2764	Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?. Basic Research in Cardiology, 2022, 117, 27.	2.5	21
2765	Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?. Journal of Nephrology, 2022, , .	0.9	5
2766	Sodiumâ€glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation. Clinical Transplantation, 2022, 36, e14718.	0.8	11
2767	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1927-1938.	2.2	10
2768	Type 2 diabetes: summary of updated NICE guidance. BMJ, The, 2022, 377, o775.	3.0	8
2769	Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. Cardiovascular Diabetology, 2022, 21, 67.	2.7	27
2772	Empagliflozin as a part of optimal medical therapy for chronic heart failure. Kardiologicheskii Vestnik, 2022, 17, 16.	0.1	0
2773	Hypertension in Patients with Insulin Resistance: Etiopathogenesis and Management in Children. International Journal of Molecular Sciences, 2022, 23, 5814.	1.8	13
2774	The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovascular Diabetology, 2022, 21, .	2.7	51
2775	Carbohydrate-based drugs launched during 2000â^'2021. Acta Pharmaceutica Sinica B, 2022, 12, 3783-3821.	5.7	68
2776	Dapagliflozin partially restores reproductive function in MC4R KO obese female mice. Journal of Endocrinology, 2022, 254, 65-76.	1.2	4
2777	SGLT2 inhibitors in acute decompensated heart failure, what do we know?. Terapevticheskii Arkhiv, 2022, 94, 565-571.	0.2	1

#	Article	IF	Citations
2778	Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2022, 13, .	1.5	8
2779	Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	5
2780	SGLT2 Inhibitors and Peripheral Vascular Events. Heart Failure Clinics, 2022, 18, 609-623.	1.0	5
2781	Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6/J mice. Current Research in Physiology, 2022, 5, 232-239.	0.8	8
2782	Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective. Pharmaceutics, 2022, 14, 1180.	2.0	0
2783	Impact of Sodiumâ€“Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Agingâ€”What Do We Know So Far? (A Narrative Review). Life, 2022, 12, 803.	1.1	11
2784	Fibroblast Growth Factor 23 and Cardiovascular Risk in Diabetes Patientsâ€”Cardiologists Be Aware. Metabolites, 2022, 12, 498.	1.3	1
2785	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2022, 24, 1829-1839.	2.2	23
2786	SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. Current Diabetes Reports, 2022, 22, 317-332.	1.7	4
2788	Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Metformin. Annals of Internal Medicine, 2022, 175, 927-937.	2.0	20
2789	Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacistâ€™s Perspective. Frontiers in Endocrinology, 2022, 13, .	1.5	2
2790	Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2. Journal of Clinical and Translational Hepatology, 2022, 10, 965-971.	0.7	2
2791	Gliflozins in the Management of Cardiovascular Disease. New England Journal of Medicine, 2022, 386, 2024-2034.	13.9	113
2792	The impact of medical therapy on left ventricular strain: Current state and future perspectives. Journal of Clinical Ultrasound, 0, , .	0.4	1
2793	Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients. Journal of Clinical Medicine, 2022, 11, 2935.	1.0	4
2794	Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes. Journal of Diabetes Research, 2022, 2022, 1-10.	1.0	4
2795	Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 835-842.	2.2	15
2797	SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?. Current Atherosclerosis Reports, 2022, 24, 627-634.	2.0	8

#	Article	IF	Citations
2798	Validation of the WATCHâ€ĐM and TRSâ€HF _{DM} Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. Journal of the American Heart Association, 2022, 11, .	1.6	10
2799	Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors. Journal of Diabetes and Its Complications, 2022, 36, 108225.	1.2	1
2800	Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease. Diabetes and Metabolism Journal, 2022, 46, 701-712.	1.8	8
2801	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care, 2022, 45, 1670-1690.	4.3	109
2802	Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure. Journal of Clinical Medicine, 2022, 11, 3192.	1.0	10
2803	Promise of sodiumâ€"glucose coâ€transporterâ€2 inhibitors in heart failure with mildly reduced ejection fraction. ESC Heart Failure, 0, , .	1.4	2
2804	Sex and Gender Related Differences in Diabetic Kidney Disease. Seminars in Nephrology, 2022, 42, 170-184.	0.6	7
2805	Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy. Current Pharmaceutical Design, 2022, 28, 2131-2139.	0.9	0
2806	Cardiorenal prevention as the key player in the reduction of all-cause mortality. Nefrologia, 2022, , .	0.2	0
2807	Renoprotective mechanisms of SGLT2 inhibitor in diabetic kidney disease. Diabetic Nephropathy, 2022, .	0.1	0
2808	Diabetes: how to manage chronic kidney disease. Drugs in Context, 0, 11, 1-10.	1.0	0
2809	Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review. Advances in Therapy, 2022, 39, 3472-3487.	1.3	4
2810	Anthropomorphic Character Animations Versus Digital Chalk Talks in a Resident Diabetes Pharmacotherapy Curriculum: a Randomized Controlled Trial. Journal of General Internal Medicine, 2022, 37, 2251-2258.	1.3	6
2811	Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D. Diabetes Therapy, 2022, 13, 35-49.	1.2	5
2812	Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy. Diabetes Therapy, 2022, 13, 1281-1298.	1.2	5
2813	Risk of volume depletion events with concomitant use of sodium glucose coâ€transporter 2 inhibitors and loop diuretics: A selfâ€controlled case series study. Pharmacoepidemiology and Drug Safety, 2022, 31, 1102-1109.	0.9	1
2814	Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). Diabetes Care, 2022, 45, 1893-1899.	4.3	8
2815	<scp>SGLT2</scp> inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the <scp>HIF</scp>â€2Î± signaling pathway in arrhythmogenic cardiomyopathy. FASEB Journal, 2022, 36, .	0.2	24

#	Article	IF	Citations
2816	Pharmacokinetics and Tissue Distribution of Enavogliflozin in Mice and Rats. Pharmaceutics, 2022, 14, 1210.	2.0	8
2817	Clinical Benefits of Sodiumâ€“Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. JACC Asia, 2022, 2, 287-293.	0.5	6
2818	Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies. European Journal of Clinical Pharmacology, 2022, 78, 1205-1216.	0.8	5
2819	Analysing the impact of modifiable risk factors on cardiovascular disease mortality in Brazil. PLoS ONE, 2022, 17, e0269549.	1.1	3
2820	New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. Frontiers in Pharmacology, 0, 13, .	1.6	7
2821	Expert consensus on personalized initiation of glucoseâ€lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. Journal of Evidence-Based Medicine, 2022, 15, 168-179.	0.7	3
2822	The sodiumâ€glucose coâ€transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoEâ€deficient mice with streptozotocinâ€induced diabetes. Pharmacology Research and Perspectives, 2022, 10, .	1.1	3
2823	Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021). Aging Medicine (Milton (N S W)), 2022, 5, 78-93.	0.9	7
2824	Hypertension and Type 2 Diabetesâ€”The Novel Treatment Possibilities. International Journal of Molecular Sciences, 2022, 23, 6500.	1.8	13
2825	Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors â€“ Lessons From a Case Series and Strategies to Decrease Incidence. Endocrine Practice, 2022, 28, 884-888.	1.1	16
2826	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. Frontiers in Endocrinology, 0, 13, .	1.5	6
2827	Significant reduction in chronic kidney disease progression with sodiumâ€glucose cotransporterâ€2 inhibitors compared to dipeptidyl peptidaseâ€4 inhibitors in adults with type 2 diabetes in a <scp>UK</scp> clinical setting: An observational outcomes study based on international guidelines for kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 2138-2147.	2.2	4
2828	Cost-Effectiveness Analysis of Initiating TypeÂ2 Diabetes Therapy with a Sodiumâ€“Glucose CotransporterÂ2 Inhibitor Versus Conventional Therapy in Japan. Diabetes Therapy, 2022, 13, 1367-1381.	1.2	9
2829	Combined therapy with dapagliflozin and entresto offers an additional benefit on improving the heart function in rat after ischemia-reperfusion injury. Biomedical Journal, 2023, 46, 100546.	1.4	4
2830	The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD. Frontiers in Neurology, 0, 13, .	1.1	3
2831	Hypoglycaemic therapy in frail older people with type 2 diabetes mellitusâ€”a choice determined by metabolic phenotype. Aging Clinical and Experimental Research, 2022, 34, 1949-1967.	1.4	11
2832	Updated NICE guidelines on type 2 diabetes â€“ what's new?. Independent Nurse, 2022, 2022, 12-16.	0.0	0
2833	Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2â€”Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes. Healthcare (Switzerland), 2022, 10, 1153.	1.0	1

#	Article	IF	Citations
2835	Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus. International Journal of Cardiology, 2022, 364, 104-111.	0.8	7
2836	The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1. Kidney and Dialysis, 2022, 2, 349-368.	0.5	4
2837	Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na+/H+ exchanger-1. International Journal of Cardiology, 2022, , .	0.8	7
2838	Side effects and treatment initiation barriers of sodiumâ€“glucose cotransporter 2 inhibitors in heart failure: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2022, 24, 1625-1632.	2.9	10
2839	Prevention of Cardiorenal Complications with Sodiumâ€“Glucose Cotransporter Type 2 Inhibitors: A Narrative Review. Diabetes Therapy, 2022, 13, 5-17.	1.2	6
2840	Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors. Frontiers in Pharmacology, 0, 13, .	1.6	5
2841	Novel perspectives of sodium handling in type 2 diabetes mellitus. Expert Review of Endocrinology and Metabolism, 0, , 1-9.	1.2	1
2842	Diabetes: how to manage cardiovascular risk in secondary prevention patients. Drugs in Context, 0, 11, 1-12.	1.0	1
2843	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. Journal of Diabetes Investigation, 2022, 13, 1472-1488.	1.1	2
2844	Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis. EClinicalMedicine, 2022, 50, 101510.	3.2	11
2845	Is There Room for New Drugs in the Treatment of Advanced Heart Failure: SGLT2i?. , 2022, 2, 195-197.		0
2846	The protective effects and underlying mechanisms of dapagliflozin on diabetes-induced testicular dysfunction. Asian Journal of Andrology, 2023, 25, 331-338.	0.8	5
2847	Treating Cardiodiabetic Continuum by SGLT2 Inhibitors: From Diabetes Mellitus to Heart Failure. Cardiometabolic Syndrome Journal, 0, 2, .	1.0	0
2848	SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways. Theranostics, 2022, 12, 5034-5050.	4.6	35
2849	SGLT2-Inhibitors are Effective and Safe in the Elderly: The SOLD Study. SSRN Electronic Journal, 0, , .	0.4	0
2850	SEA 2022 standards for the comprehensive control of cardiovascular risk. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2022, 34, 130-179.	0.1	1
2851	Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States. Kidney Medicine, 2022, 4, 100510.	1.0	9
2852	Asian Best Practices for Care of Diabetes in Elderly (ABCDE). Review of Diabetic Studies, 2022, 18, 100-134.	0.5	0

#	Article	IF	Citations
2853	Appropriate Dose of Dapagliflozin Improves Cardiac Outcomes by Normalizing Mitochondrial Fission and Reducing Cardiomyocyte Apoptosis After Acute Myocardial Infarction. Drug Design, Development and Therapy, 0, Volume 16, 2017-2030.	2.0	6
2854	Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. Current Medical Research and Opinion, 2022, 38, 1785-1795.	0.9	2
2855	Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. International Journal of Molecular Sciences, 2022, 23, 7261.	1.8	4
2856	Cardiodiabetology: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks. Canadian Journal of Physiology and Pharmacology, 0, , .	0.7	0
2857	Improvement in Age at Mortality and Changes in Causes of Death in the Population with Diabetes: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018. Endocrinology and Metabolism, 2022, 37, 466-474.	1.3	4
2858	New strategies and therapies for the prevention of heart failure in highâ€risk patients. Clinical Cardiology, 2022, 45, .	0.7	4
2859	New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease. Frontiers in Physiology, 0, 13, .	1.3	0
2860	The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovascular Diabetology, 2022, 21, .	2.7	16
2861	Current Updates in the Pharmacotherapy of Heart Failure with a Preserved Ejection Fraction. Cardiovascular & Hematological Disorders Drug Targets, 2022, 22, 87-95.	0.2	1
2862	Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1448-1457.	2.2	13
2864	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. Endocrinology and Metabolism, 2022, 37, 415-429.	1.3	3
2865	The 2021â€“2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD. Diabetology and Metabolic Syndrome, 2022, 14, .	1.2	3
2866	Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis. International Journal of Cardiology, 2022, 366, 51-56.	0.8	9
2867	The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 1259-1271.	0.9	2
2868	Dapagliflozin use in type 1 diabetes: industry, business and ethics. British Journal of Diabetes, 2022, 22, 47-48.	0.1	0
2869	A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection. Cureus, 2022, , .	0.2	5
2871	Initiating SGLT2 inhibitor therapy to improve renal outcomes for persons with diabetes eligible for an intensified glucose-lowering regimen: hypothetical intervention using parametric g-formula modeling. BMJ Open Diabetes Research and Care, 2022, 10, e002636.	1.2	2
2873	Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions. Cardiovascular Diabetology, 2022, 21, .	2.7	8

#	Article	IF	Citations
2874	Prevention of sudden death in heart failure with reduced ejection fraction: do we still needÂan implantable cardioverterâ€defibrillator for primary prevention?. European Journal of Heart Failure, 2022, 24, 1460-1466.	2.9	12
2875	Sodiumâ€glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?. Diabetes, Obesity and Metabolism, 2022, 24, 1897-1900.	2.2	2
2876	Diagnosis and Management of Heart Disease. , 2022, , 139-172.		0
2877	Dapagliflozin for the treatment of chronic kidney disease. Expert Review of Endocrinology and Metabolism, 2022, 17, 275-291.	1.2	7
2878	New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2493-2499.	1.8	10
2879	Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized. Frontiers in Pharmacology, 0, 13, .	1.6	1
2880	NADPH oxidase inhibitor development for diabetic nephropathy through water tank model. Kidney Research and Clinical Practice, 2022, 41, S89-S98.	0.9	6
2881	The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture. Frontiers in Endocrinology, 0, 13, .	1.5	12
2882	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S80-S112.	0.6	5
2883	Sodiumâ€“Glucose Cotransporter 2 Inhibitors in Cardiovascular and Renal Outcomes in Patients With Diabetes but Without Established Cardiovascular Disease: A Nationwide Population-Based Cohort Study. Diabetes Care, 0, , .	4.3	1
2884	Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodiumâ€“glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. European Heart Journal Quality of Care & Clinical Outcomes, 0, , .	1.8	2
2885	Part Three: A Brief Primer of Non-Insulin Treatments for Type 2 Diabetes Mellitus in Older People. , 2022, 37, 251-259.		1
2886	Effects of 26â€‰weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, openâ€label, crossover, activeâ€comparator FIORE trial. Diabetes, Obesity and Metabolism, 2022, 24, 2319-2330.	2.2	6
2887	Cardiovascular protection by SGLT2 inhibitors â€“ Do anti-inflammatory mechanisms play a role?. Molecular Metabolism, 2022, 64, 101549.	3.0	23
2888	Sodiumâ€“Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy. Cardiac Failure Review, 0, 8, .	1.2	2
2889	The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data. Diabetologia, 2022, 65, 1424-1435.	2.9	8
2890	Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. Journal of Cardiovascular Development and Disease, 2022, 9, 225.	0.8	3
2891	Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation. American Journal of Cardiology, 2022, 178, 35-42.	0.7	6

#	Article	IF	Citations
2892	Update on Hypertension Research in 2021. Hypertension Research, 2022, 45, 1276-1297.	1.5	13
2893	Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review. Expert Review of Cardiovascular Therapy, 2022, 20, 529-541.	0.6	3
2894	Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites. Frontiers in Endocrinology, 0, 13, .	1.5	9
2895	Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy. Diabetes Care, 0, , .	4.3	3
2896	Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!. World Journal of Diabetes, 2022, 13, 471-481.	1.3	3
2897	Reâ€examining the widespread policy of stopping sodiumâ€glucose cotransporterâ€2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 2022, 24, 2071-2080.	2.2	16
2898	Predicting incident heart failure among patients with type 2 diabetes mellitus: The <scp>DMâ€CURE</scp> risk score. Diabetes, Obesity and Metabolism, 2022, 24, 2203-2211.	2.2	6
2899	Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model. Biomedicine and Pharmacotherapy, 2022, 153, 113357.	2.5	12
2900	Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment. Life, 2022, 12, 1111.	1.1	22
2901	Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes. JAMA Cardiology, 0, , .	3.0	1
2902	Sodium-glucose cotransporter-2 inhibitors as first-line pharmacological therapy for type 2 diabetes?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, , 102580.	1.8	0
2903	Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 381-393.	1.5	7
2904	Effect of sodiumâ€“glucose cotransporterâ€‰2 inhibitor medication on new prescriptions of antihypertensives, antigout/antihyperuricemics and antidyslipidemics in Japan: Analysis using the <scp>JMDC</scp> Claims Database. Journal of Diabetes Investigation, 2022, 13, 1842-1851.	1.1	4
2905	Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes. Diabetes Care, 2022, 45, 2055-2063.	4.3	17
2906	Dapagliflozin Improves Cardiac Autonomic Function Measures in Type 2 Diabetic Patients with Cardiac Autonomic Neuropathy. , 0, , .		4
2907	Contrast-Induced Acute Kidney Injury in Diabetic Patients and SGLT-2 Inhibitors: A Preventive Opportunity or Promoting Element?. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, .	0.8	6
2908	Dapagliflozin Improves Diabetic Cardiomyopathy by Modulating the Akt/mTOR Signaling Pathway. BioMed Research International, 2022, 2022, 1-10.	0.9	2
2909	Efficacy of three novel drugs in the treatment of heart failure: A network meta-analysis. Medicine (United States), 2022, 101, e29415.	0.4	0

#	Article	IF	Citations
2910	SGLT2 inhibitors: suggestions from the amphibian world. Giornale Di Clinica Nefrologica E Dialisi, 0, 34, 63-69.	0.0	0
2911	A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation. Journal of Cardiovascular Development and Disease, 2022, 9, 236.	0.8	5
2912	Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2Â°Pâ€ TIMI 50 trial. Clinical Cardiology, 2022, 45, 831-838.	0.7	4
2913	Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry. American Journal of Medicine, 2022, 135, 1336-1341.	0.6	1
2914	Sodium-glucose cotransporter 2 (SGLT2) inhibitors for the prevention and treatment of diabetic kidney disease: A network meta-analysis of randomized controlled trials. Diabetic Nephropathy, 2021, 1, 114-124.	0.1	0
2915	Risk Factors, Outcomes and Healthcare Utilisation in Individuals with Multimorbidity Including Heart Failure, Chronic Kidney Disease and Type 2 Diabetes Mellitus - a National Electronic Health Record Study. SSRN Electronic Journal, 0, , .	0.4	0
2916	Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives. Diabetes Mellitus, 2022, 25, 275-287.	0.5	1
2917	Consensus statement on the current pharmacological prevention and management of heart failure. Medical Journal of Australia, 2022, 217, 212-217.	0.8	14
2918	Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort. CKJ: Clinical Kidney Journal, 2022, 15, 2124-2134.	1.4	4
2919	Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
2920	Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism. International Journal of Molecular Sciences, 2022, 23, 7966.	1.8	8
2921	Diabetes without Overt Cardiac Disease Is Associated with Markers of Abnormal Repolarization: A Case-Control Study. Life, 2022, 12, 1173.	1.1	0
2922	New concepts in heart failure with preserved ejection fraction and hypertension. Current Opinion in Cardiology, 2022, 37, 424-430.	0.8	1
2923	Information and consensus document for the detection and management of chronic kidney disease. Nefrologia, 2022, 42, 233-264.	0.2	8
2924	Sodium-glucose co-transporter 2 inhibitors beyond diabetes. Australian Prescriber, 2022, 45, 121-124.	0.5	0
2925	Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors. Current Diabetes Reviews, 2022, 19, .	0.6	1
2926	Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. Expert Review of Clinical Pharmacology, 0, , 1-16.	1.3	2
2927	2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Canadian Journal of Cardiology, 2022, 38, 1153-1167.	0.8	17

#	Article	IF	Citations
2928	Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis. Frontiers in Pharmacology, 0, 13, .	1.6	12
2930	SGLT2 inhibition reduces myocardial oxygen consumption. Metabolism Open, 2022, 15, 100207.	1.4	0
2931	Potential molecular mechanism of action of sodium-glucose co-transporter 2 inhibitors in the prevention and management of diabetic retinopathy. Expert Review of Ophthalmology, 0, , 1-12.	0.3	0
2932	SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation. Cardiovascular Research, 2023, 119, 843-856.	1.8	2
2933	SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart. International Journal of Molecular Sciences, 2022, 23, 9559.	1.8	6
2934	Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and metaâ€analysis. European Journal of Clinical Investigation, 2022, 52, .	1.7	10
2935	SGLT2 Inhibitorsâ€"A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling. Journal of the American Heart Association, 2022, 11, .	1.6	0
2936	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€"2022 Update. Endocrine Practice, 2022, 28, 923-1049.	1.1	146
2937	Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	2.7	18
2938	The complex interplay between diabetes mellitus and atrial fibrillation. Expert Review of Cardiovascular Therapy, 2022, 20, 707-717.	0.6	3
2939	Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction. European Journal of Medical Research, 2022, 27, .	0.9	3
2940	Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?. International Journal of Molecular Sciences, 2022, 23, 8631.	1.8	7
2941	New and developing pharmacotherapies for hypertension. Expert Review of Cardiovascular Therapy, 2022, 20, 647-666.	0.6	1
2942	Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes Care, 2022, 45, 2350-2359.	4.3	19
2943	SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia, 2022, 65, 2000-2010.	2.9	26
2944	Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment. Diabetes, Obesity and Metabolism, 2022, 24, 2297-2308.	2.2	14
2945	â€œDipâ€•in eGFR: Stay the Course With SGLT-2 Inhibition. Circulation, 2022, 146, 463-465.	1.6	3
2946	Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors. Kidney International, 2022, 102, 1147-1153.	2.6	10

#	Article	IF	Citations
2947	Signal Detection of Acute Renal Failure Following the Use of SGLT-2 Inhibitors: Stratified Analysis and Time Trend Analysis in Japan and the United States. Biological and Pharmaceutical Bulletin, 2022, 45, 1077-1083.	0.6	0
2948	Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update. Journal of Clinical Medicine, 2022, 11, 4660.	1.0	6
2949	Patterns and Patientsâ€™ Characteristics Associated With Use of Sodium-Glucose Cotransporter-2 Inhibitors Among Adults With TypeÂ2ÂDiabetes: A Population-based Cohort Study. Canadian Journal of Diabetes, 2023, 47, 58-65.e2.	0.4	4
2950	The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. Pharmaceutics, 2022, 14, 1730.	2.0	18
2951	Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	2.7	21
2952	Potential diabetic cardiomyopathy therapies targeting pyroptosis: A mini review. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
2953	SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease. Current Medicinal Chemistry, 2023, 30, 2039-2060.	1.2	4
2954	Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease. Molecular Biology Reports, 2022, 49, 10915-10924.	1.0	1
2955	The Effectiveness of Sodium-Glucose Cotransporter 2ÂInhibitors and Glucagon-like Peptide-1 Receptor AgonistsÂon Cardiorenal Outcomes: Systematic Review andÂMeta-analysis. Canadian Journal of Cardiology, 2022, 38, 1201-1210.	0.8	12
2956	Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
2957	Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1. International Journal of Molecular Sciences, 2022, 23, 8777.	1.8	6
2958	A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: A revisit to the ACCORD trial. Journal of Diabetes and Its Complications, 2022, 36, 108287.	1.2	2
2959	Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study. Pharmacological Research, 2022, 183, 106374.	3.1	9
2960	Cardiorenal protection of SGLT2 inhibitorsâ€”Perspectives from metabolic reprogramming. EBioMedicine, 2022, 83, 104215.	2.7	26
2961	Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure.. European Journal of Pharmacology, 2022, 931, 175194.	1.7	8
2962	A novel therapeutic combination of dapagliflozin, Lactobacillus and crocin attenuates diabetic cardiomyopathy in rats: Role of oxidative stress, gut microbiota, and PPARÎ³ activation. European Journal of Pharmacology, 2022, 931, 175172.	1.7	6
2963	Incidence, risk factors and predictors of cardiovascular mortality for aortic stenosis among patients with diabetes mellitus. Diabetes Research and Clinical Practice, 2022, 191, 110050.	1.1	1
2964	Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes. Diabetes Research and Clinical Practice, 2022, 191, 110043.	1.1	1

#	Article	IF	Citations
2965	SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacological Research, 2022, 183, 106396.	3.1	19
2966	Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovascular Diabetology, 2022, 21, .	2.7	19
2967	Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin. Heliyon, 2022, 8, e10615.	1.4	3
2968	Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2023, 28, 7-13.	0.4	1
2969	Severe hypoglycemia and risk of hospitalization for heart failure in adults with diabetes treated with oral medications with or without insulin: A population-based study. Diabetes Research and Clinical Practice, 2022, 192, 110083.	1.1	3
2970	Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. Journal of the American College of Cardiology, 2022, 80, 1302-1310.	1.2	49
2971	Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacological Research, 2022, 184, 106448.	3.1	20
2972	Evidencia molecular y clÃnica del beneficio cardiovascular de los inhibidores SGLT2: estado del arte. Medicina UPB, 2022, 41, 145-156.	0.1	1
2973	Sodium-Glucose Cotransporter-2 (SGLT2) Expression in Diabetic and Non-Diabetic Failing Human Cardiomyocytes. SSRN Electronic Journal, 0, , .	0.4	0
2974	Therapie von Begleiterkrankungen: Diabetes mellitus und DyslipoproteinÃmie. , 2022, , 211-225.		0
2975	SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review. Methodist DeBakey Cardiovascular Journal, 2022, 18, 62-72.	0.5	3
2976	Herz und Diabetes. Springer Reference Medizin, 2022, , 1-14.	0.0	0
2977	Therapeutic peptidomimetics in metabolic diseases. , 2022, , 521-550.		0
2978	SGLT-2 Inhibitors Substantially Reduce the Development of Diabetic Retinopathy in Patients with Type 2 Diabetes: A Nationwide Population Cohort Study. SSRN Electronic Journal, 0, , .	0.4	0
2979	Flozins in heart failure â€“ a new reimbursement indication. , 2022, 20, 19-25.		1
2980	Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. Cardiovascular Diabetology, 2022, 21, .	2.7	3
2981	Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction. JAMA Cardiology, 2022, 7, 1067.	3.0	12
2982	Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure. , 0, , .		0

#	Article	IF	Citations
2983	Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction. Medicina (Lithuania), 2022, 58, 1128.	0.8	4
2984	Protective or inhibitory effect of pharmacological therapy on cardiac ischemic preconditioning: a literature review. Current Vascular Pharmacology, 2022, 20, .	0.8	2
2985	Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Medicine (United States), 2022, 101, e30072.	0.4	2
2986	Glifozins and Atrial Fibrillation. Journal of the American College of Cardiology, 2022, , .	1.2	0
2987	Epidemiology and resource use in Spanish type 2 diabetes patients without previous cardiorenal disease: CaReMe Spain study summary. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2022, 69, 509-519.	0.1	0
2988	Tratamiento farmacolÃ³gico del paciente que vive con diabetes mellitus tipo 2. CES Medicina, 2022, 36, 81-105.	0.1	0
2989	How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases. International Journal of Cardiology, 2023, 371, 236-243.	0.8	4
2991	SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study. Diabetes Care, 2022, 45, 2718-2728.	4.3	21
2992	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2022, 65, 1925-1966.	2.9	273
2994	Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. International Journal of Molecular Sciences, 2022, 23, 10146.	1.8	26
2995	Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling. BMC Medicine, 2022, 20, .	2.3	9
2996	Effects of Antidiabetic Medications on the Risk of Bone Fracture in Patients With Type 2 Diabetes Mellitus. ADCES in Practice, 0, , 2633559X2211227.	0.2	0
2997	Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
2998	Diabetic Proteinuria Revisited: Updated Physiologic Perspectives. Cells, 2022, 11, 2917.	1.8	12
3000	External validation and extension of the <scp>TIMI</scp> risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the <scp>EXAMINE</scp> trial. Diabetes, Obesity and Metabolism, 2023, 25, 229-237.	2.2	3
3001	Sodiumâ€“Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care, 2022, 45, 2907-2917.	4.3	6
3002	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2022, 45, 2753-2786.	4.3	435
3003	HeartÂFailure Drug Treatmentâ€”Inertia,ÂTitration, and Discontinuation. JACC: Heart Failure, 2023, 11, 1-14.	1.9	51

#	Article	IF	Citations
3004	Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. International Journal of Molecular Sciences, 2022, 23, 10882.	1.8	9
3005	Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Scientific Reports, 2022, 12, .	1.6	3
3006	Derivation and External Validation of a Clinical Model to Predict Heart Failure Onset in Patients With Incident Diabetes. Diabetes Care, 2022, 45, 2737-2745.	4.3	1
3007	Sodium-Glucose Cotransporter 2 Inhibitors and Urinary Tract Infection: Is There Room for Real Concern?. Kidney360, 2022, 3, 1991-1993.	0.9	3
3008	Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice. Frontiers in Physiology, 0, 13, .	1.3	2
3009	Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review. Cureus, 2022, , .	0.2	0
3010	Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors. Minerva Endocrinology, 2022, 47, .	0.6	1
3011	The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding. Cardiovascular Drugs and Therapy, 2024, 38, 57-68.	1.3	2
3012	An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy. Frontiers in Endocrinology, 0, 13, .	1.5	2
3013	Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care. American Heart Journal, 2022, 254, 203-215.	1.2	7
3014	Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodiumâ€glucose cotransporterâ€2 (<scp>SGLT2)</scp> inhibitors compared with glucagonâ€like peptideâ€1 receptor agonists (<scp>GLP</scp>â€1 <scp>RAs)</scp>: A pooled analysis of type 2 diabetes trials. Diabetes, Obesity and Metabolism, 2023, 25, 166-176.	2.2	2
3015	New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
3016	Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glycemic control. Annals of Medicine and Surgery, 2022, 81, .	0.5	0
3017	Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. , 0, Publish Ahead of Print, .		0
3018	Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	30
3019	Sodiumâ€“glucose cotransporter 2 inhibitor ameliorates high fat dietâ€induced hypothalamicâ€“pituitaryâ€“ovarian axis disorders. Journal of Physiology, 2022, 600, 4549-4568.	1.3	3
3020	The Sodiumâ€“Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study. Antioxidants, 2022, 11, 1878.	2.2	6
3021	Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan. Circulation Journal, 2022, 86, 2021-2028.	0.7	2

#	Article	IF	Citations
3022	Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. Biomedicines, 2022, 10, 2274.	1.4	22
3024	Ethnic and socioeconomic disparities in initiation of secondâ€line antidiabetic treatment for people with type 2 diabetes in England: A crossâ€sectional study. Diabetes, Obesity and Metabolism, 2023, 25, 282-292.	2.2	7
3025	The societal impact of early intensified treatment in patients with type 2Âdiabetes mellitus. Journal of Comparative Effectiveness Research, 2022, 11, 1185-1199.	0.6	1
3026	Incident heart failure, arrhythmias and cardiovascular outcomes with sodiumâ€glucose cotransporter 2 (<scp>SGLT2</scp>) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database. Diabetes, Obesity and Metabolism, 2023, 25, 602-610.	2.2	17
3027	Mechanisms underlying the blood pressureâ€lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial. Diabetes, Obesity and Metabolism, 2023, 25, 198-207.	2.2	4
3029	Renal Histologic Findings in Necropsies of Type 2 Diabetes Mellitus Patients. Journal of Diabetes Research, 2022, 2022, 1-9.	1.0	0
3030	Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study. Frontiers in Pharmacology, 0, 13, .	1.6	2
3031	Sacubitril/Valsartan in Patients With Heart Failure and Concomitant Endâ€Stage Kidney Disease. Journal of the American Heart Association, 2022, 11, .	1.6	14
3032	Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives. Pharmaceutics, 2022, 14, 1964.	2.0	0
3033	Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. Scientific Reports, 2022, 12, .	1.6	9
3034	The Clinical Effect of Dapagliflozin in Patients with Angiographically Confirmed Coronary Artery Disease and Concomitant Type 2 Diabetes Mellitus. Ukrainian Journal of Cardiovascular Surgery, 2022, 30, 35-43.	0.0	0
3035	Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?. Metabolism: Clinical and Experimental, 2022, , 155309.	1.5	0
3036	Accuracy of the Number Needed to Treat Compared With Diagnostic Testing. Archives of Pathology and Laboratory Medicine, 2022, , .	1.2	0
3037	Patient preferences for newer oral therapies in type 2 diabetes. International Journal of Cardiology, 2023, 371, 526-532.	0.8	4
3038	A review of cardiovascular benefits of SGLT2 inhibitors. Medicine (United States), 2022, 101, e30310.	0.4	1
3039	A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country. International Journal of Clinical Pharmacy, 2022, 44, 1342-1350.	1.0	2
3040	Use of Glucose-Lowering Agents in Diabetes and CKD. Kidney International Reports, 2022, 7, 2589-2607.	0.4	7
3041	Current Status of Dapagliflozin in Congestive Heart Failure. Cureus, 2022, , .	0.2	0

#	Article	IF	Citations
3042	Diabetes and cardiovascular risk according to sex: An overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. Annales D'Endocrinologie, 2023, 84, 57-68.	0.6	2
3043	A 96â€week, doubleâ€blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, Obesity and Metabolism, 2023, 25, 293-301.	2.2	7
3044	Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Research and Clinical Practice, 2022, 192, 110094.	1.1	0
3045	Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
3046	SGLT2Âinhibitors for treating diabetes in people with chronic kidney disease. The Cochrane Library, 2022, 2022, .	1.5	1
3047	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 3442-3451.	1.8	7
3049	Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events. Heart Failure Clinics, 2022, 18, 597-607.	1.0	2
3050	SGLT2 Inhibitors in Type 2 Diabetes Mellitus. Heart Failure Clinics, 2022, 18, 551-559.	1.0	2
3051	Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century. Mayo Clinic Proceedings, 2022, 97, 1904-1919.	1.4	10
3052	First-Line Therapy for Type 2 Diabetes With Sodiumâ€“Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Annals of Internal Medicine, 2022, 175, 1392-1400.	2.0	32
3053	Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the <scp>CANDLE</scp> trial. Diabetes, Obesity and Metabolism, 2023, 25, 354-364.	2.2	1
3054	Actualization of Positions of Gliflozins in Treatment Algorithms for Patients with Heart Failure: Chronology of Success. I P Pavlov Russian Medical Biological Herald, 2022, 30, 411-421.	0.2	1
3055	The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review. Hormones, 2022, 21, 599-610.	0.9	2
3056	Renoprotective Effects of SGLT2 Inhibitors. Heart Failure Clinics, 2022, 18, 539-549.	1.0	4
3057	SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction. Heart Failure Clinics, 2022, 18, 561-577.	1.0	2
3058	The presence of sodium glucose co-transporter 2 in mesangial cells and pericytes and its roles in mesangial lesions and in capillaries under diabetic and ischemic conditions. Diabetes Research and Clinical Practice, 2022, 192, 110096.	1.1	0
3059	The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age and Ageing, 2022, 51, .	0.7	13
3060	SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2022, 18, 579-586.	1.0	3

#	Article	IF	Citations
3061	Cardiovascular disease management in Australian adults with type 2 diabetes: insights from the <scp>CAPTURE</scp> study. Internal Medicine Journal, 2023, 53, 1796-1805.	0.5	1
3062	SGLT2 Inhibitors Are Lifesavers in Heart Failure. Heart Failure Clinics, 2022, 18, xi-xiv.	1.0	0
3063	SGLT2 Inhibitors and Safety in Older Patients. Heart Failure Clinics, 2022, 18, 635-643.	1.0	9
3064	Using modern risk engines and machine learning/artificial intelligence to predict diabetes complications: A focus on the BRAVO model. Journal of Diabetes and Its Complications, 2022, 36, 108316.	1.2	6
3065	Key updates to the management of type 2 diabetes in adults: how to embrace and embed the new <scp>NICE</scp> guidance. Practical Diabetes, 2022, 39, 6-8.	0.1	0
3066	The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney. International Journal of Molecular Sciences, 2022, 23, 11987.	1.8	7
3067	Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLYÂ® study. Cardiovascular Diabetology, 2022, 21, .	2.7	1
3068	Diabetes Mellitus and Heart Failure. Journal of Personalized Medicine, 2022, 12, 1698.	1.1	4
3069	Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure. Healthcare (Switzerland), 2022, 10, 2133.	1.0	1
3070	Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease. PLoS ONE, 2022, 17, e0269414.	1.1	4
3071	Preoperative evaluation and perioperative management of patients undergoing major vascular surgery. Vascular Medicine, 2022, 27, 496-512.	0.8	9
3072	Physiciansâ€™ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors. Journal of Clinical Medicine, 2022, 11, 6051.	1.0	3
3073	Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial. RMD Open, 2022, 8, e002686.	1.8	9
3074	The <scp>DAPAâ€ÐIET</scp> study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesityâ€"A longitudinal cohort study. Endocrinology, Diabetes and Metabolism, 2022, 5, .	1.0	4
3077	New principles for the treatment of chronic heart failure: the phenomenon of sodium-glucose cotransporter type 2 inhibitors. Meditsinskiy Sovet, 2022, , 44-51.	0.1	0
3078	Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus. Klinicist, 2022, 16, 10-16.	0.1	0
3079	SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice. Biomedicines, 2022, 10, 2458.	1.4	9
3080	Effect of Dapagliflozin on Left Ventricular Diastolic Function in Diabetics - A Prospective Interventional Study. Indian Journal of Cardiovascular Disease in Women WINCARS, 0, 7, 137-142.	0.1	0

#	Article	IF	Citations
3083	Ketones: the double-edged sword of SGLT2 inhibitors?. Diabetologia, 2023, 66, 23-32.	2.9	14
3084	Obesity as a risk factor for cardiac arrhythmias. , 2022, 1, e000308.		4
3085	Dapagliflozin DELIVERs for HFmrEF/HFpEF. , 0, , .		0
3086	Tetrahydrobiopterin (BH4) Supplementation Prevents the Cardiorenal Effects of Diabetes in Mice by Reducing Oxidative Stress, Inflammation and Fibrosis. Biomedicines, 2022, 10, 2479.	1.4	2
3087	Sodium-glucose co-transporter-2 inhibitors in Type 1 Diabetes: A Scoping Review. Hormone Research in Paediatrics, 0, , .	0.8	0
3088	Septic Shock Due to Urinary Tract Infection in an Immunosuppressed Patient Prescribed Dapagliflozin. Cureus, 2022, , .	0.2	1
3089	New strategies to improve clinical outcomes for diabetic kidney disease. BMC Medicine, 2022, 20, .	2.3	20
3090	Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 888-896.	1.8	3
3091	Benefits of SGLT2 inhibitors in arrhythmias. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	7
3092	Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 2022, 12, e060655.	0.8	15
3093	Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
3094	Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetology and Metabolic Syndrome, 2022, 14, .	1.2	3
3095	Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States. Kidney Medicine, 2023, 5, 100564.	1.0	10
3096	The quest for the mechanism responsible for the cardiovascular benefits of novel antidiabetic agents. REC: CardioClinics, 2022, , .	0.1	0
3097	Safety of sodiumâ€“glucose c<scp>otransporter</scp>Â2 inhibitors in Asian typeâ€‰2 diabetes populations. Journal of Diabetes Investigation, 2023, 14, 167-182.	1.1	3
3098	New paradigm for the management of cardio-nephro-metabolic syndrome: multidisciplinary approach and role of telemedicine. Minerva Medica, 2023, 114, .	0.3	2
3099	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. , 2022, 1, 100513.		3
3100	Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology, 0, 13, .	1.5	21

#	Article	IF	Citations
3101	Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics. JAMA Network Open, 2022, 5, e2237606.	2.8	10
3102	SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. European Journal of Pharmacology, 2022, 936, 175354.	1.7	4
3103	Influence of SGLT2 Inhibitors in Remodeling, Substrate and Ion Metabolism of Myocardium to Prevent Cardiovascular Risks: Recent Work and Advancement. Current Molecular Pharmacology, 2022, 16, .	0.7	2
3104	Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China. Frontiers in Pharmacology, 0, 13, .	1.6	9
3105	Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2022, 108, 221-231.	1.8	10
3106	Expert opinion on the cooperation of diabetologists and internists with nephrologists in the care of patients with chronic kidney diseases. Vnitrni Lekarstvi, 2022, 68, 426-431.	0.1	1
3107	Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice. International Journal of Molecular Sciences, 2022, 23, 12823.	1.8	9
3108	The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study. Frontiers in Public Health, 0, 10, .	1.3	7
3109	Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on OutcomesÂAfter Catheter Ablation forÂAtrial Fibrillation. JACC: Clinical Electrophysiology, 2022, 8, 1393-1404.	1.3	15
3110	2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care. Journal of the American College of Cardiology, 2023, 81, 292-317.	1.2	19
3111	Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) â€“ Diabetes: rationale and design. American Heart Journal, 2023, 256, 2-12.	1.2	3
3112	An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina (Lithuania), 2022, 58, 1475.	0.8	11
3113	Sodiumâ€glucose coâ€transporterâ€2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in realâ€world clinical practice? A systematic review and metaâ€analysis of observational studies. Diabetes, Obesity and Metabolism, 2023, 25, 501-515.	2.2	5
3115	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2022, 102, S1-S127.	2.6	246
3116	Cardiorenal disease management in type 2 diabetes: An expert consensus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102661.	1.8	1
3117	Musculoskeletal complications in patients with diabetes mellitus. Korean Journal of Internal Medicine, 2022, 37, 1099-1110.	0.7	6
3119	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 1957-1974.	0.9	0
3120	Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives. International Journal of Nephrology and Renovascular Disease, 0, Volume 15, 289-308.	0.8	3

#	Article	IF	Citations
3121	Cardiovascular Effects of Canagliflozin inÂRelation to Renal Function andÂAlbuminuria. Journal of the American College of Cardiology, 2022, 80, 1721-1731.	1.2	3
3122	APOL1 Genotype, Proteinuria, and the Risk of Kidney Failure: A Secondary Analysis of the AASK (African) Tj ETQq1 1 0.784314 rgBT /Ove Studies. Kidney Medicine, 2022, 4, 100563.	1.0	2
3123	Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK/Ta-Ins2 mice with progressive diabetic kidney disease. Biochemical and Biophysical Research Communications, 2022, 635, 84-91.	1.0	5
3124	Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy. Biomedicine and Pharmacotherapy, 2022, 156, 113947.	2.5	13
3125	Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease. Journal of Clinical and Translational Endocrinology, 2022, 30, 100309.	1.0	0
3126	Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism: Clinical and Experimental, 2022, 137, 155332.	1.5	35
3127	Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos. Biomedicine and Pharmacotherapy, 2022, 156, 113882.	2.5	3
3128	Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis. EClinicalMedicine, 2022, 54, 101697.	3.2	13
3129	The treatment of diabetes in advanced liver disease: change of a paradigm. Annals of Hepatology, 2023, 28, 100772.	0.6	4
3130	Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. Journal of Kidney Care, 2022, 7, 216-224.	0.1	0
3131	Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program. Cardiovascular Drugs and Therapy, 0, , .	1.3	7
3132	Assessment of Glucose Lowering Medicationsâ€™ Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes. International Journal of Environmental Research and Public Health, 2022, 19, 14825.	1.2	2
3133	Estimated Glomerular Filtration Rate (eGFR) Slope Assessment as a Surrogate End-point in Cardiovascular trials: Implications, Impediments, and Future Directions. Current Problems in Cardiology, 2023, 48, 101508.	1.1	1
3134	Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	2.7	4
3135	Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet, The, 2022, 400, 1788-1801.	6.3	249
3136	Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review. Transplantation Reviews, 2023, 37, 100729.	1.2	6
3137	Alogliptin and Heart Failure Outcomes in Patients With Type 2 Diabetes. Journal of Pharmacy Practice, 2024, 37, 410-414.	0.5	1
3138	Prescribing Trends of the Sodiumâ€“Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015â€“2021). Canadian Journal of Diabetes, 2023, 47, 153-161.	0.4	1

#	Article	IF	Citations
3139	The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes. Diabetes, Obesity and Metabolism, 2023, 25, 639-648.	2.2	3
3140	Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update. Cmaj, 2022, 194, E1460-E1480.	0.9	5
3141	Role of Ertugliflozin in the Management of Diabetes Mellitus. Cureus, 2022, , .	0.2	0
3142	Renal function during hospitalization and outcome in Chinese patients with acute decompensated heart failure: A retrospective study and literature review. Clinical Cardiology, 0, , .	0.7	2
3143	Diabetic cardiomyopathy: a brief summary on lipid toxicity. ESC Heart Failure, 2023, 10, 776-790.	1.4	6
3144	Impact of early initiation of sodium-glucose cotransporter 2 inhibitor on cardiovascular outcomes in people with diabetes and known or at risk of atherosclerotic cardiovascular disease: Propensity score matched analysis. PLoS ONE, 2022, 17, e0277321.	1.1	1
3145	Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 15, 3533-3541.	1.1	0
3146	Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure. Diabetes Care, 2023, 46, 65-74.	4.3	8
3147	Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. American Heart Journal, 2023, 256, 25-36.	1.2	5
3148	Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. Diabetes Research and Clinical Practice, 2022, 194, 110161.	1.1	11
3149	Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart, 2023, 109, 470-477.	1.2	14
3150	Risk of hypovolemia associated with sodiumâ€“glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
3151	Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible. European Heart Journal Supplements, 2022, 24, I153-I159.	0.0	1
3152	Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease. Kidney Diseases (Basel, Switzerland), 2023, 9, 12-25.	1.2	1
3153	Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease. ESC Heart Failure, 2023, 10, 578-593.	1.4	7
3154	Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovascular Diabetology, 2022, 21, .	2.7	16
3155	NAFLD as the metabolic hallmark of obesity. Internal and Emergency Medicine, 2023, 18, 31-41.	1.0	5
3156	Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada. BMJ Open Diabetes Research and Care, 2022, 10, e002995.	1.2	6

#	Article	IF	Citations
3157	Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Circulation, 2023, 147, 284-295.	1.6	13
3158	OnkodiabetolÃ³gia II.. Orvosi Hetilap, 2022, 163, 1575-1584.	0.1	0
3159	Sodiumâ€glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside. Fundamental and Clinical Pharmacology, 2023, 37, 481-492.	1.0	2
3161	Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. Diabetes Care, 0, , .	4.3	0
3163	PHARMACOKINETIC INVESTIGATION OF REMOGLIFLOZIN IN RAT PLASMA SAMPLES BY HIGH-THROUGHPUT HPLC-MS-MS. International Journal of Applied Pharmaceutics, 0, , 178-185.	0.3	0
3164	Meta-Analysis on the Safety and Efficacy of Sodium Glucose Cotransporters 2 Inhibitors in Patients With Heart Failure With and Without Diabetes. American Journal of Cardiology, 2023, 187, 93-99.	0.7	2
3165	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist DeBakey Cardiovascular Journal, 2022, 18, 40-53.	0.5	0
3166	Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882211424.	1.4	0
3167	Efficacy of dapagliflozin and empagliflozin for prevention of cardiovascular complications in patients with type 2 diabetes mellitus: a network meta-analysis. Medical Technologies Assessment and Choice (ÐœÐµÐ´Ð¸Ñ†Ð¸Ð½ÑºÐ¸Ð¹ Ñ‚ÐµÑ…Ð½Ð¾Ð»Ð¾Ð³Ð¸Ð¸ Ð¸ ÐžÑ†ÐµÐ½ÐºÐ° Ð¸ Ð²Ñ‹Ð±Ð¾Ñ€Ð°), 2022, , 42.	0.1	0
3168	Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis. Journal of Diabetes and Its Complications, 2023, 37, 108362.	1.2	5
3169	Effect of empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia, and hypoglycaemia. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2023, 17, 102680.	1.8	4
3170	Corrigendum to â€œMechanisms and pharmacotherapy of hypertension associated with type 2 diabetesâ€• [Biochem. Pharmacol. 206 (2022) 115304]. Biochemical Pharmacology, 2023, 207, 115349.	2.0	0
3171	SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study. Diabetes Research and Clinical Practice, 2023, 195, 110200.	1.1	6
3172	Bioactive compound identification and in vitro evaluation of antidiabetic and cytotoxic potential of Garcinia atroviridis fruit extract. Food Bioscience, 2023, 51, 102285.	2.0	3
3173	Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study. Canadian Journal of Kidney Health and Disease, 2022, 9, 205435812211450.	0.6	4
3174	Metabolic effects of empagliflozine. , 2022, , 38-56.		1
3175	Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria. European Endocrinology, 2022, 18, 102.	0.8	4
3176	THE CLINICAL EXPERIENCE OF THE EFFECTIVE USE OF DAPAGLIFLOZIN IN COMORBID CARDIAC PATIENTS WITH CONCOMITANT TYPE 2 DIABETES MELLITUS AND ARTERIAL HYPERTENSION ON THE BACKGROUND OF OVERWEIGHT IN OUTPATIENT SETTING. WiadomoÅ›ci Lekarskie, 2022, 75, 2397-2401.	0.1	2

#	Article	IF	Citations
3177	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodiumâ€“Glucose Co-transporter-2 Inhibitors. European Endocrinology, 2022, 18, 106.	0.8	4
3178	Le patient atteint de maladies cardiovasculaires. , 2022, , 99-122.		0
3179	Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease. Nefrologia, 2022, 42, 390-403.	0.2	2
3181	VPS34-dependent control of apical membrane function of proximal tubule cells and nutrient recovery by the kidney. Science Signaling, 2022, 15, .	1.6	5
3182	Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	1
3183	SGLT-2 Inhibitors in Cancer Treatmentâ€”Mechanisms of Action and Emerging New Perspectives. Cancers, 2022, 14, 5811.	1.7	24
3184	Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9). Diabetes and Metabolism Journal, 2022, 46, 953-955.	1.8	0
3185	Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials. Cureus, 2022, , .	0.2	0
3186	Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease. Terapevticheskii Arkhiv, 2022, 94, 1188-1196.	0.2	0
3187	Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes. Current Atherosclerosis Reports, 2022, 24, 925-937.	2.0	2
3188	The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction. Pharmacy (Basel, Switzerland), 2022, 10, 166.	0.6	2
3189	Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence. Pulmonary Therapy, 2022, 8, 343-358.	1.1	2
3190	Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease. American Journal of Cardiology, 2022, , .	0.7	0
3191	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nature Reviews Endocrinology, 2023, 19, 151-163.	4.3	21
3192	Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World Journal of Cardiology, 0, 14, 599-616.	0.5	1
3193	Mechanisms of GLPâ€'1 Receptor Agonists on the Cardio-Renal Protective Effects. Japanese Journal of Clinical Pharmacology and Therapeutics, 2022, 53, 249-262.	0.1	0
3194	Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow). Diabetes Mellitus, 2022, 25, 439-448.	0.5	2
3195	Combined Therapy of Low-Dose Angiotensin Receptorâ€“Neprilysin Inhibitor and Sodiumâ€“Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects. Pharmaceutics, 2022, 14, 2629.	2.0	1

#	Article	IF	Citations
3196	Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience. Cureus, 2022, , .	0.2	0
3197	Secular trends in the utility of <scp>SGLT</scp> â€2 inhibitors in heart failure patients with type 2 diabetes mellitus across Metro South Health hospitals in <scp>Southâ€East</scp> Queensland. Internal Medicine Journal, 0, , .	0.5	0
3198	Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications. Diabetes Therapy, 0, , .	1.2	0
3199	Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
3200	Diabetic cardiomyopathy: Clinical phenotype and practice. Frontiers in Endocrinology, 0, 13, .	1.5	12
3201	Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit. Journal of Pharmacy Practice, 2024, 37, 435-441.	0.5	0
3202	Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. Cardiovascular Research, 2023, 118, 3467-3481.	1.8	4
3203	Cardiorenal prevention as the key player in the reduction of all-cause mortality. Nefrologia, 2023, 43, 514-515.	0.2	0
3204	Ageâ€dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data. Diabetes, Obesity and Metabolism, 2023, 25, 767-775.	2.2	3
3205	Managing Diabetes. Physician Assistant Clinics, 2022, , .	0.1	0
3206	Cardiorenal protections of SGLT2 inhibitors in the treatment of type 2 diabetes. Current Diabetes Reviews, 2022, 19, .	0.6	1
3207	The Impact of Pharmacist Intervention to Improve Medication Access for Patients with Diabetes. Journal of the American Pharmacists Association: JAPhA, 2022, , .	0.7	0
3208	Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis. Diabetes Therapy, 0, , .	1.2	0
3209	Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials. American Journal of Cardiovascular Drugs, 2023, 23, 113-126.	1.0	2
3210	Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe. European Heart Journal Supplements, 2022, 24, L29-L37.	0.0	0
3211	Sodiumâ€“Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study. Diabetes Care, 2023, 46, 351-360.	4.3	9
3212	13. Older Adults: Standards of Care in Diabetesâ€”2023. Diabetes Care, 2023, 46, S216-S229.	4.3	71
3213	Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study. Cardiovascular Diabetology, 2022, 21, .	2.7	5

#	Article	IF	Citations
3214	Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin. EBioMedicine, 2022, 86, 104342.	2.7	2
3215	Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19. JAMA Network Open, 2022, 5, e2244652.	2.8	10
3216	Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Safety, 0, , .	1.4	2
3217	Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics. Cardiosomatics, 2022, 13, 115-123.	0.2	0
3218	Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: Rationale for and design of the EMPA-AHF trial. American Heart Journal, 2023, 257, 85-92.	1.2	1
3219	The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors. Expert Review of Cardiovascular Therapy, 2023, 21, 15-34.	0.6	4
3220	SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis. Acta Pharmacologica Sinica, 2023, 44, 1161-1174.	2.8	2
3221	Implementing the new NICE guidelines for type 2 diabetes (NG28): Focusing beyond HbA1c targets and clinically phenotyping patients to the appropriate second-line agent. British Journal of Diabetes, 2022, 22, 87-94.	0.1	0
3222	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetesâ€”2023. Diabetes Care, 2023, 46, S158-S190.	4.3	156
3223	Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women. Journal of the Endocrine Society, 2022, 7, .	0.1	2
3224	Dapagliflozinâ€Loaded Exosome Mimetics Facilitate Diabetic Wound Healing by HIFâ€1 Î±â€Mediated Enhancement of Angiogenesis. Advanced Healthcare Materials, 2023, 12, .	3.9	20
3225	What Is the Best Medicine for Chronic Kidney Disease in Diabetes?. Diabetes Care, 2022, 45, 2814-2816.	4.3	0
3226	Diabetic Kidney Care Redefined with a New Way into Remission. Endocrinology and Metabolism Clinics of North America, 2022, , .	1.2	0
3227	Integrating Coronary Atherosclerosis Burden and Progression with Coronary Artery Disease Risk Factors to Guide Therapeutic Decision Making. American Journal of Medicine, 2023, 136, 260-269.e7.	0.6	10
3228	A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes. Diabetology International, 2023, 14, 1-14.	0.7	8
3229	Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease. Annals of Internal Medicine, 2023, 176, 59-66.	2.0	7
3230	Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis. Frontiers in Endocrinology, 0, 13, .	1.5	3
3231	Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. , 2023, 242, 108330.		5

#	Article	IF	Citations
3232	Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
3233	Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review. World Journal of Diabetes, 0, 13, 1168-1183.	1.3	0
3234	The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy. Antioxidants, 2022, 11, 2500.	2.2	4
3235	Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study. , 2022, 23, .		6
3236	Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review. ESC Heart Failure, 2023, 10, 1555-1569.	1.4	3
3237	Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD. Kidney360, 0, 4, 10.34067/KID.0006982022.	0.9	0
3238	New Insights into the Use of Empagliflozinâ€"A Comprehensive Review. Biomedicines, 2022, 10, 3294.	1.4	6
3239	Renal disease in patients with type 2 diabetes: Magnitude of the problem, risk factors and preventive strategies. Presse Medicale, 2023, 52, 104159.	0.8	1
3240	<scp>Sodiumâ€glucose cotransporterâ€2</scp> inhibitor prescribing practices. Diabetes, Obesity and Metabolism, 2023, 25, 1136-1139.	2.2	0
3241	Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes. Presse Medicale, 2023, 52, 104160.	0.8	1
3242	Comprehensive Oral Diabetes Medication Resource 2022. ADCES in Practice, 2023, 11, 42-49.	0.2	0
3243	Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review. Scientific Reports, 2022, 12, .	1.6	0
3244	Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register. European Journal of Preventive Cardiology, 2023, 30, 546-551.	0.8	2
3245	Efficacy and safety of janagliflozin as addâ€on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, doubleâ€blind, placeboâ€controlled, phase 3 trial. Diabetes, Obesity and Metabolism, 2023, 25, 785-795.	2.2	4
3246	11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetesâ€"2023. Diabetes Care, 2023, 46, S191-S202.	4.3	97
3247	A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes. Journal of Diabetes Investigation, 2023, 14, 151-164.	1.1	15
3248	Bibliometric and visualized analysis of sodiumâ€"Glucose cotransporter 2 inhibitors. Frontiers in Pharmacology, 0, 13, .	1.6	1
3249	The impact of SGLT2-inhibitor therapy on platelet function in type 2 diabetes mellitus. Journal of Health Sciences and Medicine, 2023, 6, 140-144.	0.0	0

#	Article	IF	Citations
3251	Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia. Journal of the American Heart Association, 2023, 12, .	1.6	15
3252	Obesity and diabetes: the final frontier. Expert Review of Endocrinology and Metabolism, 2023, 18, 81-94.	1.2	4
3253	Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nature Reviews Cardiology, 2023, 20, 347-363.	6.1	17
3254	Dapagliflozin Treatment Augments Bioactive Phosphatidylethanolamine Concentrations in Kidney Cortex Membrane Fractions of Hypertensive Diabetic db/db Mice and Alters the Density of Lipid Rafts in Mouse Proximal Tubule Cells. International Journal of Molecular Sciences, 2023, 24, 1408.	1.8	4
3255	Blood Pressure Control in Patients with Diabetic Kidney Disease. Electrolyte and Blood Pressure, 2022, 20, 39.	0.6	0
3256	New Antidiabetic Agents: Relevance to Cardiovascular Outcomes. Updates in Hypertension and Cardiovascular Protection, 2023, , 337-349.	0.1	0
3257	Dysmetabolic Iron Overload Syndrome: Going beyond the Traditional Risk Factors Associated with Metabolic Syndrome. Endocrines, 2023, 4, 18-37.	0.4	1
3258	Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms. Pharmacological Research, 2023, 188, 106667.	3.1	6
3259	Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study. CKJ: Clinical Kidney Journal, 2023, 16, 1022-1034.	1.4	7
3260	Costâ€effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure. European Journal of Heart Failure, 0, , .	2.9	3
3261	Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on HeartÂFailureÂWith Preserved EjectionÂFraction and Diabetes. JACC Asia, 2023, 3, 93-104.	0.5	8
3262	Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. Vascular Medicine, 2023, 28, 62-76.	0.8	4
3263	The effect of dapagliflozin on myocardial ischemiaâ€"reperfusion injury in diabetic rats. Canadian Journal of Physiology and Pharmacology, 0, , .	0.7	0
3264	Effect of Dapagliflozin on Visceral Fat Index in Overweight Type 2 Diabetes Patients. Advances in Clinical Medicine, 2023, 13, 420-426.	0.0	0
3265	Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease. International Journal of Molecular Sciences, 2023, 24, 1646.	1.8	18
3266	Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodiumâ€"glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 301-310.	1.4	4
3267	Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. Journal of Cardiovascular Pharmacology, 2023, 81, 4-14.	0.8	11
3268	Canagliflozin Pretreatment Attenuates Myocardial Dysfunction and Improves Postcardiac Arrest Outcomes After Cardiac Arrest and Cardiopulmonary Resuscitation in Mice. Cardiovascular Drugs and Therapy, 0, , .	1.3	1

#	Article	IF	Citations
3269	Albuminuria and HeartÂFailure. Journal of the American College of Cardiology, 2023, 81, 270-282.	1.2	15
3270	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. Contemporary Cardiology, 2023, , 67-138.	0.0	0
3271	The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis. Frontiers in Physiology, 0, 13, .	1.3	3
3272	Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice. Scientific Reports, 2023, 13, .	1.6	1
3273	The prevalence of cardiovascular disease in adults with type 2 diabetes mellitus in Saudi Arabia - CAPTURE study. Journal of King Abdulaziz University, Islamic Economics, 2023, 44, 57-66.	0.5	5
3274	Effects of sodiumâ€glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients. Diabetes, Obesity and Metabolism, 2023, 25, 1271-1279.	2.2	5
3275	Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Diabetology and Metabolic Syndrome, 2023, 15, .	1.2	0
3276	AvanÃ§os na abordagem terapÃªutica da insuficiÃªncia cardÃaca com fraÃ§Ã£o de ejeÃ§Ã£o preservada (ICFEP): O uso de inibidores de SGLT-2. Brazilian Journal of Health Review, 2023, 6, 286-300.	0.0	0
3277	Control of Blood Glucose and Cardiovascular Risk Profile. Updates in Hypertension and Cardiovascular Protection, 2023, , 451-469.	0.1	0
3278	Ligne directrice C-CHANGE pour lâ€™harmonisation des lignes directrices nationales de prÃ©vention et de prise en charge des maladies cardiovasculaires en contexte de soins primaires au Canada: mise Ã jour 2022. Cmaj, 2023, 195, E21-E42.	0.9	1
3279	Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis. Acta Diabetologica, 2023, 60, 435-445.	1.2	5
3280	Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, doubleâ€blind, placeboâ€controlled, Phase 3 trial. Diabetes, Obesity and Metabolism, 2023, 25, 1229-1240.	2.2	1
3281	Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction. Drugs in Context, 0, 12, 1-16.	1.0	2
3282	Evaluation of sodiumâ€glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics. Kaohsiung Journal of Medical Sciences, 2023, 39, 416-425.	0.8	1
3283	Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2023, 43, 1-7.	1.2	3
3284	Effectiveness and safety of angiotensin receptor-neprilysin inhibitor and sodiumâ€“glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction: a meta-analysis. Journal of Cardiovascular Medicine, 2023, 24, 123-131.	0.6	1
3285	Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis. Diabetes Research and Clinical Practice, 2023, 196, 110239.	1.1	4
3286	Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?. Diabetes and Metabolism, 2023, 49, 101419.	1.4	9

#	Article	IF	Citations
3287	Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial. Metabolism: Clinical and Experimental, 2023, 140, 155396.	1.5	11
3288	Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. European Journal of Medical Research, 2022, 27, .	0.9	6
3289	From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors. International Journal of Molecular Sciences, 2023, 24, 351.	1.8	5
3291	Role of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension. , 0, , 8.		1
3292	Clinical spotlight intervention to accelerate translation of evidence-based practices in primary care. BMJ Open Quality, 2022, 11, e002032.	0.4	1
3293	Use of sodiumâ€“glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. European Journal of Preventive Cardiology, 2023, 30, 634-643.	0.8	7
3294	Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective PercuÂtaneous Coronary Intervention for Type 2 Diabetes Mellitus. Kardiologiya, 2022, 62, 64-72.	0.3	0
3295	Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Safety, 0, , .	1.4	1
3297	à¸œà¸¥à¸ªà¸³à¹€à¸£à¹‡à¸ˆà¸‚à¸à¸‡à¸à¸²à¸£à¸£à¸±à¸à¸©à¸²à¸”à¹‰à¸§à¸¢à¸¢à¸²à¸à¸¥à¸¸à¹ˆà¸¡à¸¢à¸±à¸šà¸¢à¸±à¹‰à¸‡à¸„à¸§à¸šà¸„à¸¸à¸¡à¸™à¹‰à¸³à¸•à¸²à¸¥à¹ƒà¸™à¹€à¸¥à¸·à¸à¸”à¹ƒà¸™à¸œà¸¹à¹‰à¸›à¹ˆà¸§à¸¢à¹€à¸šà¸²à¸«à¸§à¸²à¸™à¸Šà¸™à¸´à¸”à¸—à¸µà¹ˆ		
3298	Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials. Medicine (United States), 2022, 101, e32489.	0.4	1
3299	The Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Stroke and Atrial Fibrillation: A Systematic Review and Meta-Analysis. Current Problems in Cardiology, 2023, 48, 101582.	1.1	8
3301	Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus. Irish Journal of Medical Science, 0, , .	0.8	0
3302	Targeted drug delivery strategy: a bridge to the therapy of diabetic kidneyÂdisease. Drug Delivery, 2023, 30, .	2.5	5
3303	Patientsâ€™ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Patient Preference and Adherence, 0, Volume 16, 3415-3428.	0.8	2
3304	Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	11
3307	Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight. ESC Heart Failure, 2023, 10, 1242-1249.	1.4	4
3308	SGLT2 Inhibitors: The Sweet Success for Kidneys. Annual Review of Medicine, 2023, 74, 369-384.	5.0	14
3309	Research Progress in Treatment of Diabetic Proteinuria. Advances in Clinical Medicine, 2023, 13, 1252-1260.	0.0	0

#	Article	IF	Citations
3310	Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods. ESC Heart Failure, 2023, 10, 1231-1241.	1.4	5
3311	Onchidium struma polysaccharides exhibit hypoglycemic activity and modulate the gut microbiota in mice with type 2 diabetes mellitus. Food and Function, 2023, 14, 1937-1951.	2.1	1
3312	Glifozinas en el tratamiento de la diabetes tipo 2: mÃ¡s allÃ¡ de los beneficios en el control metabÃ³lico. AnatomÃa Digital, 2023, 6, 49-64.	0.0	1
3313	Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. , 2023, 5, 100056.		11
3314	SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. Biomedicines, 2023, 11, 279.	1.4	7
3315	The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (â‰¥â€‰75Âyears): a retrospective, pharmacovigilance study. Cardiovascular Diabetology, 2023, 22, .	2.7	9
3316	Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. Frontiers in Endocrinology, 0, 14, .	1.5	6
3317	Efficacy of Polydeoxyribonucleotide in Promoting the Healing of Diabetic Wounds in a Murine Model of Streptozotocin-Induced Diabetes: A Pilot Experiment. International Journal of Molecular Sciences, 2023, 24, 1932.	1.8	0
3318	Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Diabetes Care, 2023, 46, 602-607.	4.3	5
3319	Impact of baseline kidney function on the effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors on kidney and heart failure outcomes: A systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2023, 25, 1341-1350.	2.2	7
3320	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. Diabetes and Metabolism Journal, 2023, 47, 10-26.	1.8	4
3321	Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update. Biomedicines, 2023, 11, 291.	1.4	7
3322	Medical therapy. , 2023, , 353-361.		0
3323	SGLT2 inhibitors: new kids on the block to control hyperkalemia. Nephrology Dialysis Transplantation, 2023, 38, 1345-1348.	0.4	2
3324	The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts. Journal of the American Society of Nephrology: JASN, 2023, 34, 482-494.	3.0	8
3325	Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait. Journal of Medical Economics, 2023, 26, 271-282.	1.0	1
3326	Clinical and Pharmacotherapeutic Profile of Patients with Type 2 Diabetes Mellitus Admitted to a Hospital Emergency Department. Biomedicines, 2023, 11, 256.	1.4	0
3327	Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 343-352.	1.4	2

#	Article	IF	Citations
3328	Advances in contemporary medical management to treat patients with heart failure. Current Opinion in Cardiology, 2023, 38, 136-142.	0.8	4
3329	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. International Journal of Heart Failure, 2023, 5, 1.	0.9	2
3330	Cell-Cycle Dysregulation in the Pathogenesis of Diabetic Kidney Disease: An Update. International Journal of Molecular Sciences, 2023, 24, 2133.	1.8	3
3331	Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor. Scientific Reports, 2023, 13, .	1.6	3
3332	II. Details: Therapeutic Agents for Chronic Heart Failure; 2. SGLT2 Inhibitor. The Journal of the Japanese Society of Internal Medicine, 2022, 111, 228-234.	0.0	0
3333	Beyond Blood Glucose and Blood Pressure Control in Type 2 Diabetes: Alternative Management Strategies to Prevent the Development and Progression of CKD. Journal of Primary Care and Community Health, 2023, 14, 215013192311535.	1.0	0
3334	Progress in Studying Serum Uric Acid in Cardiovascular Diseases. Advances in Clinical Medicine, 2023, 13, 1812-1818.	0.0	0
3335	Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. Biomedicines, 2023, 11, 662.	1.4	3
3337	The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review. Cureus, 2023, , .	0.2	0
3338	The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. Journal of Clinical Medicine, 2023, 12, 2253.	1.0	3
3339	Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment. Frontiers in Endocrinology, 0, 14, .	1.5	3
3340	Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction. International Journal of Cardiology, 2023, 376, 83-89.	0.8	8
3341	Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes and Endocrinology,the, 2023, 11, 233-241.	5.5	8
3342	Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury. Ageing Research Reviews, 2023, 86, 101884.	5.0	3
3343	Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study. Clinical Diabetes, 0, , .	1.2	0
3344	Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis. Kidney International Reports, 2023, 8, 700-714.	0.4	2
3345	Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: <scp>IVS</scp> study. Diabetes, Obesity and Metabolism, 2023, 25, 1922-1931.	2.2	3
3346	Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis. Journal of Clinical Medicine, 2023, 12, 2814.	1.0	5

#	Article	IF	Citations
3347	Integrated analysis for treatment scheme of sodiumâ€“glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study. Scientific Reports, 2023, 13, .	1.6	1
3348	Heart failure and diabetes: Clinical significance and epidemiology of this twoâ€way association. Diabetes, Obesity and Metabolism, 2023, 25, 3-14.	2.2	4
3349	Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12â€week, multicentre, randomized, doubleâ€blind, placeboâ€controlled, phase 2 trial. Diabetes, Obesity and Metabolism, 2023, 25, 2096-2104.	2.2	4
3350	Management of diabesity: Current concepts. World Journal of Diabetes, 0, 14, 396-411.	1.3	10
3351	Diabetes care among individuals with and without schizophrenia in three Canadian provinces: A retrospective cohort study. General Hospital Psychiatry, 2023, 82, 19-25.	1.2	0
3352	New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling. International Immunopharmacology, 2023, 118, 110072.	1.7	2
3353	Type 2 Diabetes: SGLT2i-Associated Genitourinary Infections and Lower Urinary Tract Dysfunction. Journal for Nurse Practitioners, 2023, 19, 104615.	0.4	0
3354	Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America, 2023, 52, 355-375.	1.2	1
3355	Lower risk of cardiovascular events and death associated with initiation of sodiumâ€glucose cotransporterâ€2 inhibitors versus sulphonylureas: Analysis from the <scp>CVDâ€REAL</scp> 2 study. Diabetes, Obesity and Metabolism, 2023, 25, 2402-2409.	2.2	0
3356	Advances in Chronic Kidney Disease in Africa. Applied Sciences (Switzerland), 2023, 13, 4924.	1.3	0
3357	Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients â€“ DACAMI (a randomized controlled clinical trial). International Journal of Cardiology, 2023, 379, 9-14.	0.8	4
3358	CommonABCB1SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Translational and Clinical Pharmacology, 2022, 30, 212.	0.3	3
3359	Recent developments in adjunct therapies for type 1 diabetes. Expert Opinion on Investigational Drugs, 2022, 31, 1311-1320.	1.9	3
3360	Clinical pharmacology of SGLT-2 inhibitors in heart failure. Expert Review of Clinical Pharmacology, 2023, 16, 149-160.	1.3	5
3361	The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 0, 14, .	1.5	5
3362	Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment. Journal of Managed Care & Specialty Pharmacy, 2023, 29, 139-150.	0.5	0
3363	SGLT2 Inhibitors for Nephrologists. , 0, , 114-119.		0
3364	Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trial. Frontiers in Endocrinology, 0, 14, .	1.5	0

#	Article	IF	Citations
3365	Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?. Kidney Medicine, 2023, 5, 100608.	1.0	2
3366	Luseogliflozin and caloric intake restriction increase <scp>superoxide dismutase 2</scp> expression, promote antioxidative effects, and attenuate aortic endothelial dysfunction in dietâ€induced obese mice. Journal of Diabetes Investigation, 2023, 14, 548-559.	1.1	2
3367	Cardiovascular Manifestations in Rheumatoid Arthritis. Cardiology in Review, 2024, 32, 146-152.	0.6	1
3368	Dapagliflozin attenuates myocardial remodeling in hypertension by activating the circadian rhythm signaling pathway. Archives of Pharmacal Research, 2023, 46, 117-130.	2.7	3
3369	Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?. Archives of Medical Science, 2023, 19, 528-531.	0.4	0
3370	Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial. American Heart Journal Plus, 2023, 26, 100264.	0.3	0
3371	Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA_{1c}Levels. JAMA Internal Medicine, 2023, 183, 242.	2.6	17
3373	Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors. Journal of Cardiothoracic and Vascular Anesthesia, 2023, 37, 956-963.	0.6	4
3374	Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	2
3375	Comparative efficacy of <scp>sodiumâ€glucose</scp> coâ€transporterâ€2 inhibitors, <scp>glucagonâ€like</scp> peptideâ€1 receptor agonists and nonâ€steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network <scp>metaâ€analysis</scp>. Diabetes, Obesity and Metabolism, 2023, 25, 1614-1623.	2.2	8
3376	Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial. Diabetes and Metabolism Journal, 2023, 47, 796-807.	1.8	7
3378	Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis. International Journal of Cardiology, 2023, 377, 104-111.	0.8	2
3379	Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong. Diabetes Research and Clinical Practice, 2023, 197, 110576.	1.1	5
3380	Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system. American Journal of Physiology - Cell Physiology, 2023, 324, C951-C962.	2.1	8
3381	Benefits vs risks: SGLT-2 inhibitors in older adults living with frailty: a retrospective study from a university hospital. International Journal of Diabetes in Developing Countries, 0, , .	0.3	0
3382	Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors. Frontiers in Endocrinology, 0, 14, .	1.5	4
3383	Cáºp nháºt vai trÃ² cá»§a thuá»‘c á»©c cháº¿ SGLT2 trong dá»± phÃ²ng vÃ Ä‘iá»u trá»‹ suy tim. , 2022, , 10-17.		0
3387	SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?. Medicina (Lithuania), 2023, 59, 388.	0.8	4

#	Article	IF	Citations
3388	Metabolic Impact of Frailty Changes Diabetes Trajectory. Metabolites, 2023, 13, 295.	1.3	9
3389	Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Annals of Pharmacotherapy, 2023, 57, 1291-1301.	0.9	1
3390	The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. Expert Opinion on Drug Safety, 2023, 22, 133-140.	1.0	1
3391	Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. International Journal of Molecular Sciences, 2023, 24, 4144.	1.8	4
3393	Emerging Role of Sodiumâ€“Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease. International Journal of Nephrology and Renovascular Disease, 0, Volume 16, 43-57.	0.8	1
3394	Deep-learning-based prognostic modeling for incident heart failure in patients with diabetes using electronic health records: A retrospective cohort study. PLoS ONE, 2023, 18, e0281878.	1.1	3
3395	The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. Current Pharmaceutical Design, 2023, 29, 481-493.	0.9	1
3396	Analysis of the Value of SGLT2i Combined with GLP-1RAs in Cardiovascular Benefit of Elderly T2DM Patients. Advances in Clinical Medicine, 2023, 13, 2736-2743.	0.0	0
3397	Effects of dietary sodium and protein intake on glomerular filtration rate in subjects with type 2 diabetes treated with sodium glucose cotransporter 2 inhibitors. Experimental and Clinical Endocrinology and Diabetes, 0, , .	0.6	0
3398	Sudden cardiac death prevention in the era of novel heart failure medications. American Heart Journal Plus, 2023, 27, 100281.	0.3	0
3399	Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of Diabetes Research, 2023, 2023, 1-11.	1.0	0
3400	Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes. Cardiology Research, 2023, 14, 12-21.	0.5	6
3401	Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes. Internal Medicine, 2023, 62, 681-688.	0.3	0
3402	Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes. JAMA Cardiology, 2023, 8, 503.	3.0	3
3403	SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	3
3404	Clinicodemographic Profile and Outcomes of Type 2 Diabetes Mellitus in the Indonesian Cohort of DISCOVER: A 3-Year Prospective Cohort Study. Journal of the ASEAN Federation of Endocrine Societies, 2023, 38, 68-74.	0.1	0
3405	Estimating the value of <scp>sodiumâ€glucose cotransporterâ€2</scp> inhibitors within the context of contemporary guidelines and the totality of evidence. Diabetes, Obesity and Metabolism, 2023, 25, 1830-1838.	2.2	5
3406	SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat. Journal of Internal Medicine, 2023, 293, 550-558.	2.7	0

#	Article	IF	Citations
3407	Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. European Heart Journal, 2023, 44, 1594-1607.	1.0	23
3408	Safety and cardiometabolic efficacy of novel antidiabetic drugs. Expert Opinion on Drug Safety, 2023, 22, 119-124.	1.0	1
3409	Effect of sodiumâ€“glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial. International Urology and Nephrology, 0, , .	0.6	3
3410	Significant publications in diabetes pharmacotherapy and technology in 2020. Expert Review of Endocrinology and Metabolism, 0, , .	1.2	0
3411	Significant publications in diabetes pharmacotherapy and technology in 2020. Expert Review of Endocrinology and Metabolism, 2023, 18, 131-142.	1.2	0
3413	New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy. International Journal of Molecular Sciences, 2023, 24, 5089.	1.8	8
3414	Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-Î²1/MAPK mediated mitochondrial damage. Frontiers in Pharmacology, 0, 14, .	1.6	3
3415	Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. American Journal of Kidney Diseases, 2023, 82, 84-96.e1.	2.1	5
3416	Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Preâ€“Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2023, 8, 366.	3.0	11
3417	Paradigm sift of the medical care in diabetes. Nihon Ika Daigaku Igakkai Zasshi, 2023, 19, 32-41.	0.0	0
3418	SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis. Indian Heart Journal, 2023, 75, 122-127.	0.2	9
3419	Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials. Cardiovascular Diabetology, 2023, 22, .	2.7	1
3420	Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk. Nutrients, 2023, 15, 1384.	1.7	0
3421	Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 2203-2210.	1.8	2
3424	CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovascular Diabetology, 2023, 22, .	2.7	4
3425	Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy. Pharmacy (Basel, Switzerland), 2023, 11, 58.	0.6	0
3426	SGLT2 Inhibitorâ€”Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism. Pharmaceutics, 2023, 15, 965.	2.0	2
3427	Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis. Journal of Diabetes and Its Complications, 2023, 37, 108456.	1.2	2

#	Article	IF	Citations
3428	Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. Cardiovascular Diabetology, 2023, 22, .	2.7	4
3429	Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study. Frontiers in Neuroscience, 0, 17, .	1.4	2
3430	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. Frontiers in Clinical Drug Research Diabetes and Obesity, 2023, , 117-167.	0.1	0
3431	Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences. Pharmaceutics, 2023, 15, 1002.	2.0	1
3432	Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of <scp>SOUL</scp>, a randomized trial. Diabetes, Obesity and Metabolism, 2023, 25, 1932-1941.	2.2	22
3433	A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome. International Journal of Molecular Sciences, 2023, 24, 5983.	1.8	2
3434	Update on Medical Management of Diabetes. Orthopedic Clinics of North America, 2023, , .	0.5	0
3435	Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct. Frontiers in Pharmacology, 0, 14, .	1.6	3
3436	SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. International Journal of Heart Failure, 2023, 5, 82.	0.9	14
3437	Role of Sodium-Glucose Cotransporter 2 Inhibitors for Management of Diabetes Mellitus in Renal Transplant Recipients and Management Strategies for Posttransplant Hypertension. American Journal of Nephrology, 2023, 54, 136-144.	1.4	0
3438	Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register. Internal and Emergency Medicine, 2023, 18, 1049-1063.	1.0	1
3439	Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction. Cardiovascular Diabetology, 2023, 22, .	2.7	6
3440	Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review. American Journal of Health-System Pharmacy, 0, , .	0.5	0
3441	Systematic review of sodiumâ€glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failureâ€related events. ESC Heart Failure, 2023, 10, 1499-1530.	1.4	8
3442	Lower-limb peripheral arterial disease and amputations in people with diabetes: Risk factors, prognostic value and management. Presse Medicale, 2023, 52, 104164.	0.8	3
3443	Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Cardiovascular Diabetology, 2023, 22, .	2.7	0
3445	The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands. Journal of Medical Economics, 2023, 26, 547-553.	1.0	0
3446	Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. The Lancet Healthy Longevity, 2023, 4, e143-e154.	2.0	6

#	Article	IF	Citations
3447	Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?. World Journal of Cardiovascular Diseases, 2023, 13, 138-169.	0.0	0
3448	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. Pharmaceutics, 2023, 15, 1092.	2.0	1
3450	Safety of SGLT2 Inhibitors in Three Chronic Diseases. International Heart Journal, 2023, 64, 246-251.	0.5	1
3451	The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 858-868.	2.2	0
3452	Treatment Strategies of Improving Quality of Care in Patients With Heart Failure. Korean Circulation Journal, 2023, 53, 294.	0.7	4
3453	Cardiac energy metabolism in heart failure. , 2023, , 175-198.		0
3454	Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. , 2023, , 337-363.		0
3455	The use of sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: new guidelines hot off the press and directly into guidelines!. Postgraduate Medical Journal, 0, , .	0.9	0
3456	Management of diabetic kidney disease: where do we stand?: A narrative review. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	3
3457	How SGLT2 inhibitors interact with metformin? A molecular dynamics study. Molecular Simulation, 2023, 49, 867-876.	0.9	0
3458	Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States. American Journal of Cardiology, 2023, 196, 89-98.	0.7	4
3459	Embedding guidelines into clinical practice. Practical Diabetes, 2023, 40, 28.	0.1	0
3460	Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation, 2023, 43, 209-225.	1.1	4
3461	Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovascular Diabetology, 2023, 22, .	2.7	13
3462	How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients. Endocrine, 2023, 80, 491-499.	1.1	3
3463	Metformin adherence and the risk of cardiovascular disease: a population-based cohort study. Therapeutic Advances in Chronic Disease, 2023, 14, 204062232311631.	1.1	0
3464	Evolving Diagnostic and Management Advances in Coronary Heart Disease. Life, 2023, 13, 951.	1.1	3
3465	Chronic Kidney Disease Management in the Middle East and Africa: Concerns, Challenges, and Novel Approaches. International Journal of Nephrology and Renovascular Disease, 0, Volume 16, 103-112.	0.8	3

#	Article	IF	Citations
3466	Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study. Critical Care Medicine, 2023, 51, 1074-1085.	0.4	2
3467	Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study. BMJ Open Diabetes Research and Care, 2023, 11, e003302.	1.2	1
3468	Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease. Annals of Pharmacotherapy, 0, , 106002802311657.	0.9	2
3469	Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice. Cureus, 2023, , .	0.2	0
3470	Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	42
3471	Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review. Cureus, 2023, , .	0.2	0
3472	Strategies to Improve Long-Term Outcomes for Patients with Chronic Kidney Disease in China. Kidney Diseases (Basel, Switzerland), 2023, 9, 265-276.	1.2	0
3473	Impact of diabetes duration on left ventricular mass regression with empagliflozin. ESC Heart Failure, 2023, 10, 2134-2140.	1.4	3
3474	Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. Journal of Clinical Medicine, 2023, 12, 2824.	1.0	1
3475	Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors. Journal of Cardiovascular Translational Research, 2023, 16, 975-986.	1.1	3
3476	The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitusâ€"A Systematic Review. International Journal of Molecular Sciences, 2023, 24, 7184.	1.8	4
3477	Use of Computation Ecosystems to Analyze the Kidney-Heart Crosstalk. Circulation Research, 2023, 132, 1084-1100.	2.0	1
3478	Speckle tracking echocardiography in early disease stages: a therapy modifier?. Journal of Cardiovascular Medicine, 2023, 24, e55-e66.	0.6	3
3479	Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease. Circulation Research, 2023, 132, 993-1012.	2.0	18
3480	Metabolic Syndrome and Cardiac Remodeling Due to Mitochondrial Oxidative Stress Involving Gliflozins and Sirtuins. Current Hypertension Reports, 2023, 25, 91-106.	1.5	2
3481	Cardiac Reverse Remodeling in Ischemic Heart Disease with Novel Therapies for Heart Failure with Reduced Ejection Fraction. Life, 2023, 13, 1000.	1.1	1
3482	Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. Cardiovascular Diabetology, 2023, 22, .	2.7	18
3483	A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. Life, 2023, 13, 1012.	1.1	4

#	Article	IF	Citations
3484	SGLT-2 Inhibitors: Discrepancy Between MACE Reduction and Incident MI & Stroke. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	0
3485	Perspectives in weight control in diabetes â€“ SGLT2 inhibitors and GLP-1â€“glucagon dual agonism. Diabetes Research and Clinical Practice, 2023, 199, 110669.	1.1	1
3486	Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the <scp>EMPERORâ€Preserved</scp> trial. European Journal of Heart Failure, 2023, 25, 1337-1348.	2.9	12
3487	Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. Life, 2023, 13, 1024.	1.1	1
3488	Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action. Journal of Cardiovascular Pharmacology and Therapeutics, 2023, 28, 107424842311622.	1.0	0
3489	Treatment of type 2 diabetes patients with heart conditions. Expert Review of Endocrinology and Metabolism, 2023, 18, 255-265.	1.2	9
3490	Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease. Expert Opinion on Pharmacotherapy, 2023, 24, 935-945.	0.9	1
3491	The Role of SGLT2 Inhibitors in Cardiovascular Management. Cardiology in Review, 0, Publish Ahead of Print, .	0.6	0
3492	Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art. Iberoamerican Journal of Medicine, 2023, 5, 68-77.	0.1	1
3493	Relationship between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients with Diabetes and Mild Heart Failure: Results from the CANDLE trial. Journal of Cardiovascular Pharmacology, 2023, Publish Ahead of Print, .	0.8	0
3494	Dapagliflozin induced hypernatremia via osmotic diuresis: a case report. CEN Case Reports, 2024, 13, 9-13.	0.5	1
3495	SGLT 2 inhibitors: Searching for the best in class. International Journal of Cardiology, 2023, 384, 48-49.	0.8	2
3496	Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice. Korean Journal of Physiology and Pharmacology, 2023, 27, 221-230.	0.6	0
3497	The interplay between bone and heart health as reflected in medication effects: A narrative review. Women's Health, 2023, 19, 174550572311655.	0.7	1
3498	Reduced incidence of cardiovascular disease in patients with type 2 diabetes through the integrated improvement of diabetes care by comparing two prospective observational cohorts in real-world clinical practice (JDDM 72). Diabetes Research and Clinical Practice, 2023, , 110674.	1.1	0
3499	Impact of Baseline Clinical Variables on SGLT2iâ€™s Antiproteinuric Effect in Diabetic Kidney Disease. Life, 2023, 13, 1061.	1.1	1
3500	Recent advances in the treatment of patients with obesity and chronic kidney disease. Annals of Medicine, 2023, 55, .	1.5	4
3556	The Management of Hyperglycemia and DM in Patients with an Acute Coronary Syndrome. Contemporary Cardiology, 2023, , 683-696.	0.0	0

#	Article	IF	Citations
3557	SGLT2 Inhibitors and GLP1 Antagonists on Diabetes and Cardiovascular Disease. Contemporary Cardiology, 2023, , 923-968.	0.0	0
3558	Sodium-Glucose Cotransporter 2 Inhibitors. , 2023, , 581-592.		0
3559	Diabetes Management in the United States. , 2023, , 309-328.		0
3560	Renal Disease in Diabetes. , 2023, , 905-922.		0
3572	Overview of Inpatient Management of Diabetes and COVID-19. Contemporary Endocrinology, 2023, , 111-122.	0.3	0
3585	The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of TypeÂ2 Diabetes: A Narrative Review. Advances in Therapy, 0, , .	1.3	0
3600	Optimizing Pharmacotherapy in Older Patients: An Interdisciplinary Approach: Chronic Kidney Disease. Practical Issues in Geriatrics, 2023, , 405-426.	0.3	0
3640	Effects of Diabetes and Insulin Resistance on Endothelial Functions. Contemporary Cardiology, 2023, , 45-80.	0.0	0
3641	Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual. Contemporary Cardiology, 2023, , 1043-1070.	0.0	0
3644	Heart Failure and Cardiac Dysfunction in Diabetes. Contemporary Cardiology, 2023, , 747-781.	0.0	0
3650	Systematic Review of the Economic Evaluation of Sodiumâ€“Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure. Clinical Drug Investigation, 2023, 43, 463-474.	1.1	0
3667	Novel insights into the role of mitochondria in diabetic cardiomyopathy: molecular mechanisms and potential treatments. Cell Stress and Chaperones, 2023, 28, 641-655.	1.2	1
3675	A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus. Pharmacoeconomics, 2023, 41, 1469-1514.	1.7	1
3692	Metabolomics signature of cardiovascular disease in patients with diabetes, a narrative review. Journal of Diabetes and Metabolic Disorders, 0, , .	0.8	0
3733	SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms. American Journal of Cardiovascular Drugs, 0, , .	1.0	2
3743	Summary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines. Cardiology and Therapy, 0, , .	1.1	0
3760	Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review. Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262, 717-752.	1.0	2
3775	Hypertension in diabetes. Pediatric Nephrology, 0, , .	0.9	0

#	Article	IF	Citations
3803	Beginning and Managing Underlying Comorbidities. , 2023, , 49-63.		0
3822	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 1-25.		0
3839	From a glycocentric approach in the patient with type 2 diabetes mellitus to a multi-organ prevention treatment and a decrease in the neuro-nephro-cardiovascular outcomes.. , 0, , .		0
3840	Diabetes Mellitus:. , 2024, , 439-455.		0
3884	Management of Type 2 DiabetesMellitus. , 0, , .		0
3888	The role and mechanisms of microvascular damage in the ischemic myocardium. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	0
3896	Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodiumâ€“Glucose Cotransporter 2 Inhibitors. Advances in Therapy, 0, , .	1.3	1
3926	SGLT-2i: Nanoparticular-Based Strategies, Solutions, and Clinical Applications in Opposition to Low Bioavailability. Journal of Pharmaceutical Innovation, 0, , .	1.1	0
3977	Who benefits from the blood pressure-lowering effects of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease? â€” Obese or non-obese?. Hypertension Research, 2024, 47, 681-682.	1.5	0
4001	Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes. Current Atherosclerosis Reports, 0, , .	2.0	0
4002	Herz und Diabetes. Springer Reference Medizin, 2023, , 205-218.	0.0	0
4074	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 713-737.		0
4125	Heart Failure with Preserved Ejection Fraction: Current Management and Future Strategies Pre-Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2023, , 477-489.	0.1	0